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ABSTRACT 
Bacteraemia and sepsis are major causes of mortality worldwide. Individual subjects seem to have 
different risks of developing bacteraemia and sepsis, individual organ failures and death. Despite 
novel options in the treatment of sepsis, the course of disease in individuals remains unpredicted 
and the mortality rate high. The lack of knowledge of sepsis pathogenesis and the heterogeneity of 
patients with bacteraemia and sepsis make risk stratification difficult. The main purpose of this 
study was to elucidate the role of host genetic factors, living habits, and underlying diseases in 
bacteraemia outcome, to study the effect of genetic factors on susceptibility to bacteraemia, and to 
find new approaches in understanding the pathogenesis and prognostication in bacteraemia. 
This prospective cohort study involved 149 in-hospital patients (79 male and 70 female) with 
bacteraemia caused by Staphylococcus aureus (S. aureus) (41 patients), Streptococcus pneumoniae 
(Str. pneumoniae) (42 patients), ß-haemolytic streptococcus (ß-hml str.) (23 patients) and 
Escherichia coli (E. coli) (43 patients) recruited in Tampere University Hospital during the years 
1999-2004. Nineteen (12.8%) bacteraemic patients died.  
Mannose-binding lectin (MBL) insufficiency caused by point mutations in the MBL2 gene has 
been associated with increased susceptibility to infections, but the data are controversial. To study 
the effect of MBL2 polymorphisms on susceptibility to and the clinical course of bacteraemia, 145 
patients with bacteraemia and 400 controls were examined. In study I, MBL2 structural 
polymorphisms at codons 52, 54 and 57, and promoter region polymorphisms at position -221 were 
determined. No difference in MBL2 genotype frequencies was detected between bacteraemic 
patients and controls, and MBL2 genotype had no independent effect on mortality. However, 
smoking proved a significant risk factor for gram-positive (S. aureus, Str. pneumoniae or ß-hml. 
str.) bacteraemia among carriers of the variant O allele, while it had no effect on those homozygous 
for the A allele.  
Nitric oxide (NO) is a crucial element in the pathogenesis of sepsis. Endothelial nitric oxide 
synthase (eNOS) is a key regulator of vascular NO production. The eNOS gene polymorphism at 
position 894 (G>T, Glu298Asp), resulting in the T allele, has been studied in the context of vascular 
diseases, but its role in sepsis is unclear. In study II, the polymorphism of the eNOS gene, G894T, 
was genotyped in patients with bacteraemia. Carriage of the T allele was associated with 
hypotension and severe disease in patients suffering from E. coli bacteraemia, but not in 
bacteraemia caused by a gram-positive organism. The Glu298Asp polymorphism had no effect on 
case fatality.  
In study III, the major underlying conditions associated with case fatality in bacteraemia were 
studied. Obesity (body mass index (BMI #30)) and smoking were independently associated with 
case fatality in a multivariate model adjusted for the effect of potential confounders. The median 
BMI was significantly higher among those who died compared to survivors (33 vs. 26, p=0.003) 
Indoleamine 2,3-dioxygenase (IDO), which is the rate-limiting enzyme for tryptophan 
catabolism, may play a critical role in various inflammatory disorders. IDO degrades tryptophan 
(trp) to its metabolite kynurenine (kyn), constituting a suppressor of T-cells. However, the precise 
role of IDO in different disease processes is largely unknown. In study IV, serum tryptophan and 
kynurenine concentrations were determined by high-performance-liquid chromatography (HPLC) in 
bacteraemic patients. The kyn/trp ratio, reflecting the activity of the IDO enzyme, was calculated. 
Maximum IDO activity 1-4 days after blood culture was significantly higher in nonsurvivors 
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compared to survivors. High IDO activity remained an independent predictor of case fatality in the 
multivariate model.  
In summary, this study showed that obese patients and smokers had significantly higher case 
fatality rates in bacteraemia compared to their normal-weight and non-smoking counterparts. 
Smoking also increased the risk of gram-positive bacteraemia in patients carrying the MBL2 gene 
structural variant O allele, this constituting a novel example of gene-environment interaction. 
Carriage of the eNOS gene T allele at nucleotide position 894 was associated with hypotension in 
patients with E. coli bacteraemia. A high kyn/trp ratio, reflecting IDO activity was strongly 
associated with case fatality in patients with bacteraemia. The present findings provide evidence of 
fundamental differences between gram-negative and gram-positive sepsis and interindividual 
differences in predisposition to bacteraemia relating to genetic and smoking interactions, and of 
lifestyle effects on outcome. The contribution of the eNOS gene, a gene regulating vascular tone, on 
disease severity in bacteraemia is shown. IDO may constitute a novel key to the understanding of 
sepsis pathogenesis. 
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TIIVISTELMÄ 
Bakteremia ja sepsis ovat maailmanlaajuisesti merkittäviä kuolleisuuden aiheuttajia. Yksilöiden 
herkkyydessä sairastua bakteremiaan, saada siihen liittyvä elinhäiriö tai kuolla siihen on merkittäviä 
eroja. Vaikka bakteremian ja sepsiksen hoitomenetelmät ovat kehittyneet viime vuosina, 
taudinkuvat ovat edelleen huonosti ennustettavia ja kuolleisuus tautiin on korkea. Sepsiksen 
patogeneesiä ei tunneta riittävän hyvin ja potilaiden kuolemanriskiä ei osata arvioida. Tämän 
tutkimuksen tärkein tavoite on selvittää geneettisten tekijöiden, elintapojen ja yleissairauksien 
merkitystä bakteremiapotilaiden ennusteeseen, sekä selvittää bakteremiariskiin liittyviä geneettisiä 
tekijöitä. Tutkimuksessa etsitään entistä parempia keinoja bakteremian ja sepsiksen patogeneesin 
ymmärtämiseksi, jotta näiden potilaiden hoito voidaan jatkossa suunnata tehokkaamin. 
Prospektiivinen tutkimusaineisto koostui 149 bakteremiapotilaasta (79 miestä ja 70 naista), joita 
hoidettiin vuosina 1999-2004 Tampereen yliopistollisessa sairaalassa. Bakteremian aiheutti 41 
potilaalla Staphylococcus aureus (S. aureus), 42 potilaalla Streptococcus pneumoniae (Str. 
pneumoniae), 23 potilaalla ß-hemolyyttinen streptokokki (ß-hml str.) ja 43 potilaalla Eschericia coli 
(E. coli). Potilaista kuoli 19 (12.8%). 
Mannoosia sitovan lektiinin (MBL) puute, jonka aiheuttaa pistemutaatiot MBL2-geenissä, on 
yhdistetty riskiin sairastua infektioihin, vaikka ristiriitaisiakin tutkimustuloksia on esitetty. 
Osatyössä I tutkittiin MBL2-polymorfioiden vaikutusta riskiin sairastua bakteremiaan ja toisaalta 
polymorfioiden vaikutusta ennusteeseen 145:n bakteremiapotilaan ja 400:n kontrolliväestöön 
kuuluvan ihmisen aineistossa. Tutkimuksessa määritettiin MBL2-rakennealueen polymorfiat 
codoneissa 52, 54 ja 57, ja promoottorialueen polymorfiat nukleotidikohdassa -221. MBL2-geenin 
genotyyppifrekvenssit eivät eronneet potilaiden ja kontrolliryhmän välillä, eikä MBL2-genotyypillä  
ollut itsenäistä vaikutusta bakteremian ennusteeseen. Tupakointi oli merkitsevä grampositiivisen 
bakteerin aiheuttaman bakteremian riskitekijä strukturaalialueen O-alleelin kantajilla, mutta ei 
niillä, jotka olivat homotsygootteja A-alleelin suhteen.  
Typpioksidi (NO) on keskeisessä roolissa bakteremian ja sepsiksen patogeneesissä. Endoteelin 
typpioksidi syntaasi (eNOS) on olennainen verisuonen NO-synteesin säätelijä. eNOS-geenin 
polymorfia nukleotidikohdassa 894 (G>T, Glu298Asp), joka johtaa T-alleeliin, on liitetty 
verisuonisairauksien patogeneesiin, mutta tämän polymorfian merkitystä sepsiksen patogeneesissä 
ei tiedetä. Osatyössä II bakteremiapotilaiden eNOS-geenin polymorfinen nukleotidikohta 894 
genotyypattiin. T-alleeli liittyi E. coli-bakteremiaa sairastavien merkitsevään verenpaineen laskuun 
ja vaikeaan taudinkuvaan. T-alleelilla ei ollut vaikutusta grampositiivisen bakteerin aiheuttamissa 
bakteremioissa. Glu298Asp polymorfialla ei ollut vaikutusta kuolleisuuteen. 
Osatyössä III tutkittiin elintapojen ja yleissairauksien merkitystä bakteremiapotilaiden 
ennusteeseen. Lihavuus (body mass index (BMI #30)) ja tupakointi säilyivät 
bakteremiakuolleisuuteen liittyvinä itsenäisinä ennustetekijöinä, vaikka niiden vaikutusta tutkittiin 
monimuuttujamallissa potentiaalisten sekoittavien tekijöiden kanssa. Bakteremiaan kuolleiden BMI 
oli tilastollisesti merkitsevästi korkeampi verrattuna niihin, jotka säilyivät hengissä (mediaanit 33 vs 
26, p=0.003). 
Indoleamine 2,3-dioxygenase (IDO) hajottaa tryptofaania (trp) sen metaboliitiksi, kynureniiniksi 
(kyn). Aiemmat tutkimukset viittavat siihen, että IDO:lla voi olla merkittävä rooli erilaisissa 
tulehduksellisissa tiloissa. IDO lamaa T-solujen toimintaa, mutta sen kliininen merkitys eri 
sairauksissa on pitkälti tuntematon. Osatyössä IV seerumin tryptofaani- ja kynureniini-pitoisuudet 
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määritettiin high-performance-liquid chromatography (HPLC)-menetelmällä. IDO-aktiivisuutta 
kuvastava kyn/trp-suhde laskettiin. Kuolleilla bakteremiapotilailla IDO-aktiivisuus 
(maksimipitoisuus 1-4 päivää veriviljelystä) oli tilastollisesti merkitsevästi korkeampi verrattuna 
henkiin jääneisiin. Korkea IDO-pitoisuus säilyi monimuuttujamallissa itsenäisenä kuoleman 
ennustajana.  
Yhteenvetona todetaan, että lihavuus ja tupakointi olivat bakteremiapotilaiden itsenäisiä 
kuoleman vaaratekijöitä. Tupakointi myös lisäsi grampositiivisen bakteremian riskiä potilailla, jotka 
kantoivat MBL2-geenin strukturaalialueella O-alleelia. Tämä on uusi löydös geenien ja ympäristön 
välisistä vuorovaikutussuhteista. eNOS-geenin T-alleelin kantajuus nukleotidikohdassa 894 liittyi 
hypotensioon E. coli bakteremiassa. Korkea kyn/trp-suhde IDO-aktiivisuuden kuvastajana liittyi 
voimakkaasti bakteremiapotilaiden kuolemanriskiin. Esitetyt havainnot antavat lisää todisteita siitä, 
että gramnegatiivisten ja grampositiivisten bakteerien aiheuttamat bakteremiat ovat 
patogeneettisesti erilaisia. Yksilöiden väliset erot sairastumisherkkyydessä bakteremiaan 
selittynevät osittain geeni-ympäristöinteraktioilla ja elintavoilla on merkitystä bakteremiapotilaiden 
ennusteen kannalta. Väitöstyössä osoitettiin, että verisuonitonusta säätelevällä eNOS-geenillä voi 
olla merkitystä sepsispotilaan hemodynamiikan säätelyssä. IDO-välitteisten mekanismien 
selvittäminen jatkossa tuonee lisää työkaluja sepsiksen patogeneesin ymmärrykseen.  
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1. INTRODUCTION 
Bacteraemia accompanied by a systemic inflammatory response to infection, defined as sepsis, is a 
heterogeneous class of syndromes and the host response to the disorder involves many concomitant 
integrated and antagonistic processes involving both exaggerated inflammation and immune 
suppression (van der Poll and Opal 2008). Septic shock, a severe form of sepsis, is associated with 
the development of progressive damage in multiple organs and is a leading cause of patient 
mortality in intensive care units (ICUs) (Feihl et al. 2001). Despite important advances in 
understanding its pathophysiology, therapy remains largely symptomatic and supportive, as the 
syndromes of sepsis are defined by nonspecific alterations in physiology rather than by specific 
cellular processes which would represent potential therapeutic targets. In Finland, the incidence of 
severe sepsis is 0.38/1000 adults/year (Karlsson et al. 2007). 
The successful translation of novel research findings from basic research laboratories into useful 
clinical strategies for the management of severely ill septic patients has proved to be a difficult 
challenge (Opal and Patrozou 2009). Despite almost half a century of clinical trials and more than 
two decades of extensive research, only two pharmaceutical strategies have survived and reached 
the septic patient: recombinant human activated protein C (rhAPC) and low-dose corticosteroids 
(Riedemann et al. 2003,  Cauwels 2007). The Recombinant Human Activated Protein C Worldwide 
Evaluation in Severe Sepsis (PROWESS) study (Bernard et al. 2001), a phase III trial which led to 
the licensing of rhAPC, suggested that a nonantimicrobial life-saving drug had finally been found 
for sepsis (Poole et al. 2009). Nonetheless, the beneficial effects of even this agent in terms of 
survival seem to depend on the severity of the illness (Bernard et al. 2001) and it may even be 
harmful in patients with a lower risk of death (Riedemann et al. 2003). Recently, the European 
Medicine Agency (EMEA) has required a confirmatory trial of rhAPC without however recalling 
the drug from the market (Poole et al. 2009). This reflects the despair encountered in attempts to 
find a resolution to the clinical challenge called sepsis. Studies of the benefits of low- dose 
corticosteroids have also yielded controversial results (Sprung et al. 2008,  Annane et al. 2009). 
However, some therapeutic interventions have been acknowledged as live-saving in sepsis; there is 
evidence that mechanical ventilation with low tidal volumes, and prompt and adequate fluid 
resuscitation may save a significant number of lives (Rivers et al. 2001,  Dellinger et al. 2004).  
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The currently available biomarkers or nonspecific physiologic criteria for the sepsis syndrome 
or the systemic inflammatory response syndrome (SIRS) do not adequately identify patients who 
might benefit either from conventional antimicrobial therapies or from therapies targeting specific 
mediators of inflammation (Marshall and Reinhart 2009). We currently lack the capacity to 
delineate distinct groups of patients with a discrete disease - a prerequisite in developing specific 
biologically rational sepsis therapies (Marshall and Reinhart 2009). The significance of underlying 
diseases and modes of living on bacteraemia outcome have as yet been insufficiently elucidated. 
Currently, we do not in fact know what causes the death of patients with bacteraemia and sepsis. 
A number of factors, for example certain microorganisms, primary focus of infection, blood 
pressure, body temperature, focus of infection, advanced age, severe underlying diseases and 
inappropriate initial antimicrobial therapy, have been identified as being significantly associated 
with the outcome in bacteraemic patients (Weinstein et al. 1983,  Pittet et al. 1993,  Weinstein et al. 
1997). There is evidence that host genetic factors may be involved in the clinical course (Arcaroli et 
al. 2005). Functional and association studies involving genetic polymorphisms in essential genes, 
including toll-like receptors (TLRs), cytokines and coagulation factors, have provided important 
insights into the mechanisms involved in the pathogenesis of sepsis-induced organ dysfunction and 
failure (Arcaroli et al. 2005).  
Mannose-binding lectin (MBL) is a serum acute-phase reactant secreted by the liver. It activates 
the complement system by binding to carbohydrate structures presented by microorganisms, and is 
thus considered an important component in the innate immune defence system (Turner and Hamvas 
2000,  Turner 2003). MBL insufficiency caused by MBL2 gene polymorphisms in the structural 
region (codons 52, 54 and 57) and the promoter region (at position -221) of the gene have been 
shown to increase the risk of infections and worsen outcomes especially in children, in patients with 
cancer, and in ICU patients (Summerfield et al. 1997,  Koch et al. 2001,  Gordon et al. 2006,  
Vekemans et al. 2007). MBL is present in the upper airways and buccal cavity and may thus protect 
against respiratory infections as a part of innate immunity (Hickling et al. 2004). Smoking, in turn, 
has substantial detrimental effects on the lung immune system (Sopori 2002). However, the possible 
interplay of these two, MBL2 genotypes representing MBL insufficiency and smoking, has not been 
previously studied. 
Nitric oxide (NO) is one of many vasoactive substances released under conditions of 
endotoxaemia and sepsis. Endothelial nitric oxide synthase (eNOS) is, in turn, a key regulator of 
vascular NO production (Nathan 1992,  Parratt 1998). The NOS3 gene is highly polymorphic (Jones 
and Hingorani 2005). Of eNOS polymorphisms, the eNOS gene polymorphism at position 894 
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(G>T, Glu298Asp), resulting in the T allele, has also been studied in the context of vascular 
diseases (Miyamoto et al. 1998), but its role in sepsis has not yet been explored.  
Obesity and smoking are major health concerns in Western countries. The consequences of 
obesity for critical illness are of great public health importance. In the general population, obesity is 
associated with an increased risk of mortality and excess costs of care (Thompson et al. 1999). 
Although frequently studied as a chronic disease, the influence of obesity on acute illnesses is 
poorly understood and the data on the outcome of specific infections, such as bacteraemia in obese 
people are so far limited (Falagas and Kompoti 2006). Given the high prevalence of obesity in the 
Finnish population (24% in men, and 28% in women) (Saaristo et al. 2008), this issue is of 
particular importance. Smoking has substantial effects on the immune system, affecting both innate 
and adaptive immunity (Sopori 2002). Although the predisposition to invasive bacterial infections 
has been clearly shown (Fischer et al. 1997,  Nuorti et al. 2000), data regarding the outcome of 
infections in smokers remain limited. 
Indoleamine 2,3-dioxygenase (IDO), which is the rate-limiting enzyme for tryptophan 
catabolism, suppresses T-cells and may play a critical role in various inflammatory disorders. A 
decreased tryptophan concentration and increased concentrations of kynurenine have been 
described in various clinical conditions, for example infection, autoimmune syndromes, 
malignancies, neurodegenerative disorders and pregnancy (Schrocksnadel et al. 2006). IDO activity 
in human serum is commonly measured by determining the ratio of kynurenine to tryptophan 
(kyn/trp). It is not clear whether IDO activity is beneficial or detrimental to the host (Mellor and 
Munn 2004). Recent studies on trauma patients have suggested that the degradation of tryptophan 
may be associated with the development of sepsis (Pellegrin et al. 2005,  Logters et al. 2009). 
However, the role of IDO activity in bacteraemic patients is unclear and its potential prognostic 
value warrants investigations. This would be essential in order to further define the role of IDO in 
the pathogenesis of sepsis and to investigate the possibility of scavenging IDO as a part of sepsis 
therapy.  
In this series, the influence of host characteristics, underlying diseases and host genetic factors 
on the highly variable course of bacteraemia were studied. The risk of bacteraemia in relation to the 
MBL2 genotype was investigated and the prognostic value of IDO activity in bacteraemic patients 
was studied. The data presented might be of value in assessing the prognosis in different individuals 
in order to target preventive efforts such as immunomodulative therapies on individuals likely to 
derive the greatest benefit. 
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2. REVIEW OF THE LITERATURE 
2.1. Overview of bacteraemia and sepsis 
2.1.1. Definitions 
A consensus conference between the American College of Chest Physicians (ACCP) and the 
Society of Critical Care Medicine (SCCM) has defined bacteraemia as the presence of viable 
bacteria in the blood (Bone et al. 1992). Sepsis was defined as a SIRS in the presence of infection. 
The SIRS criteria include two or more of the following: temperature >38 or <36ºC, heart rate 
>90/min, respiratory rate >20 or PaCO2 <32mmHg, white blood cell count >12 or <4 x10
9
/l or 
presence of immature forms >10%. Severe sepsis is sepsis associated with organ dysfunction, 
hypoperfusion or hypotension. Septic shock is sepsis-induced hypotension despite adequate fluid 
resuscitation (Bone et al. 1992). In 2001, an International Sepsis Definitions Conference concluded 
that the diagnostic criteria for SIRS published in 1992 were overly sensitive and non-specific, and 
thus published an expanded list of signs and symptoms of sepsis which might better reflect the 
clinical response to infection. The sepsis definition, however, was left practically unchanged (Levy 
et al. 2003). 
One of the most widely used scores for the assessment of organ dysfunction in sepsis is the 
sequential organ failure assessment (SOFA) score (Vincent et al. 1996). Organ function is graded 
from 0-4 points (0= no dysfunction, 4= severe dysfunction) in six different organ systems (Vincent 
et al. 1996). Increasing or constantly high SOFA scores correlate with mortality in patients with 
severe sepsis (Levy et al. 2005). Organ failure has been defined as a SOFA score # 3 (Brun-Buisson 
et al. 2004). 
Despite the definitions for sepsis, severe sepsis and septic shock outlined above, these terms do 
not allow of a precise characterization and staging of patients with this condition. To be clinically 
useful, such a system would stratify patients by both their baseline risk of an adverse outcome and 
their potential to respond to therapy. Intensive care scoring systems predict the outcome of 
populations, but they may not be sufficient for the evaluation of individual patients (Skrobik and 
Kavanagh 2006). Using a variation of the tumours/nodes/metastasis (TNM) classification of 
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malignant tumours in oncology (Harmer et al. 1970), the International Sepsis Definitions 
Conference in 2001 developed a classification scheme called PIRO, for sepsis, which stratifies 
patients on the basis of their Predisposing conditions, the nature and extent of the insult (in the case 
of sepsis, infection), the nature and magnitude of the host response, and the degree of concomitant 
organ dysfunction (Levy et al. 2003). The PIRO approach is a step towards the concept of 
“personalized medicine”. Eight years after the introduction of the concept, a few studies have tested 
and further refined it (Moreno et al. 2008,  Rubulotta et al. 2009).  
2.1.2. Incidence 
During the period 1995-2002, over 50 000 cases of bloodstream infections (BSI) were reported in 
Finland and the annual incidence increased from 104 to 145 cases/100,000 (40%) (Skogberg et al. 
2008). Elderly persons (aged #75 years) accounted for 28% of cases and showed the largest rate 
increase. E. coli, coagulase-negative staphylococci, S. aureus and Str. pneumoniae accounted for 
over half of the obtained isolates and their relative proportions remained unchanged during the 
period (Skogberg et al. 2008). The increasing incidence was partly explained by increasing blood-
culturing activity (Skogberg et al. 2008). According to the national annual infectious diseases report 
published by the National Institute of Health and Welfare (THL), E. coli was noted as the most 
common organism isolated in blood-culture positive infections in Finland in 2007 (THL 2008) . 
The annual incidence of pneumococcal bacteraemia in Finland is 9.9/100 000 (Klemets et al. 
2008a). The incidence of S. aureus bloodstream infections rose from 11/100 000 population in 1995 
to 17/100 000 in 2001. Altough the increase in incidence was seen in all adult age groups, it was 
most striking in patients >74 years of age (Lyytikäinen et al. 2005). The incidence of ß-haemolytic 
streptococcus bacteraemia varies between Lancefield groups; in the Pirkanmaa Hospital District 
(HD), the incidence of Lancefield group G streptococci (GGS) was the highest in 2004 (4.3/100 000 
population) and that of group C lowest (<1/100 000 population in 2004) (Rantala et al. 2009a).  
2.1.3. Prognosis 
The prognosis of bacteraemia varies between causative organisms and according to whether sepsis, 
severe sepsis or septic shock is present. Increasing severity correlates with increasing mortality, 
which rises from 25-30% for severe sepsis up to 40-70% for septic shock (Lever and Mackenzie 
2007). The case fatality rate in methicillin-susceptible S. aureus (MSSA) bacteraemia has been 
shown to vary between 13-24% (Lyytikäinen et al. 2005,  Ruotsalainen et al. 2006,  Laupland et al. 
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2008b). The presence of infective endocarditis and a nosocomial origin of bacteraemia increase the 
case fatality rate in S. aureus bacteraemia (Lyytikäinen et al. 2005). The rate has been reported to be 
11-17% in E. coli bacteraemia (Kuikka et al. 1997,  Laupland et al. 2008a), 10-30% in Str. 
pneumoniae bacteraemia (Watanakunakorn et al. 1993,  Lujan et al. 2004,  Lynch and Zhanel 2009) 
and 12-14% in ß-haemolytic  streptococcal bacteraemia (O'Loughlin et al. 2007,  Broyles et al. 
2009,  Rantala et al. 2009a). The presence of toxic shock syndrome or necrotizing fasciitis in 
streptococcal bacteraemia increases the case fatality rates to 36% and 24%, respectively 
(O'Loughlin et al. 2007).  
2.2. Pathophysiology of bacteraemia and sepsis 
Figure 1 represents a summary of the key events in the pathogenesis of bacteraemia/sepsis. Upon 
inflammatory stimulus, tissue macrophages, monocytes, other myeloid cells, and to some extent 
endothelial cells contribute to the cellular response seen in sepsis, responding as a first-line defence 
(Aird 2003). These cells recognize pathogens via pattern recognition receptors (PRRs) which have 
the ability to interact with the structures of microbes (Janeway and Medzhitov 2002). The 
interactions between pathogens and host cells induce multiple changes, leading to activation of 
inflammatory, coagulation and complement cascades (Aird 2003,  Opal and Esmon 2003,  Ward 
2008). This leads to the release of soluble mediators, reactive oxygen and/or reactive nitrogen 
species (ROS/RNS), cytokines such as tumour necrosis factor alpha (TNF-"), IL-1, and IL-6, 
arachidonic acid metabolites and NO, which amplify the inflammatory response, affecting the 
endothelium and activating inflammatory cells (Marsh and Wewers 1996). These changes are 
manifested as the SIRS. Sepsis perturbs immune homeostasis by inducing an initially unbridled 
systemic inflammation, which is accompanied by an anti-inflammatory reaction acting as negative 
feedback. This compensatory inhibitory response, secondly, becomes deleterious, as nearly all 
immune system functions are compromised (Monneret et al. 2008). However, the timing of the first 
occurrence of immunosuppression in sepsis is a matter of debate and some investigators suggest 
that it constitutes a primary rather than a compensatory response to sepsis (Hotchkiss and Nicholson 
2006).  
Several overlapping mechanisms have been proposed to explain the development of the multiple 
organ dysfunction syndrome. These may be divided into groups; circulatory failure, leading to an 
inadequate supply of oxygen to tissues, direct cytotoxic effects of various mediators released in the 
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course of generalized inflammation, and subsequent immunoparalysis (Parrillo 1993,  Feihl et al. 
2001,  Hotchkiss and Karl 2003).  
It has not been completely established what causes the death of sepsis patients. Although the 
prevailing conception has been that mortality in sepsis results from a tremendous hyper-
inflammatory cytokine reaction, novel studies suggest that most deaths from sepsis are actually the 
result of a substantially impaired immune response due to extensive apoptosis and subsequent death 
of immune effector cells (Hotchkiss and Nicholson 2006). Table 1 summarizes the factors 
associated with susceptibility to or outcome of bacteraemia/sepsis. 
 
Figure 1. Schematic presentation on key events in the pathogenesis of sepsis. The inflammatory response may lead to 
a balanced response, subsequent pathogen elimination and recovery, or to various clinical presentations of sepsis 
(lower part of the figure). PAMP= pathogen-associated molecular pattern, TLR= toll-like receptor, PRR= pattern 
recognition receptor, CNS= central nervous system, O2= dioxygen, TNF= tumour necrosis factor, IL= interleukin, DIC= 
disseminated intravascular coagulation. 
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Table 1. Summary of the factors associated with susceptibililty to and outcome of bacteraemia/sepsis. TLR= toll-like 
receptor, MBL= mannose-binding lectin, rhAPC= recombinant human activated protein C. 
 
2.2.1. Inter-bacterial differences  
The mechanisms leading to organ failure and death differ between different microorganisms (Opal 
and Cohen 1999). Much of the damage inflicted on the septic patient is attributable to microbial 
toxins and the host’s response to them (van der Poll and Opal 2008). Endotoxin and superantigens 
are implicated in the pathogenesis of gram-negative and gram-positive sepsis, respectively, but 
signal via widely disparate cellular mechanisms and induce very different inflammatory patterns 
(Hotchkiss and Karl 2003,  Carlet et al. 2008). The endotoxin of gram-negative organisms is 
sufficient to induce shock when given experimentally to laboratory animals or human volunteers 
(Natanson et al. 1989,  van der Poll and Opal 2008). The cell wall of gram-positive bacteria, in turn, 
contains peptidoglycan and lipoteichoid acid (Opal and Cohen 1999). Both substances can bind to 
Factors associated with susceptibility to or outcome of bacteraemia/sepsis 
 
Organism-related factors 
 Virulence, toxins, antimicrobial resistance, bacterial load 
 Different organisms signal via disparate mechanisms (e.g. TLRs) 
 Primary focus of infection 
Genetic polymorphisms 
 Innate receptor and innate system molecule polymorphisms (e.g. MBL)  
 Cytokine polymorphisms 
Host characteristics 
 Demographic factors (gender, age, race)  
 Mode of living (BMI, smoking, alcohol abuse) 
Underlying diseases 
 Immunodeficiencies 
 Malignancies 
 Ultimately or rapidly fatal diseases 
 Diabetes 
Medical intervention-related causes 
 Haemodialysis, catheter-related causes 
 Surgery 
 Immunosuppressive therapy 
Quality of care 
 Appropriateness and timing of first selected antimicrobial agent 
 Properties and dosing of antimicrobial treatment 
 Surgical source control 
 The adoption of early goal-directed strategies, the use of rhAPC 
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cell surface receptors and are proinflammatory (Wang et al. 2000), although they are less active on 
a weight-on-weight basis than lipopolysaccharide (LPS) (Cohen 2002). The production of potent 
exotoxins like toxic shock syndrome toxin-1 (TSST) by S. aureus and the pyrogenic exotoxins by S. 
pyogenes constitute important features of gram-positive organisms.  
Pathogenic strains of bacterial species differ from commensal strains by the acquisition and 
expression of specific clusters of virulence genes. In the future, the regulators of microbial virulence 
genes may also constitute potential therapeutic targets in the care of septic patients (Merrell and 
Falkow 2004,  van der Poll and Opal 2008). Bacterial virulence factors may determine the mode of 
presentation of infection and many have been implicated in invasiveness and disease severity (van 
der Poll and Opal 2008). Quorum sensing (the ability of bacteria to assess their population density) 
is now recognised as a major virulence property (van der Poll and Opal 2008). Within bacterial 
species there may be differences between different strains in virulence properties, leading to altered 
infection presentation and mortality. Examples of such strains are the hypervirulent Clostridium 
Difficile strains capable of increased toxin production (Warny et al. 2005) and the community-
acquired methicillin-resistant S. aureus (MRSA) strains, with increased virulence due to Panton-
Valentine leucocidin (PVL) production (Deresinski 2005). 
Infections caused by antibiotic-resistant organisms may involve higher morbidity and mortality 
rates than similar infections with antibiotic-susceptible strains. However, the extent to which this is 
encountered may vary according to the causative organism, the infection site and the individual 
characteristics of the patient (Acar 1997,  Cosgrove et al. 2003).  
One major difference between organisms in the pathogenesis of sepsis is in binding to TLRs. 
TLR4 is the LPS receptor and TLR2 is predominantly responsible for recognising gram-positive 
cell wall structures (Takeuchi et al. 1999). TLR-agonistic molecules such as LPS can regulate NO 
generation through upregulation of the expression of nitric oxide synthase (NOS) isoforms through 
nuclear factor kappa B (NF-!B) activation (Forstermann et al. 1998,  Marshall et al. 2004). TLR2 
and TLR4 have been shown to induce NOS (inducible NOS, i.e. iNOS) and TNF-" by different 
signalling pathways (Paul-Clark et al. 2006).  
Different organisms cause infections in different loci. Defence mechanisms in the lung and in 
the peritoneum are dissimilar, leading to differential effects of compounds aimed at manipulating 
the same inflammatory system (Bagby et al. 1991). 
In summary, infections caused by gram-negative and gram-positive organisms differ from each 
other in several ways. Differences in signalling pathways, virulence factors, patterns of TLR 
binding and the locations where the infection takes place result in altered clinical presentations of 
infectious diseases. 
  24 
2.2.2. Nitric oxide (NO) 
Refractory hypotension with inadequate end-organ perfusion is an ominous feature of septic shock, 
resulting in the dysfunction of one or more vital organs (Cauwels 2007). In 1986 NO was found to 
be the agent which relaxed blood vessels (Palmer et al. 1987), and NO has since been shown to be 
important for the physiological and pathological control of vascular tone and a central vasoactive 
substance released under conditions of sepsis and endotoxaemia (Cauwels 2007). The NO 
metabolites nitrite and nitrate, indicators of NO production, rise progressively in various 
experimental models of sepsis (Feihl et al. 2001).  
Under physiological conditions NO is produced by two constitutive calcium-dependent enzymes 
involving NOS in neurones (nNOS) and endothelial cells (eNOS) (Nathan 1992,  Parratt 1998). 
These enzymes produce small amounts of NO in response to increases in intracellular calcium 
(Nathan 1992). eNOS is ubiquitous in the vascular endothelium, but may also be found in kidney 
tubular epithelial cells and in the placenta (Forstermann et al. 1995). NO produced by eNOS plays 
an important homeostatic role in maintaining an appropriate blood flow to vital organs such as the 
lungs, kidney and liver, and exhibits cytoprotective effects, in part by preventing platelet and 
neutrophil adhesion to the blood vessel wall (Moncada and Higgs 1993,  Forstermann et al. 1998). 
In bacterial infection, NO formation from L-arginine is enhanced due to the cytokine-mediated 
induction of an iNOS enzyme in cells (e.g. cardiac myocytes, vascular smooth muscle), which do 
not normally have the ability to synthesize NO. The result of this excessive iNOS-mediated 
increased NO production is enhanced bacterial lysis by activated macrophages and profound 
hypotension (Parratt 1998). NO is considered to be an active player in defence against invasion by 
micro-organisms, being an effector tool used by activated phagocytic cells (Shiloh et al. 1999). The 
effects of NO depend on the rate, timing and spatial distribution of its production, as well as the 
chemical microenvironment (Fang 1997,  Feihl et al. 2001). Depending on its concentration and the 
particular circumstances, NO may exert either pro- or anti-inflammatory effects (Feihl et al. 2001). 
While a key event believed to be responsible for hypotension and shock in sepsis is iNOS-
derived overproduction of NO, a pivotal role has also been indicated for eNOS (Vo et al. 2005,  
Doursout et al. 2008). Although the expression of eNOS is constitutive, the level of transcripts for 
eNOS in vascular endothelial cells is increased by shear stress (Uematsu et al. 1995), variably 
affected by hypoxia (Le Cras et al. 1998) and reduced by proinflammatory stimuli such as TNF-" 
(Nathan and Xie 1994,  Feihl et al. 2001). NO has major interactions with the pathways of gene 
expression controlled by NF-!B, which, in turn, induces the transcription of numerous genes coding 
for proteins involved in inflammation, for example cytokines and iNOS. Both activation and 
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inhibition of NF-!B by NO have been described (Janssen-Heininger et al. 2000). There have been 
attempts to improve the prognosis of sepsis by NOS inhibitors, but results have been inconsistent 
(Cobb et al. 1992,  Szabo et al. 1994,  MacMicking et al. 1995,  Assreuy 2006,  Harbrecht 2006). 
This implies that NO acts as a double-edged sword during septic shock (Cauwels 2007), and the 
focus has consequently shifted towards selective iNOS-inhibitors (Feihl et al. 2001). 
Sepsis causes perturbations in vascular responses to vasoactive agents (Julou-Schaeffer et al. 
1990). Differential effects are seen in various vascular systems; vasoconstriction may predominate 
in certain organs, e.g. the kidney and the intestines (Spain et al. 1994a,  Spain et al. 1994b), while 
profound vasodilatation occurs in others, e.g. skeletal muscle (Hershey and Bond 1993). These 
haemodynamic changes are difficult to predict, being dependent on the timing and experimental 
conditons (Feihl et al. 2001). In spite of elevated cardiac output, myocardial depression is a 
common finding in sepsis and septic shock, referred to as septic cardiomyopathy (Flierl et al. 2008). 
Its mechanisms are poorly understood, although circulating and locally produced myocardial 
depressant substances may be involved (Parrillo 1993,  Brady 1995). The role and impact of NO on 
septic cardiomyopathy remain a matter of debate (Flierl et al. 2008).  
In summary, NO synthases are responsible for the production of NO. A key event implicated in 
the context of hypotension in sepsis is iNOS-derived overproduction of NO, whereas eNOS has a 
homeostatic role in maintaining an appropriate blood flow to vital organs. The regulation of both of 
these synthases is complex, and various inflammatory stimuli play a central role. 
2.2.3. Endothelium and coagulation  
The vascular endothelium plays an important role in regulating immune and inflammatory 
responses to pathogens. The endothelial dysfunction and impaired microvascular function seen in 
sepsis are increasingly widely recognized as key characteristics contributing to multiorgan failure 
and death (Cinel and Dellinger 2007). Endothelial dysfunction is caused by reduced NO 
bioavailability, which in turn is, regulated by genes such as NOS (Horstman et al. 2004). On the 
cellular level, endothelial dysfunction derives from a progressive loss of endothelial cells 
determined by the degree of apoptosis in them (Horstman et al. 2004). Altered leukocyte 
recruitment and impaired perfusion are hallmarks of the microvascular defect (Azevedo et al. 2006). 
Early manifestation of a microcirculatory defect has been shown to predict mortality (Trzeciak et al. 
2007). 
Patients with sepsis almost invariably show evidence of activation of the coagulation system, 
and disseminated intravascular coagulation (DIC) is a central hallmark of severe sepsis. 
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Inflammation triggers clotting, dampens the activity of natural anticoagulant mechanisms and 
impairs the function of fibrinolytic system. Inflammatory cytokines are the major mediators 
involved in coagulation activation, and tissue factor is regarded as the primary initiator of 
coagulation in sepsis (Esmon 2005). Haemostasis is controlled by three major anticoagulant 
proteins: the tissue-factor pathway inhibitor (TFPI), antithrombin, and activated protein C (APC) 
(Esmon 2005). Furthermore, plasminogen activator inhibitor type 1 (PAI-1) is a major inhibitor of 
haemostasis. During severe sepsis, the activation of TFPI, antithrombin, the protein C-APC-system 
and fibrinolysis are impaired, resulting in a procoagulant state (Levi and Ten Cate 1999). 
2.2.4. Immune system 
Sepsis is a result of a complex interaction between the infecting microorganism and the host`s 
reaction to it (van der Poll and Opal 2008). The vertebrates are under constant threat of invasion by 
microorganisms and have evolved systems of immune defence to eliminate infective pathogens in 
the body. The innate immune system is an evolutionally conserved host defence mechanism against 
pathogens (Creagh and O'Neill 2006). The host possesses an array of constitutive protective 
measures to resist pathogens at the body surface, including physical barriers such as epithelial tight 
junctions and the mucociliary ladder present on the respiratory epithelium (Sriskandan and Altmann 
2008). Surfactants containing antibacterial substances such as defensins are capable of destroying 
both gram-positive and gram-negative pathogens via pore-forming activity (Selsted and Ouellette 
2005). 
Innate immune responses are initiated by pattern recognition receptors (PRRs), transmembrane 
proteins present on the surface of immune cells, which recognize specific structures of 
microorganisms and play a crucial role in innate immunity. Of the PRRs, TLRs are capable of 
sensing organisms ranging from bacteria to fungi, viruses and protozoa (Uematsu and Akira 2006). 
In mammalians, thirteen different TLRs have been found. The entire TLR family signals via four 
adaptor proteins and binding of TLRs also activates intracellular signal-transduction pathways 
responsible for the activation of transcriptional activators such as cytosolic NF- !B (Lotz et al. 
2004). Activated NF- !ß moves from the cytoplasm to the nucleus, binds to transcription sites and 
induces the activation of an array of genes for acute-phase proteins, coagulation factors, 
proinflammatory cytokines, iNOS, and the enzymatic activation of cellular proteases (Uematsu and 
Akira 2006,  Cinel and Opal 2009). The activation of iNOS thus results in the production of NO. 
Dendritic cell maturation and cytokine production are also induced, resulting in the development of 
the more specific adaptive immunity (Akira et al. 2006). Dendritic cells, migrating to the lymph 
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nodes, overexpress antigen-major-histocompatibility complexes (antigen-MHCs) and costimulatory 
molecules. TLRs, on the one hand, are essential for the early detection of infectious agents, but on 
the other hand cause excessive inflammation after uncontrolled stimulation, and a sustained 
inflammatory response can result in tissue damage (van der Poll and Opal 2008). In addition, a 
reduction in their antimicrobial capacity may predispose to opportunistic infections such as 
nosocomial infections (Cinel and Dellinger 2007).  
Bacteria, viruses, fungi and parasites all possess a limited number of unique cellular constituents 
not found in vertebrates (Cinel and Opal 2009). These structures are referred to as pathogen-
associated molecular patterns (PAMPs), or more precisely, microbial-associated molecular patterns, 
as these molecules are also present in non-pathogenic bacteria (Granucci et al. 2005,  Cinel and 
Opal 2009). PAMPs bind to PRRs such as TLRs, expressed on the surface of host cells. Previous 
studies suggest that the specific host immune response to each pathogen is mediated by various sets 
of PRRs and PAMPs (Cinel and Dellinger 2007,  Cinel and Opal 2009). Ischaemia, trauma and 
tissue necrosis are able to generate danger-associated molecular patterns (DAMPs) (i.e., high 
mobility group box-1, heat shock proteins, hyaluran etc.) which augment TLR expression like 
PAMPs (Cinel and Opal 2009). Multiple positive feedback loops between DAMPs and PAMPs and 
their overlapping receptors represent the molecular basis for the syndrome known as SIRS (Cinel 
and Opal 2009). 
Sepsis is characterized by exacerbated coagulation and impaired anticoagulation. An 
exaggerated procoagulant state may lead to ischaemic cell injury, an effect which further amplifies 
the damage caused by excessive inflammation (Cinel and Opal 2009). A microvasculature injured 
by inflammation and ischaemia further perturbs the host immune response by altering leukocyte 
trafficking, generating apoptotic microparticles and increasing cellular hypoxia (Cinel and Dellinger 
2007,  Cinel and Opal 2009). Mitochondrial dysfunction, an acquired intrinsic defect in cellular 
respiration termed “cytopathic hypoxia,” also has an important role in that it reduces cellular 
oxygen consumption in sepsis, and growing evidence suggests that perturbations of key 
mitochondrial functions play a critical role in sepsis related organ failure (Larche et al. 2006,  Cinel 
and Opal 2009). 
In summary, sepsis is a result of an interaction between the infecting microorganism and the 
host`s reaction to it. TLR-mediated signalling plays a pivotal role in this network. Like many other 
genes involved in the pathogenesis of sepsis, the expression of those regulating vascular tone are 
induced by TLR-mediated signalling pathways. 
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2.2.4.1. Apoptosis and immunosuppression  
It is now widely accepted that the host response to sepsis involves many concomitant, integrated, 
and antagonistic processes which involve both intensive inflammation and immunosuppression (van 
der Poll and Opal 2008). The past ten years of sepsis research have revealed that increased 
apoptosis and resultant immunosuppression of immune effector cells may be a hallmark of the 
condition (Hotchkiss and Nicholson 2006). In clinical practice, most patients with sepsis survive the 
initial few days but develop a protracted immunosuppressive state which is manifested by an 
inability to eradicate the primary infection and the development of secondary infections (Hotchkiss 
and Nicholson 2006). 
Initially, sepsis may be characterized by increases in inflammatory mediators, but as the 
condition persists there is a shift toward an anti-inflammatory immunosuppressive state (Oberholzer 
et al. 2001,  Hotchkiss and Karl 2003). The mechanisms of immune suppression in sepsis include a 
shift from inflammatory Th1-type cytokines to Th2-type anti-inflammatory cytokines (Abbas et al. 
1996,  Opal and DePalo 2000), T cell anergy (Heidecke et al. 1999), apoptotic cell death (Hotchkiss 
et al. 1999) and death of lymphocytes (Hotchkiss et al. 1999,  Hotchkiss and Nicholson 2006).  The 
decrease in the numbers of T and B cells impairs the adaptive immune response, and the cross-talk 
between the innate and adaptive immune systems is compromised (Hotchkiss et al. 1999). A unique 
study in which patients who died of sepsis were autopsied within 30-90 minutes of demise revealed 
extensive apoptosis of lymphocytes and gastrointestinal epithelial cells compared to patients who 
died of non-septic aetiologies (Hotchkiss et al. 1999). The degree of apoptosis of circulating 
lymphocytes has been shown to predict outcome in patients with sepsis (Guisset et al. 2007). 
Another major characteristic of monocytes from septic patients is the decreased surface expression 
of human leukocyte antigen-DR (HLA-DR) (Lin et al. 1993), and low HLA-DR expression has also 
been associated with poor sepsis outcome (Fumeaux and Pugin 2006). Although cytokines are 
considered to be the culprits, they also have beneficial effects in infection and sepsis (Hotchkiss and 
Karl 2003). Highlighting the aspect that the sepsis syndrome is not purely a syndrome of extensive 
inflammatory reaction, studies in animal models and in humans have shown that blocking TNF-" 
may further jeopardize survival (Eskandari et al. 1992,  Fisher et al. 1996). Recent data indicate that 
the proinflammatory cytokine IL-17 increases neutrophil killing capacity and plays a critical role in 
host protection against sepsis (Freitas et al. 2009). 
In summary, recent sepsis research has revealed that increased apoptosis and resultant 
immunosuppression of immune effector cells may constitute the hallmark of sepsis. The 
contributors to this phenomenon have not been established. 
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2.2.4.2. Collectins and mannose-binding lectin (MBL) 
The collectins are a small family of glycoproteins (Hickling et al. 2004). They play an important 
role in innate immune system, recognizing and binding to microorganisms via complex sugar arrays 
on the microbial surface. Their function is to enhance adhesion and phagocytosis of microorganisms 
by agglutination and opsonization (Turner 1996,  Hickling et al. 2004). 
In the lung, two members of the collectin family, the surfactant proteins A and D (SP-A and SP-
D), are major protein constituents of surfactant. Another collectin, MBL, is also present in the upper 
respiratory tract and buccal cavity and may protect against infections (Hickling et al. 2004). The 
collectins involved in respiratory defence are MBL, SP-A and SP-D. The lectin domain of each 
collectin binds, with different affinities, to a range of monosaccharides (Hoppe and Reid 1994). 
MBL is produced in the liver and is most abundant
 
in the blood but is present in most body 
fluids, e.g., in the buccal
 
cavity and upper airway secretions, the saliva (Presanis et al. 2003). MBL 
serum levels can be extremely varied, ranging from 0 to
 
over 3 $g/ml in humans (Hickling et al. 
2004). MBL deficiency is common, affecting 5% or
 
more of the population (Super et al. 1989). 
Debat prevails as to whether MBL acts like an acute-phase protein responding to inflammation 
(Perez-Castellano et al. 2006,  Herpers et al. 2009). A recent study has shown that the acute-phase 
responsiveness of MBL is highly dependent upon the MBL2 genotype (Herpers et al. 2009). Serum 
levels of MBL have been shown to be independent of age and gender (Ytting et al. 2007). In healthy 
individuals, circulating levels of MBL have been found to be stable over time, not being affected by 
physical exercise (Ytting et al. 2007). As far back as 1977, a group of infants with recurrent 
pyogenic infections was described, whose
 
serum failed to opsonize Saccharomyces cerevisiae due 
to a defect in the complement system (Soothill and Harvey 1977).  
The complement system is an important mediator of immune responses
 
and contributes to many 
innate-immune system functions including
 
inflammation, opsonization, and pathogen lysis 
(Hickling et al. 2004). The system consists of more than
 
30 proteins, soluble in serum and bound to 
cell membranes, and can be activated via three pathways, (the classical complement pathway,
 
the 
lectin pathway, or the alternative pathway) upon recognition of PAMPs (Gasque 2004). MBL 
mediates activation of the complement system via the lectin pathway in association with ficolins, 
and mediates opsonophagocytosis directly, thereby constituting an import element in innate 
immunity (Turner and Hamvas 2000,  Turner 2003). MBL binds to a large variety of sugar moieties 
expressed by many different microorganisms, bacteria, viruses, protozoa and helminths through a 
pattern-recognition mode of detection and then initiates a range of host responses (Jack and Turner 
2003). Complement activation by MBL requires MBL-associated serine proteases (MASPs, Figure 
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2). Upon MBL binding to carbohydrate-bearing pathogens, MASP-2 is activated and cleaves the C4 
and C2 components of complement. The C4b2a complex, in turn, exerts C3 convertase activity, 
generating opsonic C3b fragments (Casanova and Abel 2004).  
The capacity of MBL to bind to different organisms has been shown to vary (Neth et al. 2000). 
S. aureus and some ß-haemolytic streptococci exhibit strong binding of MBL, while its pattern of 
binding to E.coli is intermediate (van Emmerik et al. 1994,  Neth et al. 2000), while Str. 
pneumoniae binds MBL rather weakly (Neth et al. 2000).  
 
 
Figure 2. Mannose-binding lectin (MBL)-mediated generation of opsonic complement C3b fragments. MASPs=MBL-
associated serine proteases, C= complement component. 
 
1. MBL binds to 
MASPs 
2. MBL+MASP-2 binding 
to sugar arrays of 
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activates complement 
system via lectin 
pathway 
3. C4b2a complement 
complex exerts C3 
convertase activity 
4. The 
generation of 
opsonic C3b 
fragments 
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2.3. Genetic factors affecting the risk and outcome of bacteraemia and 
sepsis 
The human genome is composed of approximately 3 billion base pairs, encompassing about 30 000 
genes. There are approximately 10 million common variations known as single nucleotide 
polymorphisms (SNPs) (Collins et al. 2003). Recent evidence has revealed that the vast majority of 
SNPs are not in coding regions of proteins (McVean et al. 2004). SNP is the most common type of 
stable genetic variation in the population (Brookes 1999). An SNP occurs in approximately 1 out of 
1000 base pairs, the most frequent being a C to T substitution (Brookes 1999). It has been estimated 
that 10% of all SNPs in the genome are functional, possessing thus the potential to alter some 
biological process (Wjst 2004). 
Given the link with pathogenesis, polymorphisms in genes involved in infection, inflammation, 
and coagulation may influence the risk of bacteraemia and the outcome of patients suffering from 
sepsis and septic shock (Lin and Albertson 2004). SNPs are thought to explain interindividual 
differences in susceptibility to infectious diseases as well as the clinical outcomes of infections 
(Arcaroli et al. 2005). New technologies in molecular biology provide the opportunity to study the 
genetic basis of susceptibility to these diseases.  
2.3.1. MBL2 polymorphisms 
MBL is encoded by the MBL2 gene in chromosome 10 (10q11.2-q21). MBL insufficiency is caused 
by SNPs in codons 52 (CGT-TGT, designated D, traditionally any of the variants have also been 
given the generic designation O allele), 54 (GGC-GAC; B or O), and 57 (GGA-GAA, C or O) in 
exon 1 of that gene, leading to amino acid substitutions Arg-Cys, Gly-Asp and Gly-Glu in the 
peptide, which interfere with the encoded protein, thereby lowering the blood levels of MBL, 
compromising ligand binding, and reducing complement activation (Larsen et al. 2004). Thus, the 
O allele denotes either a D, B or C variant allele, and the A allele denotes a wild-type allele. The 
designation AO denotes a variant allele (i.e. either D, B or C) in one chromosome pair, and a wild- 
type allele in the other), AA denotes homozygozity for a wild-type allele (wild-type allele in both 
chromosome pairs), and OO genotype denotes homozygozity for the variant allele (i.e. D, B or C in 
one chromosome pair and D, B or C in the other). Furthermore, the MBL concentration is highly 
dependent upon promoter region polymorphisms, of which that at position -221 (nucleotide change 
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G-C; alleles Y-X, respectively) are functionally the most important. Two other polymorphisms of 
the MBL2 gene are located in the promoter 1 (position -550, H/L variant) and in the 5`-untranslated 
region (position +4, P/Q variant) of the gene. Common variant alleles situated in both the promoter 
and the structural region of the human MBL2 gene influence the stability and the serum 
concentration of the protein. There is considerable diversity in the definition of MBL deficiency in 
different studies, and currently there is no standard for the condition based on a direct functional 
assessment of a human cohort or an experimental animal model. Various investigators have 
therefore used either MBL2 genotypes which typically produce low MBL levels and/or measured 
low serum MBL levels to define a deficiency state. Recently, MBL2 genotypes XA/O and O/O have 
been characterized as being the lowest MBL-producing genotypes in a reanalysis of a large cohort 
applying individual data from 4 studies (Eisen et al. 2008). There is marked diversity in MBL2 
genotype frequencies between ethnic groups; Asian (Japanese), Caucasian, Hispanic and African-
Americans differ from each other in terms of allele, genotype and haplotype distribution (Ivanova et 
al. 2008).                                                            
Several studies have suggested that a genetically determined variation in MBL serum 
concentration influences the susceptibility to and the course of different types of infections, but the 
issue is still a subject of debate (Table 2). Some authors even state that human MBL is largely 
redundant for protective immunity, as approximately 5% of individuals lack functional serum MBL 
and in prospective studies have not proved prone to severe infections (Casanova and Abel 2004). 
One experimental study in MBL-knockout mice (i.e. in mice devoid of all MBL activity) showed 
that all such mice die after exposure to an intravenous inoculation of S. aureus, whereas mice with 
normal MBL production have a mortality of 45% following similar exposure (Shi et al. 2004). 
Some evidence supports the conception of a dual role for MBL in some infections. There are data 
indicating that MBL2 mutations may have a beneficial impact on host defence in leprosy (Garred et 
al. 1994) and one paper indicates that heterozygosity of MBL2 genotypes predicts an advantage 
(heterosis) in relation to fatal outcome in intensive care patients (Hellemann et al. 2007).  
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Table 2. Studies on the MBL2 genotype and susceptibility to and outcome of infections. MBL= mannose-binding lectin, 
HIV= human immunodeficiency virus, SIRS= systemic inflammatory response syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author/Country Patients, N/Controls, N Design MBL 
genotypes 
studied 
Endpoint Significant association 
between MBL2 variant 
alleles and the endpoint 
(Yes/No) 
Garred 1995, 
Denmark 
(Garred et al. 
1995) 
228 patients suspected 
of various non-HIV-
related 
immunodeficiencies, 
123 controls 
case-control codons 52, 54 
and 57 
recurrent infections yes, but only homozygous 
genotype predisposed 
Summerfield 
1997, UK 
(Summerfield 
et al. 1997) 
617 children observational 
cohort 
codons 52, 54 
and 57 
infection as a 
cause of admission 
to hospital 
yes, both heterozygous and 
homozygous genotype 
predisposed  
Garred 1999, 
Denmark 
(Garred et al. 
1999) 
149 patients with cystic 
fibrosis, 250 healthy 
Danes 
case-control promoter -221, 
codons 52, 54 
and 57 
the risk of 
infections and 
infection-related 
deaths 
yes, associated with both 
endpoints 
Hibberd 1999,  
UK (Hibberd et 
al. 1999) 
children with 
meningococcal disease, 
hospital study (194 
patients, 110 controls) 
and community study 
(272 patients, 72 
controls)   
case-control codons 52, 54 
and 57 
the risk of 
meningococcal 
disease 
yes, homozygous genotype 
was associated with the 
endpoint 
Koch 2001, 
Greenland 
(Koch et al. 
2001) 
252 children <2 years prospective, 
population-
based cohort, 
a 2 year 
morbidity 
surveillance 
promoter -221, 
codons 52, 54 
and 57 
the risk of acute 
respiratory tract 
infections 
yes, the risk association 
was restricted to children 
aged 6 to 17 months (RR 
2.92) while less effect (RR 
1.47) and no effect (RR 
1.0) was shown among 
children aged 0 to 5 months 
and 18 to 23 months, 
respectively 
Neth 2001, UK 
(Neth et al. 
2001) 
100 children with 
malignancy 
prospective 
observational 
cohort study 
codons 52, 54 
and 57 
the duration of 
febrile neutropenic 
episodes  
yes, association with 
prolonged duration of 
febrile episodes 
Kronborg 2002, 
Denmark 
(Kronborg et 
al. 2002) 
141 patients with Str. 
pneumoniae 
bacteraemia, 250 
controls 
prospective 
case-control  
promoter -221, 
codons 52, 54 
and 57 
the risk of Str. 
pneumoniae 
bacteraemia and 
outcome 
no association with the 
endpoint  
Mullighan 
2002, Australia 
(Mullighan et 
al. 2002) 
97 related allogeneic 
donor-recipient pairs 
retrospective 
cohort 
promoter -221 
and -551, 
codons 52, 54 
and 57 
the risk of major 
infection 
yes, increased risk of major 
infections after 
transplantation 
Roy 2002, UK 
(Roy et al. 
2002),  
337 patients with 
invasive pneumococcal 
disease, 1032 controls 
case-control promoter -221, 
codons 52, 54 
and 57 
the risk of  invasive 
pneumococcal 
disease 
yes, but only homozygous 
MBL codon genotype 
predisposed 
Garred 2003, 
Denmark 
(Garred et al. 
2003) 
272 patients with SIRS prospective 
cohort study 
promoter -221 
and -551, 
codons 52, 54 
and 57 
the risk of sepsis, 
severe sepsis, 
septic shock and 
death 
yes, associated with all 
endpoint variables 
Dahl 2004, 
Denmark (Dahl 
et al. 2004) 
9245 individuals from 
the adult Danish 
population  
a 24 year 
prospective  
population-
based follow-
up 
codons 52, 54 
and 57 
the risk of 
infections 
no association with 
infection susceptibility or 
mortality  
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Table 2. continues from the previous page. ICU= intensive care unit, Allo-SCT= allogeneic stem cell transplantation, 
BSI= bloodstream infection. 
Author/Country Patients, 
N/Controls, N 
Design MBL genotypes 
studied 
Endpoint Significant association 
between MBL2  variant 
allele and the endpoint 
(Yes/No) 
Fidler 2004, UK 
(Fidler et al. 
2004) 
100 consecutive 
admissions to a 
pediatric ICU 
prospective 
observational cohort 
promoter -221, 
codons 52, 54 
and 57 
the risk of SIRS, 
sepsis and septic 
shock 
yes, codon variants were 
associated with all endpoint 
variables  
Horiuchi 2005, 
Japan 
(Horiuchi et al. 
2005) 
113 children 
with cancer 
receiving 
chemotherapy 
retrospective promoter -221 
and -551, 
codons 52, 54 
and 57 
the risk of major 
bacterial infections 
yes, OR 7.9 
Sutherland 
2005, Canada 
(Sutherland et 
al. 2005) 
252 critically ill 
Caucasians with 
SIRS 
cohort study promoter -221, 
codons 52, 54 
and 57 
the risk of positive 
bacterial cultures, 
sepsis and death 
yes, associated with 
increased risk of positive 
bacterial cultures. No 
association with sepsis, 
septic shock or death 
Eisen 2006, 
Australia 
(Eisen et al. 
2006) 
195 patients 
(166 patients 
with BSI:s, 35 
with 
pneumonia), 
236 controls 
case-control promoter -221 
and -551, 
codons 52, 54 
and 57 
the risk of BSI and 
septic shock 
yes, associated with both 
endpoints 
Gordon 2006, 
UK (Gordon et 
al. 2006) 
172 patients 
with severe 
sepsis or septic 
shock, 353 
controls 
prospective case-
control 
promoter -221, 
codons 52, 54 
and 57 
the risk of severe 
sepsis and septic 
shock 
yes, codon variants 
associated with the 
endpoints. No effect on 
survival 
Smithson 2007, 
Spain 
(Smithson et 
al. 2007) 
62 female 
patients with 
acute  E. coli 
pyelonephritis, 
133 healthy 
controls. 
case-control study promoter -550,  
-221 and +4, 
codons 52, 54, 
and 57  
the risk of E. coli 
bacteraemia and 
septic shock due to 
E. coli pyelonephritis 
predisposition to septic 
shock but not to bacteraemia  
Vekemans 
2007, Belgium 
(Vekemans et 
al. 2007) 
255 adult 
patients with 
cancer receiving 
chemotherapy 
prospective 
observational 
promoter -221, 
codons 52, 54 
and 57 
the risk of severe 
infections  
yes, associated with severe 
infections.  No predisposition 
to more-frequent or more-
prolonged febrile episodes.  
Eisen 2008 
(Eisen et al. 
2008) 
675 patients reanalysis of 6 
previous studies 
(Kronborg et al. 2002,  
Fidler et al. 2004,  
Sutherland et al. 
2005,  Eisen et al. 
2006,  Gordon et al. 
2006,  Perez-
Castellano et al. 
2006,  van Till et al. 
2008) 
promoter -221, 
codons 52, 54 
and 57 
the risk of death due 
to Streptococcus 
pneumoniae 
infection 
yes 
note: XA/O and O/O MBL2 
genotypes had the lowest 
median MBL concentrations 
Rantala 2008, 
Finland 
(Rantala et al. 
2008) 
111 young men 
with asthma, 
362 without 
asthma 
prospective 
observational 
promoter -221, 
+4 and -551, 
codons 52, 54 
and 57 
the risk of 
respiratory tract 
infections 
yes, association not 
dependent on asthma status 
Neth 2010, UK 
(Neth et al. 
2010) 
131 donor-
recipient Allo-
SCT-pairs 
prospective cohort 
study 
promoter -221, 
codons 52, 54 
and 57 
the risk of infections 
related to Allo-SCT 
yes, low MBL levels pre-
transplant predisposed to 
sepsis, fungal and viral 
infection. Donors' MBL 
genotypes had no influence 
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 Taken together, previous data indicate that MBL2 genotypes representing MBL deficiency increase 
the risk of infections and the risk of poor outcome mainly in specified patient groups, for example 
in children (Summerfield et al. 1997,  Hibberd et al. 1999,  Koch et al. 2001,  Fidler et al. 2004), in 
the presence of comorbid conditions (malignancies) (Mullighan et al. 2002,  Horiuchi et al. 2005,  
Vekemans et al. 2007), and in ICU patients (Garred et al. 2003,  Fidler et al. 2004,  Gordon et al. 
2006). Studies showing an effect on susceptibility or outcomes of infections in healthy adults are 
few in number (Roy et al. 2002,  Rantala et al. 2008).  
2.3.2. eNOS gene polymorphisms 
Endothelium-derived NO is formed from L-arginine by eNOS encoded by the NOS3 gene in 
chromosome 7q35-36 (Marsden et al. 1993). The NOS3 gene is highly polymorphic (Jones and 
Hingorani 2005). Of polymorphisms within the coding region, the eNOS gene polymorphism in 
exon 7 at position 894 (Glu298Asp; glutamic acid substituted by aspartic acid), also defined as 
G894T, resulting in the T allele, has been linked to the pathogenesis of hypertension (Miyamoto et 
al. 1998), coronary artery spasms (Yoshimura et al. 1998), acute myocardial infarction (Hibi et al. 
1998) and coronary heart disease (CHD) (Casas et al. 2006). However, the data are inconsistent  
regarding the association with hypertension (Kato et al. 1999,  Karvonen et al. 2002,  Pereira et al. 
2007) and CHD (Cai et al. 1999). In a Finnish cross-sectional case-control study the eNOS genotype 
was not associated with hypertension nor with hypertension-related cardiovascular complications 
(Karvonen et al. 2002). Recent data, again, indicate a role for the eNOS Glu298Asp polymorphism 
in the pathogenesis of erectile dysfunction (Lee et al. 2009) and ischaemic stroke (Tao and Chen 
2009).  
There has been debate as to whether the eNOS Glu298Asp polymorphism is functional (Jones 
and Hingorani 2005). However, evidence shows that this polymorphism generates protein products 
with differing susceptibility to cleavage, suggesting that it has a functional effect on the eNOS 
protein (Tesauro et al. 2000).  
Of other eNOS polymorphisms, the eNOS 4a/b (intron 4) polymorphism and a T-786C 
(promoter region) polymorphism in the 5´-flanking region ot the eNOS gene have been associated 
with CHD (Casas et al. 2006). The data regarding the role of eNOS 4a/b (intron 4) polymorphism 
and a T-786C (promoter region) polymorphims in the pathogenesis of ischaemic stroke remain 
controversial (Casas et al. 2006). According to one meta-analysis studying eNOS gene 
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polymorphisms in the context of vascular diseases, there would appear to be a need for large-scale 
genetic association studies to confirm or refute the claim of a role of the eNOS gene in CHD and in 
other vascular diseases (Casas et al. 2006). 
 In non-septic state carriage of the T allele of eNOS gene has been linked to reduced basal NO 
production (Veldman et al. 2002) and blunted endothelial-dependent vasodilatation in healthy 
volunteers (Godfrey et al. 2007). In addition, mice lacking the eNOS gene have been shown to 
become hypertensive (Huang et al. 1995). Although NO plays a key role in the pathogenesis of 
sepsis and an essential role for eNOS has also been indicated, there are no data regarding the role of 
the eNOS G894T polymorphism in either bacteraemia or sepsis. 
2.3.3. Cytokine and innate immune receptor polymorphisms  
Several studies have investigated the role of cytokine, innate receptor and related molecule SNPs in 
infectious diseases. A summary of relevant studies is given in Table 3. 
 
 
 
37 
  
  
 
Table 3. Summary of the most common single nucleotide polymorphisms (SNPs) involving cytokines, innate immune 
receptors and related molecules in relation to susceptibility to and outcome of sepsis. TLR= Toll-like receptor, CD= 
cluster of differentiation, IRAK=interleukin-1 receptor-associated kinase, NOD=nucleotide-binding oligodimerization 
domain, MASP= mannose-binding lectin-associated serine protease, ICU= intensive care unit, TNF= tumour necrosis 
factor, IL= interleukin, PAI=plasminogen activator inhibitor. 
Gene Polymorphism Results in different studies reporting the effect of given polymorphism 
Arg753Gln  
 
Increased risk of life-threatening infections caused by gram-positive organism (Lorenz et al. 2000) TLR2 
T-16933A Increased risk of sepsis caused by gram-positive organism, no effect on outcome (Sutherland et al. 
2005) 
Asp299Gly Increased risk of infections (Agnese et al. 2002) and septic shock (Lorenz et al. 2002) caused by 
gram-negative bacteria 
TLR4 
Thr399Ile Increased risk of infections (Agnese et al. 2002) and septic shock caused by gram-negative bacteria 
(Lorenz et al. 2002) 
CD14 C-159T No association with the risk of sepsis or mortality (Hubacek et al. 2000) 
Increased risk of septic shock and mortality (Gibot et al. 2002) 
No association with the risk of infections caused by gram-negative organism or outcome (Agnese et 
al. 2002) 
Increased prevalence of positive bacterial cultures and sepsis but no effect on outcome (Sutherland 
et al. 2005) 
IRAK4 821delT 
Q293X 
Increased risk of infections caused by pyogenic bacteria in children (Picard et al. 2003) 
NOD2 NOD2 variant Increased risk of bacteraemia  (Henckaerts et al. 2009) 
MASP2 D120G/V377A Increased risk of death in ICU patients (Henckaerts et al. 2009) 
TNF-
alpha 
G308A No association with incidence or outcome of severe sepsis (Stuber et al. 1995) 
Increased risk of septic shock and death (Mira et al. 1999) 
Increased risk of surgical infection with sepsis and increased mortality rate due to septic shock in 
these patients (Tang et al. 2000) 
No association with susceptibility to sepsis, disease severity or outcome (Gordon et al. 2004). 
Increased risk of severe sepsis after burn injury (Barber et al. 2006) 
Associated with susceptibility to meningococcal sepsis, but not with mortality (Read et al. 2009). 
IL-6 G174C No association with incidence, but GG genotype protective of death in severe sepsis (Schluter et al. 
2002) 
Increased risk of severe sepsis after burn injury (Barber et al. 2006) 
Increased risk of sepsis and increased severity of sepsis in children (Michalek et al. 2007). 
 G572C G allele associated with increased risk of sepsis in children, no association with severity of disease 
(Michalek et al. 2007) 
C allele associated with increased risk of sepsis in trauma patients  (Gu et al. 2008) 
 
IL-1ß -511 Increased risk of death in meningococcal disease (Read et al. 2000) 
No association with susceptibility to sepsis. Increased mortality in septic patients (Ma et al. 2002) 
No association with outcome of gram-negative sepsis (Jessen et al. 2007) 
IL-1! 46 bp VNTR 
(intron 6) 
No association with susceptibility to sepsis. Increased mortality in septic patients (Ma et al. 2002) 
IL-1ra 86 bp VNTR 
(intron 2) 
Increased risk of sepsis and mortality (Fang et al. 1999,  Ma et al. 2002) 
Increased mortality in sepsis (Arnalich et al. 2002) 
PAI-1 4G/5G  No association with the risk of meningococcal infection, but increases the risk of septic shock 
(Westendorp et al. 1999) 
Increased risk of death in meningococcal disease (Hermans et al. 1999) 
No association with outcome of sepsis (Jessen et al. 2007) 
Increased risk of death in septic shock (Garcia-Segarra et al. 2007) 
IL-10 C592A Increased mortality in sepsis (Lowe et al. 2003) 
 -1082 No association with sepsis or mortality (Lowe et al. 2003) 
G allele associated with increased risk of septic shock in pneumococcal disease (Schaaf et al. 2003) 
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2.4. Host characteristics and underlying diseases affecting the risk and 
outcome of bacteraemia and sepsis 
The incidence of infectious episodes is clearly increased in many underlying chronic disorders 
leading to immunosuppression, including haematologic malignancies (Bodey et al. 1966), 
neoplasms (Angus et al. 2001,  Anatoliotaki et al. 2004), and diabetes mellitus-related organ 
damage (Dhainaut et al. 2005). Immunosuppressive therapy has been clearly associated with 
increased infection rates, and the risk of developing infections increases with the degree and 
duration of granulocytopenia (Bodey et al. 1966).  
Several factors (Table 1) have been shown to be associated with an increased risk of 
bacteraemia and sepsis, for example male sex and an ultimately or rapidly fatal underlying disease 
(Angus et al. 2001,  Martin et al. 2003,  Ortega et al. 2007), black race (Martin et al. 2003), and 
extremes of age (Martin et al. 2003). Liver disease (Foreman et al. 2003), HIV infection (Witt et al. 
1987), cancer (Williams et al. 2004) and therapeutic interventions such as in-dwelling catheters 
(Groeger et al. 1993) and red cell transfusions (Raghavan and Marik 2005) have likewise been 
associated with increased sepsis rates. Urban residence, haemodialysis, diabetes mellitus, cancer 
and lung disease have been shown to constitute risk factors for the acquisition of severe 
bloodstream infection (Laupland et al. 2004). 
Regarding various causative agents, the risk of developing invasive pneumococcal disease is 
higher in persons with certain underlying medical conditions (HIV/AIDS, asplenia, haematological 
or solid cancer, chronic lung disease, chronic heart disease, diabetes) (Kyaw et al. 2005,  Klemets et 
al. 2008b), who are of low socioeconomic status or who engage in high-risk behaviours such as 
smoking and alcohol abuse (Pastor et al. 1998,  Nuorti et al. 2000,  Robinson et al. 2001). In 
different age groups, the incidence of invasive pneumococcal disease is highest among children 
younger than 2 years and adults aged 65 years or more (Robinson et al. 2001,  Klemets et al. 
2008b). The incidence among blacks is higher than among whites (Robinson et al. 2001,  Kyaw et 
al. 2005). Nasal carriage of S. aureus is an important risk factor for staphylococcal nosocomial and 
surgical site infections (Wertheim et al. 2004). Dialysis, organ transplantation, invasive surgery, 
increased use of intravascular devices, HIV infection, cancer and diabetes are important risk factors 
for S. aureus bacteraemia (Fowler et al. 2005,  Laupland et al. 2008b). Invasive group B 
streptococcal (GBS) disease is a significant cause of death in neonates and a significant cause of 
morbidity and mortality among pregnant women (Schrag et al. 2000). In nonpregnant adults 
invasive GBS disease represents a substantial and increasing burden, particularly among older 
persons, black persons (compared to white), and adults with diabetes (Skoff et al. 2009). The 
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incidence of invasive group A streptococcal disease (GAS), in turn, is high among elderly persons, 
infants and black persons (O'Loughlin et al. 2007). Disruption of the cutaneous barrier is a common 
predisposing factor in GAS and GGS bacteraemias (Rantala et al. 2009a). Risk factors for E. coli 
bacteraemia include low or high age, female sex, dialysis, solid organ transplantation and neoplastic 
disease (Laupland et al. 2008a). 
Ultimately or rapidly fatal diseases (Brun-Buisson et al. 1995), absence of fever at the onset of 
bacteraemia and incorrect empirical antibiotic therapy have been shown to constitute risk factors for 
mortality in bacteraemia (Laupland et al. 2004,  Ortega et al. 2007). Liver cirrhosis, chronic heart 
failure and chronic severe renal failure have also been identified as prognostic factors in patients 
with sepsis (Alberti et al. 2003). Age is a risk factor for severe sepsis; the incidence increases 
sharply after 60 years (Angus et al. 2001). Several studies have suggested that men are more 
susceptible to infections (Klein 2000,  Laupland et al. 2004), and once infection sets in, they are 
more likely to die (Schroder et al. 1998,  Angus et al. 2001). 
Factors associated with poor outcome in bacteraemia vary between different organisms. In S. 
aureus bacteraemia, age > 60 years (Mylotte and Tayara 2000), noneradicable or noneradicated 
foci, underlying cirrhosis and cancer have been found to be independent predictors of mortality 
(Kim et al. 2003). Although the mortality rate in MRSA infections has been shown to be greater 
than in MSSA infections (Cosgrove et al. 2003,  Laupland et al. 2008b) and despite the fact that 
appropriate therapy is essential in treating sepsis, the real impact of resistance on the outcome of 
patients has remained somewhat controversial (Cosgrove et al. 2003,  Kim et al. 2003,  Figueiredo 
Costa 2008). In E. coli bacteraemia, increasing age, ciprofloxacin resistance, non-urinary focus and 
a number of comorbid illnesses are factors independently associated with an increased risk of death 
(Laupland et al. 2008a). Ultimately or rapidly fatal underlying diseases have been associated with 
increased case-fatality in ß-haemolytic streptococcal bacteraemia (Rantala et al. 2009b).  
2.4.1. Body mass index (BMI)  
Obesity has reached epidemic proportions over the last few decades. The prevalence of obesity in 
Finland is 24% in men and 28% in women (Saaristo et al. 2008). The Centers for Disease Control 
and Prevention (CDC) defines a BMI of 25-29 as overweight and a BMI #30 as obese (CDC 2010). 
Obesity is associated with increased morbidity and mortality in hypertension, stroke, cardiovascular 
diseases and cancer and is feared to lower the overall life expectancy over the next decades.   
Obesity is a predisposing factor for the acquisition of certain types of infections (Falagas and 
Kompoti 2006,  Falagas et al. 2009), surgical infections in particular (Bamgbade et al. 2007). 
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Obesity constitutes a risk factor for infection in critically ill patients (Bochicchio et al. 2006), and a 
risk factor for erysipelas (Karppelin et al. 2009) and community acquired pneumonia (Baik et al. 
2000). The underweight state may also in fact constitute a risk factor in this context (Loeb and High 
2005), through the alteration of specific immunologic mechanisms such as decreased lymphocyte 
count and function, decreased macrophage activation, and decreased phagocytosis and cytokine 
secretion (Solomons 2007,  Falagas et al. 2009).  
It has not been satisfactorily established whether obesity constitutes a risk factor for adverse  
outcome in patients with infectious diseases (Falagas and Kompoti 2006,  Falagas et al. 2009). Only 
a few studies have systematically evaluated the impact of obesity on the outcome of infectious 
diseases, and they have yielded controversial results (Kalfarentzos et al. 1987,  Carratala et al. 2003,  
Bochicchio et al. 2004,  Smith et al. 2007). There are also reports to indicate that low BMI is 
independently associated with higher case fatality (Tremblay and Bandi 2003,  Garrouste-Orgeas et 
al. 2004).  
The mechanisms of immune responses to pathogens in different body-weight categories have 
not been well established in humans (Falagas et al. 2009). Obesity is associated with multiple 
comorbidities and physiologic derangements (e.g. insulin resistance, pro-inflammatory state), 
pharmacologic alterations and physical limitations which may potentially complicate acute illness 
and impede the implementation and efficacy of evidence-based treatment strategies (Ebert et al. 
2006,  Hogue et al. 2009) in patients with infectious diseases.  
In summary, the data regarding the outcome of severe infections in obese patients are sparse. 
The mechanisms implicated in infection outcome in obese patients have not been adequately 
established. 
2.4.2. Smoking  
Cigarette smoking is one of the main preventable causes of death and disability. Although the 
prevalence of smoking has declined in the past 35 years, nonetheless 30% of Finns smoked in  2007 
(26-31% of males and 18-25% of females) (Vartiainen et al. 2009). Smokers are at increased risk of 
bacterial infections such as invasive pneumococcal disease (Pastor et al. 1998,  Nuorti et al. 2000), 
community-acquired pneumonia (Baik et al. 2000), periodontitis (Obeid and Bercy 2000), 
meningococcal disease (Fischer et al. 1997) and bacterial meningitis (Gold 1999). The risk of 
invasive pneumococcal disease has been shown to be increased 2- to 4-fold in smokers compared to 
non-smokers (Pastor et al. 1998).  
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Smoking has substantial effects on the immune system, affecting both innate and adaptive 
immunity (Sopori 2002). Tobacco smoke is a complex mixture of more than 4500 chemicals, many 
of which have toxic properties (Sopori 2002). It compromises the anti-bacterial function of 
leukocytes, including neutrophils, monocytes, T cells and B cells (Green and Carolin 1967,  
Stringer et al. 2007), providing a mechanistic explanation for the increased infection risk. Of 
specific compounds of smoke, acrorein, a toxic unsaturated aldehyde, affects neutrophil function 
and reduces the resistance of the lungs to infections (Li and Holian 1998), and nicotine has been 
shown to induce a significant loss of antibody responses and T-cell proliferation (Sopori 2002). It 
has been shown that the flora of smokers contains fewer normal flora bacteria and more potential 
pathogens compared with that of non-smokers (Brook and Gober 2005). Animal models of 
infection have shown that cigarette smoke affects respiratory immune-inflammatory responses and 
causes a delayed rate of bacterial clearance (Drannik et al. 2004). Active smoking has been 
associated with meningococcal carriage (Stuart et al. 1989) and smokers are more densely colonized 
by a variety of potentially pathogenic bacteria in buccal epithelial cells (El Ahmer et al. 1999). 
Alveolar macrophages (AMs) from smokers have a reduced ability to phagocytose and/or kill 
bacteria such as S. aureus and Listeria monocytogenes (King et al. 1988). Moreover, previous 
studies indicate that AMs from smokers are functionally impaired and secrete significantly lower 
levels of proinflammatory cytokines (McCrea et al. 1994). These cytokines are crucial for early 
responses to potential pathogens and upregulation of local host defence mechanisms (Kishimoto 
1989). As regards the adaptive immune system, long-term smoking significantly reduces serum 
levels of immunoglobulins in humans (Ferson et al. 1979). Data regarding the outcome of infections 
in smokers are, however, limited (Pittet et al. 1993,  Laurichesse et al. 2001,  Arvanitidou et al. 
2005,  Garau et al. 2008,  Leithead et al. 2008). 
In summary, smoking has been shown to predispose to invasive bacterial infections and to have 
substantial effects on the immune system, affecting both innate and adaptive immunity. However, 
the factors contributing to increased infection susceptibility in smokers are not clear and the 
possible interaction between smoking and genes regulating innate immunity responses has not 
hitherto been studied. 
2.4.3. Alcohol abuse  
A recent nationally representative sample of Finns showed that the prevalence of hazardous alcohol 
drinking (defined as 24 drinks/week in males, and 16 drinks/week in females) was 5.8%. Hazardous 
drinking was more prevalent among males than females (8.5% vs. 3.1%) (Halme et al. 2008). 
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Alcohol abuse has been shown to have adverse effects on the immune system, for example 
alterations in neutrophil and macrophage function and abnormalities in ciliary and surfactant 
function in the lung (Pavia et al. 2004,  Moss 2005). Many of its effects on the innate immune 
response are dose-dependent, with acute or moderate use associated with attenuated inflammatory 
responses, and heavy ethanol consumption linked with augmentation of inflammation (Goral et al. 
2008). Furthermore, alcohol abuse may be associated with an increased risk of aspiration, poor 
dental hygiene, malnutrition, suppresson of the normal cough reflex, with the physical proximity to 
other infected people increasing the risk of infectious diseases (Moss 2005). 
Alcohol abuse has been shown to be a significant risk factor for invasive pneumococcal disease 
(Burman et al. 1985), pneumonia (Fernandez-Sola et al. 1995) and severe bloodstream infections 
(Laupland et al. 2004). Alcoholism has been shown to be associated with the incidence of sepsis in 
ICU patients (O'Brien et al. 2007).  
Several studies suggest that alcohol abuse predisposes to increased severity of infections in 
subjects with established pneumonia (Fernandez-Sola et al. 1995,  Ruiz et al. 1999,  Foreman et al. 
2003) and sepsis (Moss et al. 2003,  O'Brien et al. 2007). Some findings would indicate that 
alcoholism is a significant risk factor for case fatality in bacteraemia (Ortqvist et al. 1988,  Kaech et 
al. 2006,  Rantala et al. 2009b), but not all studies have confirmed this (Pittet et al. 1993, Lääveri et 
al. 1996, Laupland et al. 2004, Arvanitidou et al. 2005). 
2.5. Indoleamine 2,3 dioxygenase enzyme (IDO)  
IDO is expressed in a variety of cells, including antigen-presenting cells such as monocyte-derived 
macrophages and dendritic cells, and is preferentially induced by Th1-type cytokine interferon-% 
(IFN-%) (Mellor and Munn 2004). Other cytokines and LPS are also capable of inducing IDO 
(Mellor and Munn 2004). IDO catalyzes the degradation of the essential amino acid tryptophan to 
kynurenine and its derivatives, thereby limiting its availability. Tryptophan in plasma originates 
both from dietary sources (particularly plentiful in milk, meat, fish, chocolate) (Peters 1991), but is 
also released by protein turnover (Brown 1996). Tryptophan catabolism has long been known to be 
operative in antimicrobial defence; since tryptophan is required for protein synthesis, withdrawal of 
this essential amino acid from the micro-environment arrests this process, with a subsequent growth 
of pathogens and proliferating cells (Mellor and Munn 2004,  Schrocksnadel et al. 2006). However, 
the biological efficacy of IDO in controlling infections in vivo has remained unclear (Mellor and 
Munn 2004). 
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A decreased tryptophan concentration and increased concentrations of kynurenine have been 
described in various clinical entities, for example infection, autoimmune syndromes, malignancies, 
neurodegenerative disorders and pregnancy (Schrocksnadel et al. 2006). Recently, IDO has been 
shown to play a role in the process of immune evasion by tumours (Munn and Mellor 2007) by 
IDO-mediated depletion of tryptophan levels and production of toxic metabolites, resulting in 
suppression of T cell activation and induction of T cell apoptosis. The overexpression of IDO has 
been associated with disease progression in cancer (Brody et al. 2009,  Curti et al. 2009, Suzuki et 
al. 2010), and rheumatoid arthritis (Schroecksnadel et al. 2006), and in Alzheimer’s disease 
(Widner et al. 2000). The overexpression of IDO by tumour cells, as well as in the dendritic cells 
that located in the tumour-draining lymph nodes, has been shown to be an independent prognostic 
variable for reduced survival in patients with melanoma, lung cancer and haematologic 
malignancies (Brody et al. 2009,  Curti et al. 2009, Suzuki et al. 2010). Tryptophan degradation has 
been shown to be enhanced in patients with Sjögren`s syndrome (Pertovaara et al. 2005) and recent 
data indicate a role for it in the immunoregulation of atherosclerosis (Pertovaara et al. 2007). 
In the context of infectious diseases, increased tryptophan degradation has been previously 
documented in patients with HIV infection (Fuchs et al. 1990) and the overexpression of IDO has 
also been linked with disease progression and complications such as weight loss and 
neuropsychiatric disorders (Schroecksnadel et al. 2007). Furthermore, antiretroviral therapy 
significantly reduces tryptophan degradation (Fuchs et al. 1990). Enhanced degradation of 
tryptophan has been found in patients with neuroborreliosis (Gasse et al. 1994) and in chronic active 
Epstein-Barr virus infection-associated fatigue syndrome (Bellmann-Weiler et al. 2008). 
Upregulation of IDO in chronic hepatitis C virus infection has been documented (Larrea et al. 
2007). In the case of bacterial infections, recent studies in trauma patients indicate that tryptophan 
degradation may be associated with the development of sepsis (Pellegrin et al. 2005,  Logters et al. 
2009,  Ploder et al. 2009), and findings in one small study were suggestive of an association 
between highly increased tryptophan degradation and the severity of Streptococcus pyogenes 
infection (Murr et al. 2001). Recent data indicate that IDO expression during influenza virus 
infection alters the inflammatory response and facilitates the outgrowth of pneumococci during 
secondary bacterial pneumonia (van der Sluijs et al. 2006), suggesting that IDO-mediated pathways 
may contribute to susceptibility to acquire infection. 
IDO induces inhibition of T cell proliferation (Hwu et al. 2000) and may thus contribute to the 
pathophysiology of immunodeficiency. On the other hand, IDO may serve as a natural 
immunoregulatory mechanism. For example, it prevents rejection of the foetus during pregnancy 
(Munn et al. 1998). IDO has been shown to be operative in T cell tolerance to tumours (Mellor et al. 
 44 
2002), and may contribute to the regulation of T cell activity in some autoimmune disorders such as 
multiple sclerosis (Sakurai et al. 2002). Although the mechanism of T cell suppression has been 
shown to be mediated by a shortage of tryptophan, toxic catabolites may also play a role (Mellor et 
al. 2002,  Terness et al. 2002). IDO activity in human serum can be measured by determining the 
ratio of kynurenine to tryptophan (i.e. the first metabolite to substrate). This ratio is regarded as a 
more reliable marker of IDO-induced tryptophan catabolism than the serum tryptophan 
concentration alone, which may be influenced by dietary intake of the essential amino acid 
(Schrocksnadel et al. 2006). 
Under normal conditions, the kynurenine concentration is related to the tryptophan level. 
However, reduced dietary intake of tryptophan lowers tryptophan levels without an effect on 
kynurenine and kyn/trp levels (Schrocksnadel et al. 2006). Enhanced tryptophan degradation may 
result from the activation of either IDO or the hepatic tryptophan 2,3 dioxygenase (TDO) enzyme. 
TDO is known to regulate homeostatic serum tryptophan concentrations and IDO is up-regulated in 
response to inflammatory conditions (Schrocksnadel et al. 2006). 
Recently an increased body of new data has shown that IDO serves more than one function in 
the immune system (Mellor and Munn 2004,  Jung et al. 2009). Its precise role in different disease 
processes remains nonetheless largely unknown. In particular, it is not clear whether it is beneficial 
or detrimental to the host. The precise role of IDO activity in bacteraemia patients is likewise 
unclear, and the utility of IDO measurement as a marker of prognosis in infectious diseases has not 
previously been studied. 
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3. AIMS OF THE STUDY 
The aims of the present study were to establish: 
 
 
 
1. the role of MBL2 gene polymorphisms in the promoter region (position -221) and in the structural 
region (codons 52, 54 and 57) in susceptibility to or outcome of bacteraemia 
 
2. the impact of eNOS gene polymorphism at position 894 (G>T, Glu298Asp) on the disease 
severity or case fatality in bacteraemia patients 
 
3. the impact of host characteristics and underlying diseases on the outcome of bacteraemia 
 
4. the role of the kynurenine to tryptophan ratio, reflecting IDO activity, in predicting disease 
severity and case fatality in bacteraemic patients 
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4. SUBJECTS AND METHODS 
4.1. Subjects (studies I-IV) 
4.1.1. Patients 
Studies I-IV were carried out in Tampere University Hospital and in the Medical School, 
University of Tampere. All patients were treated in Tampere University Hospital. The study 
material comprised 149 Caucasian patients with bacteraemia hospitalized in Tampere University 
Hospital, Tampere, Finland, from June 1999 to February 2004. The cohort comprised 79 male and 
70 female patients with bacteraemia. Their ages ranged from 16 to 93 year (mean 59 years).  
In Tampere University Hospital blood cultures are routinely taken from patients with symptoms 
or signs of systemic infection (fever or hypothermia, tachycardia or tachypnea combined with 
leukocytosis or leukopenia and/or elevated C-reactive protein (CRP)). Patients were identified 
according to microbiological blood culture findings and all participants suffered from blood culture-
confirmed bacteraemia caused by Staphylococcus aureus (S. aureus), Streptococcus pneumoniae 
(Str. pneumoniae), ß-haemolytic streptococcae (ß-hml.str.), and Escherichia coli (E. coli). 
According to the study plan other microbes were excluded beforehand. Blood culture-negative 
patients with or without sepsis syndrome and those not consenting were not included. Patients at 
least 16 years of age were enrolled. The clinicians were informed by the clinical microbiologist of a 
positive blood culture and the patients were thereafter enrolled for the study. The day on which the 
positive blood culture was drawn was designated as day 0 (diagnosis day). The clinicians (J.S. or 
J.L.) were informed by the clinical microbiologist (R.V.) of a positive blood culture from Mondays 
to Thursdays and the patients were enrolled whenever possible to adjust to the daily schedule. Thus, 
zero to two patients per week during the study period were recruited. Clinicians were not able to 
obtain details on the patients prior to recruitment. After being informed by the clinical 
microbiologist the clinician asked patients to participate and interviewed and examined those 
consenting. Information was also gathered also from hospital records at the time of the hospital visit 
and hospital records were also reviewed after hospitalization. Patients with polymicrobial 
bacteraemia were not included in the study. Altogether 149 out of 152 invited patients were deemed 
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suitable for the study and agreed to participate (i.e. 3 patients did not agree consent). Bacteraemia 
was defined as hospital-acquired (nosocomial) if blood culture was drawn >48h after admission. 
During the period in question the BACTEC 9240 (BD Diagnostic Systems, Sparks, MD, USA) 
blood culture system with standard media was used. All patients were treated with an empiric 
antibiotic regimen and antimicrobial treatment was changed according to culture results if 
necessary.  
4.1.2. Host predisposing factors 
Underlying diseases, social status and alcohol and tobacco consumption were registered. Alcohol 
abuse was defined as consumption of #300g absolute alcohol per week or a known social or 
medical problem due to alcohol use. Smoking habits were registered and patients were defined as 
current smokers, ex-smokers, i.e. those who have stopped smoking, and non-smokers, i.e. those 
who have never smoked. Calculation of BMI (kg/m
2
) was based on weight and heigth as reported 
by the patient on recruitment. BMI was recorded and patients were defined as obese if their BMI 
was #30. Chronic diseases were registered and the McCabe (and Jackson) classification was used to 
assess the severity of the underlying medical condition (McCabe 1962). Preceding corticosteroid 
treatment was registered if corticosteroids (prednisone equivalent) were used in a dose of over 5 mg 
per day during 1 month before the bacteraemia episode. Neutropenic patients with cancer were not 
excluded from the study. 
4.1.3. Patient monitoring and laboratory tests 
Clinical data were registered on the day of blood culture (day 0) and during 6 consecutive days and 
on day 10-14 after blood culture (Table 4). After patient recruitment, the collection of patient 
clinical and laboratory data was prospective. Patients were closely monitored during hospitalization 
and severely ill subjects were transferred to the ICU. The possible need for mechanical ventilation 
was registered. Body temperature (ºC) was measured by tympanic thermometer. Alterations in 
mental status were evaluated on the Glasgow coma scale (GCS). Mean arterial pressure (MAP) 
((systolic+2 x diastolic blood pressure)/3) was calculated. A patient was classified as hypotensive if 
the MAP was <70mmHg during the bacteraemia episode. In study II, the lowest MAP was 
calculated for every patient on day 0 (the day of blood culture), during days 1-4 (one to four days 
after culture), or during days 5-6 (five to six days after culture). The need for vasopressive support 
was also recorded.  A SOFA score (Vincent et al. 1996) was calculated. The SOFA score recorded 
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1-3 days after blood culture was used in study III. The maximum SOFA score during days 0 to 6 
after blood culture was used in analysis in studies I-II and in study IV. Severe organ failure was 
documented if the score was #4. The laboratory tests conducted included plasma levels of C-
reactive protein (CRP) (mg/l), bilirubin ($mol/l), creatinine ($mol/l), albumin (g/l) and alanine 
aminotransferase (U/l). Other laboratory tests included capillary blood pH, blood white cell count 
(x10
9
/l) and blood platelets (x10
9
/l).  
 
Table 4. Timepoints for the recording of essential clinical and laboratory parameters in 149 patients with bacteraemia. 
MAP= mean arterial pressure, SOFA= sequential organ failure assessment, ICU= intensive care unit, CRP= C-reactive 
protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aMAP available on day 0: 139 patients, day 1: 124 patients, day 2: 120 patients, day 3: 119 patients, day 4: 114 patients, day 5: 87 
patients, day 6: 46 patients. Available median 5 blood pressure measurements/patient/separate measurement days during days 0 to 
6 after blood culture. In the case of a multiple MAP measurements/day (i.e. ICU patients), the lowest MAP of the single day was 
used in analysis. 
bAvailable median 3 SOFA measurements/patient/separate measurement days during the period of 0 to 6 days after blood culture. 
cAvailable median 6 CRP measurements/patient, 5 creatinine, leukocyte, and platelet measurements/patient, and 3 bilirubin 
measurements/patient during the period of 0 to 6 days after blood culture. 
dNeutrophil count available for 124 patients, albumin concentration available for 139, alanine transferase available for 143, and 
capillary blood pH available for 129 patients  
 
 
Parameter 
The timepoint of measurement/evaluation (days after blood 
culture).  
Clinical data  
 MAP (mmHg) On blood culture day, during days 1-6a 
 SOFA score  During days 0-6b 
 The need for vasopressive support During days 0-6 
 Case fatality  During days 0-14, during days 0-30 
 
The need for mechanical ventilation, the 
need for ICU treatment During days 0-14 
Laboratory tests  
 
Plasma CRP (mg/l), creatinine (!mol/l), and 
bilirubin  (!mol/l). Blood leucocytes (x109/l) 
and platelets (x109/l) 
 
On blood culture day, during days 1-6c 
 
 
Blood neutrophil count (x109/l), plasma 
albumin (g/l) and alanine transferase (U/l), 
capillary blood pH (c-astrup) 
 
One measurement/patient during days 1-6d 
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4.1.4. Controls (Study I) 
In study I, the control group comprised 400 adult Caucasian persons (151 male and 249 female) 
aged 60 years (mean, range 31-89), initially recruited from the normal population for an asthma 
study; only asthma and chronic obstructive pulmonary disease had been excluded (Karjalainen et al. 
2002). 
4.2. Methods 
4.2.1. MBL2 genotyping 
In study I MBL2 genetic polymorphism testing was carried out in 145/149 of the bacteraemia 
patients. Genotyping was done after hospitalization, using frozen whole blood samples taken in 
hospital. Exon 1 of the MBL2 structural gene was amplified by polymerase chain reaction (PCR) 
(Madsen et al. 1994). Genotyping of codon 52 (CGT!TGT; designated D, traditionally any of the 
variants have also been given the generic designation O allele), 54 (GGC!GAC; B or O) and 57 
(GGA!GAA; C or O) polymorphisms was performed by sequencing. Structural alleles lacking 
these SNPs were classified as wild-type (A). For genotyping of promoter region polymorphism at 
position -221 bp (G!C, designated Y or X alleles, respectively) commercially available 
fluorogenic allele-specific TaqMan probes and primers were used (rs7096206; Applied Biosystems, 
Foster City, CA, USA). Genotyping was done by means of the 5' nuclease assay for allelic 
discrimination using the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA). 
4.2.2. eNOS genotyping 
In study II eNOS genetic polymorphism testing was carried out in 147/149 patients with 
bacteraemia. Genotyping was done after hospitalization, using frozen whole blood samples taken in 
hospital. Genomic deoxyribonucleic acid (DNA) was extracted from whole blood using a 
commercially available kit (Qiagen Inc., Hilden, Germany) in accordance with the manufacturer’s 
instructions. DNA samples were genotyped employing the 5´nuclease assay in combination with 
specific fluorogenic TaqMan MGB probes, using the ABI Prism 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). The nucleotide sequences of primers and allele-
specific probes, labelled with reporter dyes, were deduced from sequences deposited in the 
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GenBank database and synthesized in conjugation with Applied Biosystems using the Assays-by-
Design tool. PCR reaction tests containing genomic DNA, 1x Universal PCR Master Mix, 900 nM 
of each primer and 200 nM of each probe, were performed in 96-well plates in a total volume of 25 
uL, in accordance with the standard protocol. The endpoint fluorescence reading was measured 
using the allelic discrimination analysis module, this resulting in clear identification of three 
genotypes. 
4.2.3. Tryptophan and kynurenine determinations 
The samples for tryptophan and kynurenine determination were taken during hospitalization. 
Samples were available for 132 patients on days 1-4 after blood culture. The serum samples were 
stored at -70º until analyzed. Tryptophan (mmol/l) and kynurenine ($mol/l) concentrations in 
peripheral blood were measured by HPLC as previously described (Laich et al. 2002). Tryptophan 
was separated with a Shimadzu liquid chromatograph LC-10AD VP (Shimadzu Co, Kyoto, Japan) 
using a 50-mm BDS Hypersil C18 5 $m column (Thermo Electron Co, Bellefonte, PA, USA). It 
was monitored by fluorescence with a Shimadzu RF-10A XL detector at 266 nm excitation and 366 
nm emission wavelengths. Kynurenine was separated with a Hewlett Packard 1100 liquid 
chromatograph (Palo Alto, CA, USA) using a Merck LiChroCart 55–4150 mm cartridge containing 
a Purospher STAR RP-18 3 $m column (Merck Co, Darmstadt, Germany). It was determined by 
ultraviolet absorption at a wavelength of 360 nm with a Hewlett Packard G13144 detector. The 
kyn/trp ($mol/mmol) ratio was calculated by relating concentrations of kynurenine (kyn) ($mol/l) 
to tryptophan (trp) (mmol/l), this allowing estimation of IDO activity.  
Samples for tryptophan and kynurenine determinations were available on day 1-2: (1-2 days 
after the blood culture was taken): 34 patients, on day 3: 80 patients, on day 4: 104 patients. In 
addition, 93 patients gave a sample on recovery (>26 days after the blood culture). Since patient 
recruitment was based on blood culture, which came positive only the day after blood culture was 
taken, no samples for tryptophan and kynurenine determinations were available on day 0 (blood 
culture day). There were 1-5 samples (median 4) available per patient, collected on separate days. 
Multiple samplings in the same patient were always performed on separate days. Patients with no 
measurements on days 1-4 after blood culture were excluded from the analysis. The maximum 
value in kynurenine and kyn/trp ratio and the minimum value in tryptophan for every patient 
measured during days 1-4 after the blood culture were used in analysis.  
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4.2.4. Main endpoints 
The occurrence of bacteraemia was an endpoint in Study I. The case fatality rate was studied within 
30 days after the blood culture (d-30 case fatality) (studies I-IV). Also day 14 case fatality was 
assessed in Study IV. The need for ICU stay, mechanical ventilation, high SOFA score (#4), 
lowered GCS and hypotension (MAP <70mmHg) were the main evaluable endpoints in all studies. 
4.2.5. Statistical methods 
The SPSS package (version 7.5) was used for statistical analyses and a two-sided p-value <0.05 was 
taken as cut-off for statistical significance. Categorical data were analysed by Pearson`s chi-square 
(X&) test or Fisher’s exact test when appropriate. Nonparametric data were analysed by Mann-
Whitney U-test.  
In study I, binary logistic regression was used to analyse the interaction between MBL genotype 
and current smoking in relation to the risk of bacteraemia in a model adjusted for age and sex, since 
the patient and control groups were not matched by age and sex. Binary logistic regression was 
performed, severity of bacteraemia (SOFA score #4) or need for ICU treatment being dependent 
factors, and MBL genotype, current smoking, interaction between MBL genotype and current 
smoking, age, and sex independent factors. Odds ratios (ORs) were expressed with their 95% 
confidence intervals (CI). In study I, structural region alleles were designated in statistical analysis 
as follows: O allele carriage (i.e. AO or OO) =1, no O allele carriage (i.e. AA) =0. Promoter region 
alleles were designated in statistical analysis as follows: X allele carriage (i.e. YX or XX) =1, no X 
allele carriage (i.e. YY) =0.  
In Study II, the effect of G894T amino acid substitution on hypotension or disease severity was 
studied in multivariate models adjusting for confounding factors (age, sex and obesity). Binary 
logistic regression was used to calculate ORs and 95% CI. Alleles were designated in statistical 
analysis as follows: T allele carriage (i.e. GT or TT genotype) =1, no T allele carriage (i.e. GG 
genotype) =0. 
In Study III, multivariate logistic regression analysis (method enter) was used to assess the 
effects of independent factors on mortality, controlling for differences in other factors possibly 
affecting the outcome. Risk ratios (RRs) were expressed with their 95% confidence intervals (CI). 
The effect of obesity, smoking and alcohol abuse was studied in a multivariate model adjusted for 
the effect of age (continuous variable), sex and organism. 
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In Study IV, a logistic regression model was used to study the independent effect of high IDO 
activity on mortality in models adjusted for potential confounders (age, sex, obesity, alcohol abuse, 
smoking, McCabe class, high CRP, SOFA score, culprit organism and high creatinine). Odds ratios 
(ORs) were expressed with their 95% confidence intervals (CI). Survival curves were calculated 
using the Kaplan-Meier method and differences in survival between groups were compared using 
the log rank test. 
4.2.6. Ethical considerations 
The study was approved by the Ethics Committee of Tampere University Hospital. Written 
informed consent was obtained from patients or first-degree relatives.
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5. RESULTS 
5.1. Characteristics of study material  
5.1.1. Bacterial aetiology 
 
The causative organisms involved were S. aureus (41 patients, 27.5%), Str. pneumoniae (42 patients 
28.2%), ß-hml str. (23 patients, 15.4%), and E. coli (43 patients, 28.9%). All patients were treated 
with an empiric antibiotic regimen, and when necessary antimicrobial treatment was changed 
according to culture results. In all patients the causative organism proved susceptible to the first 
empiric antibiotic treatment selected on the day of blood culture.  
5.1.2. Characteristics and underlying diseases of patients  
The characteristics and underlying diseases of bacteraemia patients are shown in Table 5. The 
median BMI of all patients was 26 (range 15-39) and three were underweight (BMI <18.5). The 
median ages in patients with bacteraemia caused by S. aureus, Str. pneumoniae, ß-hml. str. or E. 
coli were 61 years, 58 years, 59 years and 67 years, respectively (p=0.127). 
 
Table 5. Host characteristics and underlying diseases in bacteraemia patients. 
 
Character All patients  
N= 149 (%) 
S. aureus  
N= 41 (%) 
Str. pneumoniae  
N= 42 (%)           
ß-hml. str. 
N= 23 (%) 
E. coli 
N= 43 (%)       
Overall  
p-valuee 
Obesity (BMI "30)a 27 (23.7) 9 (25.7) 4 (16.7) 6 (31.6) 8 (22.2) 0.698 
Smokingb          66 (48.5) 18 (48.6) 26 (65.0) 11 (57.9) 11 (27.5) 0.007 
Alcohol abuse 24 (16.1) 5 (12.2) 9 (21.4) 6 (26.1) 4 (9.3) 0.211 
Diabetes (type 1 or 2) 34 (22.8) 10 (24.4) 5 (11.9) 4 (17.4) 15 (34.9) 0.077 
Malignancy  25 (16.8) 7 (17.1) 6 (14.3) 2 (8.7) 10 (23.3) 0.465 
Rheumatoid arthritis 7 (4.7) 5 (12.2) 0 1 (4.3) 1 (2.3) 0.034 
Chronic diseasec 117 (78.5) 33 (80.5) 27 (64.3) 17 (73.9) 40 (93.0) 0.013 
Male sex 79 (53.0) 28 (68.3) 24 (57.1) 14 (60.9) 13 (30.2) 0.003 
COPDd 8 (5.4) 0 5 (11.9) 2 (8.7) 1 (2.3) 0.053 
Age >60 years 78 (52.3) 21 (51.2) 20 (47.6) 10 (43.5) 27 (62.8) 0.391 
 
adata available on 114 patients, bcurrent or ex-smoking (data available on 136 patients), cat least one chronic disease, dchronic 
obstructive pulmonary disease, ep-value indicates the difference between groups of patients with different causative organisms 
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5.1.3. Sources of bacteraemia 
Sources of bacteraemia are presented in Table 6. Bacteraemia was community-acquired in 119 
patients (79.9%) and nosocomial in 30 (20.1%). 
 
Table 6. Sources of infection in 149 patients with bacteraemia. One patient may have several focuses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.4. Outcome of bacteraemia 
The clinical course in patients with bacteraemia stratified by causative organism is shown in Table 
7. Forty-seven per cent of patients had organ failure (assessed by SOFA score #3), and 77.7% had 
at least mild organ dysfunction (assessed by SOFA score >0).  
 
Table 7. Clinical data on 149 patients with bacteraemia. 
 
Endpoint All  
n=149 (%) 
S. aureus 
n=41 (%) 
Str. pneumoniae  
n=42 (%) 
ß-hml. str.  
n=23 (%) 
E. coli  
n=43 (%) 
p-valueg 
Dieda 19 (12.8) 8 (19.5) 8 (19.0) 2 (8.7) 1 (2.3) 0.031 
ICUb stay 47 (31.5) 15 (36.6) 16 (38.1) 10 (43.5) 6 (14.0) 0.029 
Maximum SOFA score "4c 58 (39.2) 13 (31.7) 17 (40.5) 13 (56.5) 15 (35.7) 0.250 
Mechanical ventilation 22 (14.8) 7 (17.1) 10 (23.8) 3 (13.0) 2 (4.7) 0.092 
CVVHDd 7 (4.7) 5 (12.2) 0 (0) 2 (8.7) 0 (0) 0.006 
Hypotensione 56 (37.6) 13 (31.7) 19 (45.2) 11 (47.8) 13 (30.2) 0.299 
Lowered GCSf 60 (40.3) 19 (46.3) 18 (42.9) 10 (43.9) 13 (30.2) 0.45 
 
adeath due to bacteraemia episode occurred within 30 days from the day of blood culture. 
bintensive care unit, csequential organ failure assessment 0 to 6 days after blood culture, dneeded continuos veno-venous 
haemodialysis, emean arterial pressure <70mmHg, fGlasgow coma scale lowered (<15), gindicates the difference between groups of 
patients with bacteraemia caused by different organisms 
Source N=149 
(%) 
S. aureus 
n=41 
Str. pneumoniae 
n=42 
ß-hml. str. 
n=23 
E. coli 
n=43 
Pneumonia 39 (26.2) 2 35 2 0 
Skin  37 (24.8) 19 2 16 0 
Urinary 30 (20.1) 1 0 1 28 
Osteomyelitis/spondylitis 15 (10.1) 12 0 3 0 
Gall bladder 7 (4.7) 0 3 0 4 
Arthritis 6 (4.0) 5 0 1 0 
Endocarditis 6 (4.0) 6 0 0 0 
Mediastinitis 4 (2.7) 4 0 0 0 
Meningitis 3 (2.0) 1 1 1 0 
Gynaecological 3 (2.0) 0 0 2 1 
Intravenous/intra-arterial catheter-related 3 (2.0) 3 0 0 0 
Focus unknown 17 (11.4) 3 4 3 7 
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5.2. Genotype frequencies in patients and in controls (Study I and II) 
The distributions of MBL2 genotypes in patients with bacteraemia and in controls, and eNOS 
genotypes at nucleotide position 894 in patients with bacteraemia are shown in Table 8. The 
genotype frequencies in MBL2 genotypes in both bacteraemia and controls, and the eNOS 
genotypes at nucleotide position 894 did not deviate from the Hardy-Weinberg equation. 
 
Table 8. Genotype and allele frequencies of polymorphisms studied in patients and controls (Studies I and II). 
 
Polymorphism Bacteraemia 
N=145 
Controls 
N=400 
P-value 
MBL2 gene (Study I)    
Structural region genotype    
A/A 91 (63%) 248 (62%)  
A/O 48 (33%) 136 (34%)  
 A/B 29 (20%) 96 (24%)  
 A/C 4 (3%) 8 (2%)  
 A/D 15 (10%) 32 (8%)  
O/Oa 6 (4%) 16 (4%)  
1p=0.788 
2p=0.980 
A allele frequency 230 (79%) 632 (79%)  
O allele frequency 60 (21%) 168 (21%) p=0.933 
Promoter region genotype    
Y/Y 93 (64%) 264 (66%)  
Y/X 44 (30%) 116 (29%)  
X/X 8 (6%) 20 (5%) p=0.915 
Y allele frequency 230 (79%) 644 (81%)  
X allele frequency 60 (21%) 156 (20%) p=0.663 
eNOS genotype, nucleotide 894 (Study II )  Bacteraemia 
N=147 
No controls 
used 
 
GG 89 (61%)   
GT 48 (33%)   
TT 10 (7%)   
G allele frequency 226 (77%)   
T allele frequency 68 (23%)   
 
avariant in regard to both structural alleles: three bacteraemia patients with 
 B/B, two with B/D and one with D/D genotype, and five controls with B/B, 
 eight with B/D, one with D/D, one with B/C and one with C/D genotype  
1the groups between which the p-value was calculated in bacteraemia patients vs controls (A/A, A/B, A/C, A/D, O/O) 
2the groups between which the p-value was calculated in bacteraemia patients vs controls (A/A, A/O, O/O) 
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5.3. Genetic factors and the risk and outcome of bacteraemia 
5.3.1. MBL2 genotype (Study I) 
Susceptibility to bacteraemia in relation to the MBL2 genotype was assessed in Study I, where the 
MBL2 genotype frequencies in patients and controls were compared. No significant difference in 
MBL2 genotype frequencies was detected between the patients with bacteraemia and controls 
(Table 8), between the different organism groups, when gram-positive or gram-negative 
bacteraemia patients and controls were compared, or between men and women.  
Bacteraemic patients who carried the structural O allele were more often current smokers than 
noncarriers of this allele [20/50 (40%) vs 17/82 (21%), OR 2.5, 95% CI 1.2-5.5; p=0.017](Table 9). 
Patients with gram-positive bacteraemia who were O allele carriers were significantly more often 
current smokers (53%), compared to controls carrying this allele (21%) (OR 4.2, 95% CI 2.0-9.0; 
p<0.001) (Table 10). The difference between the number of current smokers among O allele 
carriers was most evident in pneumococcal bacteraemia patients compared to controls (11/18 (61%) 
vs 32/152 (21%), OR 5.9, 95% CI 2.1-16.4; p<0.001). This was not the case in those with 
bacteraemia caused by a gram-negative rod as compared to controls (E. coli, OR 0.3, 95% CI 0-2.3; 
p=0.306). Despite the fact that smoking was more common among men in both bacteraemic and 
control groups, the interaction between O allele and smoking in relation to acquisition of gram-
positive bacteraemia was consistent in both genders (OR 4.6, 95% CI 1.6-13.7 in males and OR 3.6, 
95% CI 1.2-10.6 in females). When the interaction between MBL genotype and current smoking in 
relation to the risk of gram-positive bacteraemia was studied in binary logistic regression adjusted 
for age and sex, the finding remained significant (OR 3.2, 95% CI 1.1-9.0; p=0.032).  
MBL2 genotype had no effect on mortality. In a univariate model, carriage of the MBL2 
structural O allele was associated with an increased need for ICU treatment (p=0.022), high SOFA 
score (p=0.006), lowered MAP (p=0.011), lowered platelet count (p=0.016), and elevated creatinine 
level (p=0.009) in males, while this allele had no effect on disease severity in females, nor in the 
whole study group. The effect of the MBL genotype, current smoking, interaction between MBL 
genotype and current smoking, age, and sex in relation to severity of disease (SOFA #4) or need for 
ICU treatment was analyzed in a binary logistic regression model. O allele or interaction between O 
allele and smoking did not remain a significant factor associated with severe disease in this model, 
while smoking did (OR 4.4, 95% CI 1.3-15.1). The O allele, or interaction between this allele and 
smoking likewise did not remain a significant factor associated with ICU treatment, while smoking 
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and male sex remained so (OR 3.9, 95% CI 1.0-14.8 and OR 3.5, 95% CI 1.4-8.4, respectively). 
MBL2 promoter region polymorphism had no significant effect on the clinical course of the disease.  
In summary, MBL2 genotypes representing MBL insufficiency were not associated with the 
overall risk of bacteraemia, but smoking in the carriers of structural variant O allele significantly 
increased the risk of gram-positive bacteraemia. The risk was most prominent in predisposition to 
pneumococcal bacteraemia. MBL2 genotypes representing MBL insufficiency were not 
independently associated with disease severity or case fatality in patients with bacteraemia. 
 
Table 9. Predisposing factors and underlying diseases in bacteraemia stratified by MBL2 structural genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
adata available on 132 patients, bthose who had never smoked, cdata available on 111 patients 
dat least one chronic disease, eMcCabe class II or III: ultimately or rapidly fatal disease, *cannot be calculated 
 
 
Table 10.  The number of smokers (%) in gram-positive bacteraemia (including S. aureus, Str. pneumoniae  
or ß-hml.str.) and in controls in relation to MBL2 gene structural genotype.  
 
Character MBL2 structural genotype   
 AA 
n=91 
AO or OO 
n=54 
OR (95% CI) p-value 
Rheumatoid arthritis 7 (8%) 0 * 0.046 
Malignancy 11 (12%) 11 (20%) 1.9 (0.7-4.6) 0.179 
Alcohol abuse 13 (14%) 11 (20%) 1.5 (0.6-3.7) 0.341 
Current smokera 17 (21%) 20 (40%) 2.5 (1.2-5.5) 0.017 
Non-smokera, b 50 (61%) 17 (34%) 0.3 (0.2-0.7) 0.003 
Obesity (BMI !30)c 20 (30%) 7 (16%) 0.4 (0.2-1.1) 0.075 
Chronic diseased 69 (76%) 44 (82%) 1.4 (0.6-3.2) 0.427 
McCabe II or IIIe 16 (18%) 5 (9%) 0.5 (0.2-1.4) 0.169 
Age >60 years 49 (54%) 28 (52%) 0.9 (0.5-1.8) 0.816 
Diabetes (type 1 or 2) 21 (23%) 13 (24%) 1.1 (0.5-2.3) 0.891 
Male/Female 49 (54%)/42 (46%) 28 (52%)/26 (48%) 0.9 (0.5-1.8) 0.816 
COPD 5 (6%) 3 (6%) 1.0 (0.2-4.4) 1.0 
MBL2 structural genotype Bacteraemia 
n=95 
Controls 
n=400 
OR (95% CI) 
AA n=59 n=248  
 Current smokers (%) 14 (24%) 45 (18%) 1.4 (0.7-2.8) 
AO or OO n=36 n=152  
 Current smokers (%) 19 (53%) 32 (21%) 4.2 (2.0-9.0) 
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5.3.2. eNOS G894T polymorphism (Glu298Asp)
 
(Study II) 
The distribution of the eNOS genotypes at nucleotide position 894 did not differ statistically 
significantly between bacteraemias caused by four different organisms (p=0.354). Among subjects 
with E. coli bacteraemia, carriage of the T allele was associated with lower MAP (p=0.004) and 
higher SOFA score (p=0.001) compared to non-carriers (Table 11). The effect on blood pressure in 
E. coli bacteraemia was most prominent in the early stage of the disease: on blood culture day MAP 
(median) was 52 mmHg in T allele carriers compared to 91 mmHg in non-carriers  (p<0.001), as 
shown in Table 11. This was not the case in bacteraemia caused by a gram-positive organism. In 
fact patients suffering from gram-positive bacteraemia and having the GG genotype evinced greater 
severity of disease (assessed by SOFA score) than those carrying the T allele. The effect was most 
prominent in those suffering from S. aureus bacteraemia; the SOFA score was lower in carriers of 
the T allele compared to non-carriers (p=0.008, Mann-Whitney U-test). The number of hypotensive 
patients was significantly higher among E. coli bacteraemia patients carrying the T allele compared 
to non-carriers during the observation period days 1 to 4 (Table 11), whereas no difference was 
detected during days 5 to 6. T allele carriage was not associated with increased case fatality in any 
of the four pathogens studied.  
In the whole study population there were more male patients among T allele carriers compared 
to non-carriers (64% vs 46%, p=0.035). T allele carriage remained a significant factor associated 
with hypotension on day 0 in E. coli bacteraemia in a multivariate model adjusted for age 
(continuous variable) and sex (OR 10.8, 95% CI 2.0-57.7; p=0.005). Although the number of obese 
patients (BMI#30) was higher in E.coli bacteraemia patients carrying the T allele compared to non-
carriers (50% vs 12%, p=0.027), obesity was not associated with hypotension in E.coli bacteraemia. 
T allele carriage was significantly associated with hypotension on day 0 in a logistic regression 
model adjusted for obesity (OR 10.9, 95% CI 1.4-84.0, p=0.02).  
The effect of eNOS T allele carriage on disease severity (assessed by SOFA score) in gram-
positive bacteraemia was also studied in multivariate logistic regression analysis. In gram-positive 
bacteraemia, carriage of the T allele preserved its protective role as regards severe disease (defined 
as maximum SOFA score #4) in a model adjusted for the effect of age and sex (OR 0.4, 95% CI 
0.2-0.8). All endocarditis patients had GG genotype (n=6), none carried the T allele (all cases of 
endocarditis were caused by a gram-positive organism) (the difference between groups, p=0.034). 
However, if endocarditis patients were excluded from the analysis, carriage of the T allele preserved 
its protective role in gram-positive bacteraemia as regards severe disease in a model adjusted for the 
effect of age and sex (OR 0.4, 95% CI 0.2-1.0). 
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In summary, the results indicate that the T allele at nucleotide position 894 is associated with 
hypotension in the early stage of disease in patients with E. coli bacteraemia but not in bacteraemia 
caused by a gram-positive organism.
  
 
  
  Table 11. Clinical characteristics of patients with E.coli or gram-positive bacteraemia in relation to eNOS G894T (Glu298Asp) polymorphism. 
 
aintensive care unit, bacute myocardial infaction within 30 days after blood culture, csequential organ failure assessment, dmean arterial pressure (the lowest value during days 0-6), eGlasgow 
coma scale <15, fMAP=mean arterial pressure. The lowest value for each patient during the observation period was recorded, gmean arterial pressure <70mmHg at least once during the 
observation period (on day 0, during days 1 to 4, or during days 5 to 6), hneeded vasopressive support at least once during the observation period, i1 to 4 days after the blood culture, j5 to 6 
days after the blood culture, *cannot be calculated, §continuous variable (OR and CI cannot be calculated
Character E. coli    Gram-positive 
organism 
   
 GG, n=30 GT/TT, n=12 OR (95%CI) p-value GG, n=59 GT/TT, n=46 OR (95%CI) p-value 
Died (d-30 case fatality) 0 1 (8%) * 0.286 11 (19%) 7 (15%) 0.8 (0.3-2.2) 0.644 
Needed ICUa stay  2 (7%) 4 (33%) 7.0 (1.1-45.4) 0.046 25 (42%) 16 (35%) 0.7 (0.3-1.6) 0.429 
AMIb 2 (7%) 4 (33%) 7.0 (1.1-45.4) 0.046 4 (7%) 1 (2%) 0.3 (0-2.8) 0.383 
Highest SOFAc score (days 0 to 6), median 
(quartiles) 
1.5 (0-2.3) 5 (3-13) § 0.001 4 (1-9) 1.5 (1.0-4.3) § 0.021 
 Lowest MAPd (mmHg), median (quartiles) 80 (75-90) 60 (47-80) § 0.004 70 (58-84) 77 (63-94) § 0.071 
 Lowest GCSe, median (quartiles) 15 (15-15) 15 (14-15) § 0.170 14 (13-15) 15 (14-15) § 0.052 
 Needed mechanical ventilation  0 2 (17%) * 0.077 15 (25%) 5 (11%) 0.4 (0.1-1.1) 0.06 
 Highest bilirubin value (!mol/l), median 
(quartiles) 
15 (10-29) 20 (16-79) § 0.085 19.5 (12-50) 17.5 (13-29) § 0.451 
 Highest creatinine value (!mol/l), median 
(quartiles) 
98 (72-193) 148 (83-190) § 0.328 124 (83-202) 91 (71-165) § 0.098 
 Lowest platelet count (109/l), median 
(quartiles) 
178 (120-200) 105 (36-163) § 0.045 128 (62-225) 184 (126-254) § 0.023 
Blood pressure characteristics at different 
time-points 
        
 Day 0 (blood culture day)         
 MAP (mmHg)f, median (quartiles) 91 (81-97) 52 (46-81) § <0.001 80 (67-97) 87 (76-106) § 0.08 
 Hypotensiong 4 (14%) 7 (58%) 8.8 (1.8-41.6) 0.003 15 (25%) 5 (11%) 0.4 (0.1-1.1) 0.06 
 Needed vasopressivesh 1 (3%) 4 (33%) 14 (1.4-144.0) 0.02 6 (10%) 0 * 0.034 
 During days 1 to 4i         
 MAP (mmHg)f, median (quartiles) 94 (88-107) 80 (74-91) § 0.02 85 (73-100) 92 (80-107) § 0.236 
 Hypotensiong 0 4 (33%) * 0.004 15 (25%) 7 (15%) 0.5 (0.2-1.4) 0.202 
 Needed vasopressivesh 0 4 (33%) * 0.004 12 (20%) 5 (11%) 0.5 (0.2-1.5) 0.191 
 During days 5 to 6j         
 MAP (mmHg)f, median (quartiles) 99 (90-107) 83 (75-94) § 0.025 89 (71-100) 97 (81-110) § 0.045 
 Hypotensiong 0 0   7 (18%) 3 (10%) 0.5 (0.1-2.2) 0.358 
 Needed vasopressivesh 0 0   5 (11%) 3 (9%) 0.8 (0.2-3.7) 0.796 
 
6
0
 
  
 
61  
5.4. Patient characteristics and underlying diseases and outcome 
(Study III) 
The effect of patient characteristics and underlying diseases on case fatality in bacteraemia is shown 
in Table 12. The case fatality rate was 1/30 (3.3%) in patients with nosocomial bacteraemia 
compared to 18/119 (15.1%) in community-onset bacteraemia, OR 0.193, p=0.084). 
 
Table 12. Case fatality in 149 bacteraemia patients in relation to host characteristics and underlying diseases. 
 
 
 
 
 
 
adata available on 114 patients 
bcurrent smoking or ex-smoking, data available on 136 patients 
cchronic obstructive pulmonary disease 
dMcCabe class II or III: ultimately fatal or rapidly fatal disease 
ecorticosteroids (prednisone equivalent) used in a dose of over 5 mg per day during one month prior to the episode of bacteraemia 
fat least one chronic condition 
*cannot be calculated 
5.4.1. BMI 
Obesity was a prominent factor associated with case fatality in bacteraemic patients (Table 12 and 
13), the median BMI being significantly higher among those who died compared to survivors (33 
vs. 26, p=0.003). When causative organisms were analyzed separately, a statistically significant 
difference in case fatality between obese compared to non-obese subjects was documented in Str. 
pneumoniae bacteraemia (all who died were obese, p=0.002 indicating the difference between 
obese and non-obese). Obesity was associated with increased risk of death among those admitted to 
the ICU (5/7 of obese patients died vs. 3/25 of non-obese; p=0.005, RR 18.3; 95% CI 2.4-140.4). 
Underweight (BMI <18.5) was not associated with the outcome of bacteraemia. Obesity remained a 
Character Nonsurvivors 
N=19 (%) 
Survivors  
N=130 (%) 
RR (95% CI) p-value 
Obesity (BMI!30)a 7 (70.0) 20 (19.2)  9.8 (2.3-41.3) 0.002 
Smokingb        13 (92.9) 53 (43.4) 16.9 (2.1-133.5)  <0.001 
Alcohol abuse 7 (36.8) 17 (13.1)  3.9 (1.3-11.2) 0.008 
COPDc 4 (21.1) 4 (3.1) 8.4 (1.9-37.1) 0.01 
Rheumatoid arthritis 3 (15.8) 4 (3.1) 5.9 (1.2-28.8) 0.045 
Diabetes mellitus type 1 0  5 (3.8)  * 1 
Diabetes mellitus type 2 6 (31.6) 23 (17.7) 2.1 (0.7-6.2) 0.153 
Malignancy 3 (15.8) 22 (16.9) 0.9 (0.2-3.4) 0.902 
Liver cirrhosis 1 (5.3) 3 (2.3) 2.4 (0.2-23.8) 0.42 
McCabe class II or IIId 3 (15.8) 21 (16.2) 1.0 (0.3-3.6) 1 
Corticosteroid usee 2 (10.5) 16 (12.3) 0.8 (0.2-4.0) 0.824 
Chronic diseasef 18 (94.7) 99 (76.2) 5.6 (0.7-43.9) 0.065 
Male sex 14 (73.7) 65 (50.0) 2.8 (1.0-8.2) 0.053 
Age over 60 years 11 (57.9) 67 (51.5) 1.3 (0.5-3.4) 0.604 
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significant factor associated with case fatality in bacteraemia in a multivariate model adjusted for 
the effect of smoking, alcohol abuse, age, sex and causative organism (RR 6.4; 95% CI 1.2-34.4). 
Obese subjects did not differ significantly from non-obese in the number of current smokers 
(p=0.608), alcohol abusers (p=0.894), male patients (p=0.372) or the number of patients >60 years 
of age (p=0.578). 
Forty-four per cent of obese bacteraemic patients had previously been diagnosed with type 2 
diabetes, as against 12.6% of non-obese patients (p<0.001). Patients with type 2 diabetes died more 
often than those without this disorder, but the difference was not statistically significant. Obesity 
remained an independent factor associated with case fatality even after adjustment for type 2 (RR 
8.9) or type 1 diabetes mellitus (RR 9.3). 
In summary, obesity remained an independent factor associated with case fatality in bacteraemic 
patients when adjusted for the effect of smoking, alcohol abuse, age, sex and causative organism. 
The median BMI was significantly higher among deceased patients compared to survivors. 
 
Table 13. Clinical characteristics in obese bacteraemia patients compared to non-obese.  
BMI data available on 114 patients. 
 
 
 
 
 
 
 
 
 
aBMI!30, bBMI<30, cp-value indicating the difference between obese and non-obese 
dd-30 case fatality, eintensive care unit, fGlasgow coma scale <15 
gMAP<70mmHg, hsequential organ failure assessment score 1-3 days after blood culture, data available on 105 patients 
5.4.2. Smoking 
Current or ex-smokers died more often of bacteraemia than non-smokers (Table 12 and 14). When 
causative organisms were analyzed separately, no statistically significant difference in case fatality 
was documented among smokers compared to non-smokers. However, in Str. pneumoniae 
bacteraemia, all who needed mechanical ventilation (n=9) were current smokers (p-value <0.001, 
indicating a difference between smokers and non-smokers).  
When current smokers (n=38) were compared to non-smokers (ex-smokers excluded from this 
analysis) the adverse effect of smoking for prognosis of bacteraemia was emphasized. The day-30 
case fatality rate among bacteraemic patients was higher in current smokers than in non-smokers 
 Obesea 
N=27 (%) 
Non-obeseb 
N=87 (%) 
RR (95% CI) p-valuec 
Diedd 7 (25.9) 3 (3.4) 9.8 (2.3-41.3) 0.002 
Needed ICUe stay 7 (25.9) 25 (28.7) 0.9 (0.3-2.3) 0.78 
Needed mechanical ventilation 5 (18.5) 7 (8.0) 2.6 (0.8-9.0) 0.152 
Lowered CGSf 12 (44.4) 29 (33.3) 1.6 (0.7-3.9) 0.293 
Hypotensiong 10 (37.0) 27 (31.0) 1.3 (0.5-3.2) 0.561 
High SOFA score (!4)h 11 (44) 19 (23.8) 2.5 (1.0-6.5) 0.05 
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(21.1% vs. 1.4%, p<0.001, RR 18.4; 95% CI 2.2-153.7). This adverse effect remained even after 
smoking cessation; 5/28 (17.9%) patients died in the ex-smoker group compared to 1/70 (1.4%) of 
those who had never smoked (p=0.007, RR 15.0; 95% CI 1.7- 135.1). Fifty-one per cent of males 
were current or ex-smokers as against 36.9% of females (p=0.01). Smokers (current or ex-smoking) 
did not differ significantly from non-smokers in the number of obese patients (p=0.470) or in the 
number of patients with diabetes (type 1 or type 2 diabetes) (p=0.213). Smokers (current or ex-
smoking) were younger compared to non-smokers (median age 54 years in smokers and 66 years in 
non-smokers, p=0.001). Twelve per cent of smokers (current or ex-smoking) had been diagnosed 
with COPD. 
Smoking (current or ex-smoking) remained a significant factor associated with case fatality in a 
multivariate model adjusted for the effect of obesity, alcohol abuse, age, sex and causative organism 
(RR 23.0; 95% CI 1.7-321.6).  
In summary, smoking was an independent factor associated with case fatality in bacteraemia. 
The adverse effects of smoking on outcome were seen most strikingly in current smokers compared 
to non-smokers. The adverse effects of smoking persisted even after smoking cessation. 
 
Table 14. Clinical characteristics in bacteraemia patients stratified by smoking data. Smoking data  
available on 136 patients.  
 
 
 
 
 
 
 
 
acurrent or ex-smokers, bhad never smoked, cp-value indicating the difference between smokers and non-smokers  
dd-30 case fatality, eintensive care unit, fCGS= Glasgow coma scale <15, gMAP<70mmHg 
hsequential organ failure assessment score 1-3 days after blood culture, data available on 124 patients 
5.4.3. Alcohol abuse 
The case fatality rate was higher among alcohol abusers compared to those not given to alcohol 
abuse (29.2% vs 9.6%, p=0.008, RR 3.9; 95% CI 1.3-11.2). Eighteen out of 21 (85.7%) alcohol 
abusers were current smokers or ex-smokers and 4 out of 24 (16.7%) had liver cirrhosis. In Str. 
pneumoniae bacteraemia 56% of alcohol abusers died compared to 9% of those with no alcohol 
abuse (p=0.006). Eighty-eight percent of alcohol abusers were ≤60 years of age and 67% were 
 Smokersa 
N=66 
Non-smokersb 
N=70 
RR (95% CI) p-valuec 
Diedd 13 (19.7) 1 (1.4) 16.9 (2.1-133.5) <0.001 
Needed ICUe stay 26 (39.4) 13 (18.6) 2.9 (1.3-6.2) 0.007 
Needed mechanical ventilation 14 (21.2) 4 (5.7) 4.4 (1.4-14.3) 0.008 
Lowered CGSf 29 (43.9) 23 (32.9) 1.6 (0.8-3.2) 0.184 
Hypotensiong 28 (42.4) 20 (28.6) 1.8 (0.9-3.8) 0.091 
High SOFA score (≥4)h 21 (33.3) 10 (16.4) 2.6 (1.1-6.0) 0.029 
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males. Thirteen per cent of alcohol abusers had been diagnosed with type 1 or type 2 diabetes 
compared to 24.8% of those with no alcohol abuse (p=0.188). 
Alcohol abuse did not remain a significant factor associated with case fatality in a multivariate 
model adjusted for the effect of obesity and smoking, age, sex and causative organism (RR 1.9; 
95% CI 0.1-29.5).  
5.4.4. Gender and age 
Age was not associated with case fatality in the present study (median age 66 years in nonsurvivors 
and 61 in survivors, p=0.390, Mann-Whitney U-test) even after stratification by causative organism 
(data not shown). Forty-seven patients needed an ICU stay during the bacteraemia episode; age was 
not associated with case fatality in those patients, who needed ICU treatment (data not shown). 
Males needed the ICU significantly more often compared to females (39% vs. 23%, OR 2.2; 
95% CI 1.1-4.5, p=0.032), but there was no difference in maximum SOFA scores, in the need for 
mechanical ventilation or in the occurrence of hypotension (data not shown). In a multivariate 
model, male sex did not remain an independent factor associated with the need for ICU after 
adjusting for causative organism (data not shown). 
5.5. Kynurenine to tryptophan ratio reflecting IDO activity  (Study IV) 
The maximum kyn/trp ratios detected 1-4 days after blood culture in 132 patients with bacteraemia, 
stratified by causative organism are shown in Table 15. The maximum ratios were high in acute 
illness, and decreased on recovery.  
The maximum kyn/trp ratio, detected on days 1-4 after blood culture, was significantly higher in 
those who died (d-30 case fatality) compared to those who survived bacteraemia (median 193.7 
!mol/mmol (quartiles 124.1-253.3 !mol/mmol) vs. 82.4 !mol/mmol (quartiles 51.0-138.9 
!mol/mmol), respectively; p=0.001) (Table 16). Interestingly, the median values of the ratios 
increased from days 1-2 to day 4 in those who died, whereas in those who survived they decreased 
(Figure 3). A high maximum kyn/trp ratio was associated with all clinical variables indicative of 
severe disease and poor outcome (Table 17).  
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Table 15. Maximum kynurenine to tryptophan (kyn/trp) ratio 1-4 days after blood culture in patients with  
bacteraemia.  
 
 
 
 
 
 
 
aon recovery (>26 days after the blood culture) the median kyn/trp ratio was 36.8 !mol/mmol,  
bp-value 0.006 indicates difference between patient groups stratified by culprit organisms (Kruskal-Wallis test)) 
 
  
 
Table 16. Maximum kynurenine to tryptophan (kyn/trp) ratio and tryptophan and kynurenine levels in  
patients with bacteraemia in relation to outcome. 
 
 
 
 
 
 
 
 
athe day of maximum kyn/trp ratio: median tryptophan concentration 43.2 !mol/l in nonsurvivors and 51.1 !mol/l  
in survivors (p=0.208) and kynurenine concentration 7.45 !mol/l in nonsurvivors and 4.29 !mol/l in survivors (p=0.001) 
 
Causative organism kyn/trp ratio !mol/mmol, median (quartiles)b 
S. aureus 117.3 (64.4-197.5) 
Str. pneumoniae 90.9 (52.5-194.0)                                  
ß-haemolytic streptococcus 123.0 (69.6-312.3) 
E. coli 67.5 (42.3-113.4) 
All patientsa 89.9 (54.7-167.6) 
 Nonsurvivors 
n=18 
Survivors 
n=118 
 
Continuous variables, median (quartiles) 
 
  p-
value 
Maximum kyn/trp ratio (days 1-4) (!mol/mmol)a 193.7 (124.1-253.3) 82.4 (51.0-138.9) 0.001 
Minimum tryptophan concentration  !mol/l (days 1-4) 46.5 (38.0-59.7) 51.1 (38.1-64.4) 0.450 
Maximum kynurenine concentration  !mol/l (days 1-4) 8.76 (5.15-12.26) 4.27 (2.92-6.72) <0.001 
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Figure 3. The medians of kynurenine to tryptophan ratios (kyn/trp) (!mol/mmol) on day 1-2, on day 3 and on day 4 after 
blood culture in nonsurvivors (n=18) and in survivors (n=118). The difference between nonsurvivors and survivors 
statistically significant on day 3 (median in nonsurvivors 164.8 !mol/mmol, quartiles 92.7-227.9 and in survivors 88.7 
!mol/mmol, quartiles 54.8-130.8, p=0.014) and on day 4 (median in nonsurvivors 193.8 !mol/mmol, quartiles 72.7-242.5 
and in survivors 66.9 !mol/mmol, quartiles 43.6-110.3, p=0.003). 
 
 
 
 
 
Table 17. Clinical data on 132 bacteremic patients stratified with maximum kyn/trp ratio 1-4 days after blood culture 
("120 !mol/mmol vs. those with >120 !mol/mmol). Categorical data were analysed by chi-square test or Fisher’s exact 
test and continuous data by Mann-Whitney U-test. 
 
 
aintensive care unit, bsequential organ failure assessment, cmean arterial pressure, dGCS= Glasgow coma scale, §continuous 
variable (OR and CI cannot be calculated) 
 
!"
#!"
$!!"
$#!"
%!!"
%#!"
&'("$)%" &'("*" &'("+"
,-./0/1.,"
212,-./0/1.,"
Character maximum 
kyn/trp ratio 
!120"mol/mmol 
n=81 
maximum kyn/trp  
ratio 
>120"mol/mmol 
n=51 
OR (95% CI) p-
value 
Died (d-14 case fatality) 2 (3%) 10 (20%) 9.6 (2.0-46.0) 0.001 
Died (d-30 case fatality) 3 (4%) 15 (29%) 10.8 (3.0-39.8) <0.001 
Needed ICUa stay 16 (20%) 26 (51%) 4.2 (1.9-9.2) <0.001 
Needed mechanical ventilation 3 (4%) 17 (33%) 13.0 (3.6-47.3) <0.001 
Highest SOFAb score #4 23 (28%) 32 (63%) 4.2 (2.0-8.9) <0.001 
Lowest MAPc (mmHg), median (quartiles) 78 (70-93) 63 (54-77) § <0.001 
Needed vasopressive support 5 (6%) 21 (41%) 10.6 (3.7-30.8) <0.001 
Highest SOFAb score, median (quartiles) 1 (0-4) 5 (2-10) § <0.001 
Highest bilirubin level (!mol/l), median (quartiles) 14 (11-23) 30 (17-60) § <0.001 
Highest creatinine level (!mol/l), median (quartiles) 90 (71-123) 173 (114-249) § <0.001 
Lowest platelet count (x109/l), median (quartiles) 189 (117-243) 108 (65-166) § <0.001 
Lowest GCSd, median (quartiles) 15 (15-15) 14 (13-15) § <0.001 
Median neutrophil count (x109/l) (quartiles) (n=112) 6.6 (3.8-9.4) 9.3 (6.6-13.3) § 0.001 
Highest CRP (mg/l), median (quartiles) 224 (170-347) 333 (249-405) § 0.004 
!
m
ol
/m
m
ol
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The receiver operating curve (ROC) was used to estimate the optimal cut-off value for maximum 
kyn/trp ratio in predicting fatal disease. The AUC
ROC
 for maximum kyn/trp ratio was 0.754 (0.639-
0.869, p=0.001). The kyn/trp ratio at a cut-off level of 120 !mol/mmol showed a sensitivity of 83% 
and specificity 69% in detecting fatal disease, and this cut-off point was used to classify patients 
into those with "120 !mol/mmol or >120 !mol/mmol ratio of kyn/trp. The highest CRP level 
during the bacteraemia episode did not predict case fatality at any cut-off level in the ROC curve 
(p=0.292). However, the AUC
ROC
 for CRP on the day of blood culture was 0.66 (0.58-0.782, 
p=0.03). The CRP at a cut-off level of 224 mg/l showed a sensitivity of 72% and specificity 61% in 
detecting fatal disease, and this cut-off point was used to classify patients into two groups (those 
with CRP "224 mg/l or >224 mg/l in the multivariate model).  
Of underlying conditions, alcohol abusers had high kyn/trp ratios (>120 !mol/mmol) more often 
compared to those not given to alcohol abuse (p=0.017). There was no significant difference in 
kyn/trp ratios (maximum values "120 !mol/mmol or >120 !mol/mmol) between the groups of 
patients stratified by other underlying conditions or diseases, gender, age, BMI or smoking habits. 
The association between a high (>120 !mol/mmol) maximum kyn/trp ratio and case fatality in 
multivariate models adjusted for potential confounders is shown in Table 18. High kyn/trp ratio 
retained its significance in the multivariate model in all combinations. Obesity and high SOFA 
score (!4) also remained independent factors associated with case fatality. 
 
Table 18. Odds ratio for maximum kynurenine to tryptophan (trp/kyn) ratio (>120 "mol/mmol) detected 1-4 days after 
blood culture in relation to case fatality adjusted for potential confounders in multivariate model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCRP data available on 124 patients, bsequential organ failure assessment score, also remained a significant factor associated  
with case fatality in multivariate model (p<0.05), cBMI data available on 101 patients, also remained a significant factor associated 
with case fatality in multivariate model, dsmoking data available on 120 patients 
 
 
 
Variables in model  Odds ratio for high kyn/trp ratio (>120 !mol/mmol) 
kyn/trp (>120 !mol/mmol) +  
 age and male gender 10.0 (2.7-37.3) 
 McCabe class II or III 11.3 (3.0-42.0) 
 CRP >224 mg/l (blood culture day)a 9.8 (2.6-37.3) 
 SOFA score (!4)b 6.6 (1.7-25.6) 
 obesity (BMI!30)c 7.8 (1.4-42.2) 
 culprit organism 9.5 (2.5-36.1) 
 high creatinine (>120 "mol/l) 7.4 (1.8-29.5) 
 current smokingd 10.0 (2.1-48.3) 
 alcohol abuse 9.7 (2.6-36.1) 
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6. DISCUSSION 
6.1. Definitions, study population and the outcome of bacteraemia 
The present work was a prospective observational study conducted in Tampere University Hospital 
in 1999-2004. In study I, a control population was used to determine the risk of bacteraemia related 
to MBL2 genotypes.  
The overall case fatality (d-30 case fatality) attributable to bacteraemia was 12.8%. In S. aureus 
and Str. pneumoniae bacteraemias, case fatality rates (19.5% and 19%, respectively) were in accord 
with previous studies (Watanakunakorn et al. 1993,  Lujan et al. 2004,  Lyytikäinen et al. 2005,  
Laupland et al. 2008b), whereas in bacteraemias caused by E .coli and ß-haemolytic streptococcae, 
the case fatality rates (2.3% and 8.7%, respectively) were lower than in other reports (Kuikka et al. 
1997,  O'Loughlin et al. 2007,  Laupland et al. 2008a,  Broyles et al. 2009,  Rantala et al. 2009a). In 
this study, the case fatality rate was highest among S. aureus bacteraemia patients. S. aureus is 
capable of affecting multiple organs in the body and deep foci due to S. aureus bacteraemia are 
particularly common, resulting in increased case fatality (Mylotte and Tayara 2000). In the present 
study, all mediastinites and endocardites, infections which carry a marked mortality rate, were 
caused by S. aureus. Since the present study was not population-based, it is possible that some 
patient groups, e.g. very old patients with multiple comorbidities and severe sepsis had been treated 
in primary care wards without recruitment to the present study conducted in a university hospital. 
This may lower the identified case fatality rate in E. coli bacteraemia. The number of patients with 
ß-haemolytic streptococcus bacteraemia was low, which may affect the results. Median ages in the 
respective groups of patients with different culprit organisms did not differ from each other.  
Since the patients were recruited for the study according to positive blood culture, which only 
became positive one day after the blood culture was taken, not all patients were evaluated for 
respiratory rate on the day of blood culture (on diagnosis day, i.e. day 0). Evaluation of the 
respiratory rate is one out of the four contributors in the definition of sepsis by the ACCP/SCCM 
Consensus Conference Committee (Bone et al. 1992). The diagnostic criteria for SIRS are overly 
sensitive and unspecific (Levy et al. 2003) and in 2001, the International Sepsis Definitions 
Conference concluded that an expanded list of signs and symptoms of sepsis might better reflect the 
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clinical response to infection. The definition of SIRS was, however, left unchanged (Levy et al. 
2003). According to these guidelines, sepsis is defined as SIRS plus documented infection. The 
guidelines for the SIRS definition (Bone et al. 1992), strictly taken, do not allow regarding the 
currently studied population as sepsis patients. However, all patients in the study presented with 
either fever or hypothermia, elevated CRP and leukocytosis or leukopenia. Given the high 
prevalence of patients with at least mild organ dysfunction (78%), as assessed by a SOFA score >0, 
and with severe organ dysfunction (39%) assessed by SOFA score !4, it is highly probable that 
nearly all patients would eventually fulfil the official definition of sepsis (Bone et al. 1992) at some 
time-point in their disease. On the other hand, whereas most observational sepsis studies are prone 
to bias due to the unspecificity of the SIRS criteria in differentiating infectious from non-infectious 
(e.g. vasculitis) causes of inflammation (Levy et al. 2003), and a definite microbiological diagnosis 
cannot be made in one third or more of patients with clinical manifestations of sepsis (Sands et al. 
1997,  Vincent et al. 2006), this problem was overcome in the present cohort by the inclusion of 
verified bloodstream infections. All patients in the present study had a documented infection, all 
causative organisms were typical pathogens and in all cases the responsible physician prescribed 
intravenous antibiotics. 
One strength of the present study was the enrolment of patients evincing different disease 
severity; patients with milder symptoms and signs as well as those with septic shock who needed 
ICU treatment. The study included prospectively gathered detailed clinical data, among them SOFA 
scores, blood pressure data, Glasgow coma scales and laboratory markers. The inclusion of four 
different pathogens provided the opportunity to compare outcomes related to genetic and 
environmental factors in different bacteraemias. On the other hand, it allowed of comparison of 
these factors also in relation to susceptibility to bacteraemia. However, the inclusion of 
bacteraemias caused by multiple culprit organisms might also be considered a limitation, as 
different causative agents increase the infection source- and comorbidity-related heterogeneity of 
the study population, limiting likewise the sizes of separate subgroups of patients. There were 
altogether 1756 bacteraemias caused by S. aureus, Str. pneumoniae, ß-haemolytic streptococcus and 
E. coli in the Pirkanmaa HD during the period in question (children and patients treated in other 
hospitals in the HD are also included in this figure) (unpublished data, oral communication with 
clinical microbiologist Risto Vuento). Thus, one limitation was that not all patients with 
bacteraemia in the university hospital district during the study period could be enrolled. Although 
the incidence of methicillin-resistant S. aureus (MRSA) is currently increasing in Finland, during 
the study period the antimicrobial resistance rates of the organisms in question were low in 
Pirkanmaa and all pathogens proved susceptible to the first antibiotic selected on admission. 
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Bacteraemic patients constitute one fraction of all sepsis patients, so that the present material does 
not represent the whole group of sepsis patients. For example, blood culture-negative sepsis patients 
were not included in this study. In previous studies, the presence of bacteraemia has been shown to 
be associated with poor outcome in patients with documented sepsis (Bone et al. 1989,  Brun-
Buisson et al. 1995). However, patients who had received antibiotics prior to the blood culture may 
have been missing in the present study since the antimicrobial treatment given may have potentially 
affected the blood culture findings in some bacteraemic patients. Furthermore, this study represents 
patients with four specified bacteraemias, and the results may thus not be applicaple to all 
bacteraemias. 
The present study was not designed to evaluate the efficacy of different therapeutic strategies in 
regard to bacteraemia outcome. Many therapeutic interventions have been widely acknowledged as 
life-saving in sepsis (Rivers et al. 2001,  Dellinger et al. 2004). The international Surviving Sepsis 
Campaign (SSC) published severe sepsis guidelines in 2004 (Dellinger et al. 2004), this comprising 
an international effort to increase awareness and improve outcome in severe sepsis. These treatment 
guidelines, based on studies showing that relatively simple therapeutic interventions such as 
ventilation with low tidal volumes (Dellinger et al. 2004), made it possible to save a significant 
number of lives. The importance of early appropriate empirical therapy for outcome has been 
documented in several studies (MacArthur et al. 2004,  Ferrer et al. 2008). One recent study showed 
that the above-mentioned evidence-based sepsis therapies were not used in Finland as often as 
recommended (Karlsson et al. 2007). The possibility cannot be eliminated that advancing treatment 
strategies in sepsis (for example rhAPC and the adoption of early goal-directed therapy) would have 
affected individual outcomes, which would constitute a confounder in the present studies.  
Finally, there remain factors impossible to control in clinical studies in general; patients with 
sepsis typically differ with respect to the inciting organism and its virulence, the focus of infection, 
and also with respect to optimal approaches in antibiotic selection and surgical source control. 
Studies have shown that the failure to diagnose and appropriately treat patients with surgical 
drainage is a common avoidable error encountered in everyday clinical practice (Blosser et al. 1998,  
Torgersen et al. 2009) and prompt and adequate antibiotic therapy is the cornerstone of survival 
(Garnacho-Montero et al. 2006).  
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6.2. Genetic variation and the risk and outcome of bacteraemia 
6.2.1. MBL2 genotype 
In Study I, MBL2 structural O allele carriers who smoked had a strikingly increased risk of gram-
positive bacteraemia compared to O allele-carrying controls. The same was not detected in carriers 
of the AA genotype.  
Smoking has previously been shown to predispose to pneumococcal bacteraemia (Nuorti et al. 
2000). However, no previous work has studied the possible role of MBL deficiency, a defect in 
innate immunity, in conjunction with smoking in the context of susceptibility to infection. The 
effect of the MBL2 genotype on infection susceptibility and the outcome of infectious diseases, 
although fairly intensively studied to date, has yielded controversial results in different studies 
(Summerfield et al. 1997,  Hibberd et al. 1999,  Kronborg et al. 2002,  Roy et al. 2002,  Sutherland 
et al. 2005,  Smithson et al. 2007). In several reports, only the homozygous variant genotype has 
been clearly associated with the risk of bacteraemia (Hibberd et al. 1999,  Roy et al. 2002,  
Sutherland et al. 2005), though totally negative results have also been published (Kronborg et al. 
2002,  Smithson et al. 2007). In accord with the present findings, abundant data show that MBL 
deficiency increases the risk of infections in certain specific groups such as in infants (Koch et al. 
2001) and in children in general (Summerfield et al. 1997,  Hibberd et al. 1999,  Fidler et al. 2004), 
in patients with cancer (Mullighan et al. 2002,  Horiuchi et al. 2005,  Vekemans et al. 2007), in 
patients with some other defect in immunity (Garred et al. 1995) and in critically ill patients (Garred 
et al. 2003,  Fidler et al. 2004,  Sutherland et al. 2005,  Gordon et al. 2006). In non-selected patient 
populations, the effect is less apparent (Dahl et al. 2004), suggesting that the phenotypic expression 
of MBL deficiency is favoured by concomitant inherited or acquired risk factors (Casanova and 
Abel 2004), e.g. smoking in the present study. In contrast to the present findings, a few studies have 
indicated that MBL2 variants may also predispose to infections also in healthy young people (Roy et 
al. 2002,  Rantala et al. 2008). In the present study, only a few patients had severe underlying 
comorbidities, e.g. malignancies, which significantly affect host immunity. This limits conclusions 
as to the effects of MBL deficiency in cancer patients with bacteraemia in the present cohort.  
MBL deficient genotypes did not affect survival here. Previous studies have yielded conflicting 
results also regarding MBL2 polymorphisms and case fatality in sepsis/infection (Kronborg et al. 
2002,  Garred et al. 2003,  Gordon et al. 2006). The majority of previous works have focused on the 
effect of MBL2 polymorphisms on mortality and outcome in patients with severe septic infection 
(Garred et al. 2003,  Fidler et al. 2004,  Sutherland et al. 2005,  Gordon et al. 2006). Studies 
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focusing on the clinical course of bacteraemia in patients with varying disease severity, as the 
present study, are few in number (Kronborg et al. 2002,  Eisen et al. 2006,  Smithson et al. 2007). In 
accord with the present findings, a large population-based prospective study of >9000 participants 
in an ethnically homogeneous Caucasian population, produced no evidence for significant 
differences in mortality in MBL-deficient individuals versus controls (Dahl et al. 2004). In contrast, 
Eisen and associates (2008) reanalyzed individual data from 5 adult studies and 1 paediatric study 
of MBL and severe bacterial infection, and showed that the risk of death was increased among 
MBL-deficient patients with severe pneumococcal infection. The genetic heterogeneity of the 
populations studied, different study protocols, differences in definitions of MBL deficiency, and in 
the characterization of underlying conditions and way of living constitute a likely explanation for 
the considerable variability between studies. Current knowledge regarding the relationship between 
genetic variation and diseases may also be subject to publication bias (Pereira et al. 2007). There is 
marked diversity in MBL2 genotype frequencies between different ethnic groups (Ivanova et al. 
2008). In the present study, all patients were Caucasians and the genotype frequencies were in 
Hardy-Weinberg equilibrium. Furthermore, the genotype frequencies in both promoter and exon 1 
regions were very similar to those in other studies conducted in the same ethnic group (Rantala et 
al. 2008). 
The risk of bacteraemia in MBL2 O allele carriers was most prominent in the case of 
bacteraemia caused by Str. pneumoniae, an agent implicated for respiratory tract infections in 
particular. MBL, a member of the collectin family, is present in the upper airways and buccal cavity 
secretions, where it may protect against respiratory infections (Hickling et al. 2004). MBL 
insufficiency causing opsonization deficiency (Super et al. 1989), together with smoking, may have 
deleterious effects on immunity, thus increasing the risk of gram-positive bacteraemia and the risk 
of Str. pneumoniae bacteraemia in particular. Although Str. pneumoniae has been shown to bind 
MBL rather weakly, in clinical studies (Roy et al. 2002) MBL insufficiency has been associated 
with the risk of pneumococcal bacteraemia, probably due to its route of infection via the lungs. 
Interestingly, in most studies showing a positive association between MBL genotypes representing 
insufficiency and predisposition to bacteraemia caused by a specified agent, the culprit organism in 
question is encapsulated, which is the case in Neisseria meningitidis (Hibberd et al. 1999) and Str. 
pneumoniae (Roy et al. 2002) bacteria. The mechanism underlying this phenomenon is unclear. 
 The exact mechanism by which smoking contributes to increased infection risk has not been 
fully established. Smoking has substantial effects on the immune system, affecting both innate and 
adaptive immunity (Sopori 2002). The findings presented here suggest that the effects of smoking 
on immunity may, at least in part, be genetically determined. The interplay between genes and 
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environmental factors, smoking in particular, has been a subject of several other studies. As an 
example, a gene-smoking interaction on the risk of acquiring rheumatoid arthritis has been found 
(Pedersen et al. 2007). Gene-environmental interactions between smoking and the predisposition to 
infectious diseases have previously been described in bacterial vaginosis (Ryckman et al. 2009). 
A limitation in the present study was that the control population was not originally chosen for 
this study. However, smoking habits were very similar in this control group, when compared to 
corresponding results of the population-based Health 2000 Survey (THL 2007). The lack of MBL 
serum level measurements in conjunction with MBL genotype analysis could be considered another 
limitation in the present study. The number of patients homozygous for structural variant allele 
(OO, n=6) was small. This thus limits conclusions on the effects of structural variant homozygosis 
on the susceptibility to or outcome of bacteraemia.  
In summary, human MBL insufficiency probably does not confer a Mendelian susceptibility to 
bacteraemia, but it is likely that its phenotypic expression is favoured by concomitant inherited or 
acquired risk factors such as smoking. Although smoking was more common in males than females 
here, the finding was consistent in both genders. Furthermore, the effects of smoking on immunity 
may, at least in part, be genetically determined.  
6.2.2. eNOS G894T polymorphism (Glu298Asp) 
The findings in Study II show that the eNOS Glu298Asp polymorphism (T allele) is associated with 
hypotension in patients with E. coli bacteraemia but not in those with bacteraemia caused by a 
gram-positive organism. The effect on hypotension was most evident in the early stage of the 
disease. Patients with the variant infected with a gram-positive organism were not at increased risk 
of hypotension.  
In previous studies, the eNOS Glu298Asp polymorphism has been suggested to play a role in the 
development of hypertension, coronary artery spasms and acute myocardial infection (Hibi et al. 
1998,  Miyamoto et al. 1998,  Yoshimura et al. 1998), although controversial data exist (Karvonen 
et al. 2002,  Casas et al. 2006). No previous study has investigated this polymorphism in 
bacteraemia or sepsis. The phenotypic expression of the T allele in sepsis is unclear, and in non-
septic state this polymorphism has been associated with reduced vasodilatation (Godfrey et al. 
2007) and NO secretion (Veldman et al. 2002). The eNOS Glu298Asp variation has been shown to 
have biochemical consequences in the human endothelium, for example altered caveolar 
localization of eNOS and impaired response to shear stress (Joshi et al. 2007).  
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Previous studies have shown that various ethnic groups differ from each other in terms of the 
genotype distributions and allele frequencies of the eNOS gene. For example, the Finnish 
population differs from the Japanese, the T allele being less frequent in the latter (Hibi et al. 1998,  
Karvonen et al. 2002). In the present study, the frequencies of the T and G alleles in the whole 
cohort were fairly similar as compared to a control population (randomly selected from the national 
health register) in another Finnish study (23% vs 29% and 77% vs 71%, respectively) (Karvonen et 
al. 2002). 
The balance of eNOS and iNOS during sepsis has not been fully established. Transgenic mice 
overexpressing eNOS in endothelial cells have been shown to be resistant to LPS-induced 
hypotension, although iNOS-mediated NO production seemed not to be altered in transgenic 
compared to control mice (Yamashita et al. 2000). In contrast, recent findings indicate an essential 
pro-inflammatory role for eNOS; macrophages from eNOS-knockout mice evince reduced NF-!B 
activity, iNOS expression and NO production after LPS exposure, compared with wild-type mice 
(Connelly et al. 2005).  
NO may act as a double-edged sword during septic shock. The main contributor implicated for 
septic shock is cytokine–induced iNOS, whereas eNOS is considered to be physiological, releasing 
small amounts of NO to maintain tissue flow in vital organs. NO production facilitates host defence 
by its cytostatic and cytotoxic effects (Nathan 1992,  MacMicking et al. 1997) and the 
nonselectivity of NOS inhibitors may lead to toxic effects of inappropriate eNOS inhibition, as 
shown in experimental studies (Assreuy 2006). Even though T allele carriage was associated here 
with hypotension in E.coli bacteraemia, T allele carriage did not affect survival. This may also 
reflect the quality of care and the adoption of evidence-based early goal-directed strategies like fluid 
resuscitation (Dellinger et al. 2004). On the other hand, all patients with E.coli bacteraemia and 
early hypotension recovered, indicating that pathophysiological mechanisms other than hypotension 
per se may be involved in fatal cases. 
The effect of the structural T allele on hypotension was most evident in the early stage of the 
disease and the effect on blood pressure was no longer documented, starting from day 5 after the 
blood culture was taken.  This makes for a biological rationale, as the effects of NO depend on the 
rate, timing and spatial distribution of NO production as well as the chemical microenvironment 
(Fang 1997,  Feihl et al. 2001). Furthermore, it has been shown that depending on concentration and 
particular circumstances, NO may exert either pro- or anti-inflammatory effects (Feihl et al. 2001).  
The reason why the T allele was associated with hypotension specifically in E.coli bacteraemia 
in this study remains obscure. Furthermore, the effect of the T allele on disease severity in E. coli 
and in gram-positive bacteraemia here were in contrast to each other. Bacterial toxins such as 
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superantigens and endotoxin are commonly implicated in the pathogenesis of gram-positive and 
gram-negative sepsis, respectively, yet they signal via widely disparate cellular mechanisms and 
induce markedly different inflammatory cascades (Hotchkiss and Karl 2003,  Carlet et al. 2008). 
Gram-negative and gram-positive bacteria differ in binding patterns to TLRs (Uematsu and Akira 
2006) and the signalling pathways leading to iNOS induction have been shown to differ in S. aureus 
and E. coli infections (Paul-Clark et al. 2006). In experimental models, E.coli or LPS have been 
shown to induce the release of NO more rapidly compared to S. aureus (Paul-Clark et al. 2006).  
In the present study, carriage of the T allele in patients with E. coli bacteraemia was weakly 
associated with an increased risk of acute myocardial infarction. This might be explained as a 
consequence of reduced basal eNOS-derived NO secretion as a result of T allele carriage. In accord 
with this finding, T allele carriage has previously been linked to acute myocardial infarction (Hibi et 
al. 1998), coronary artery spasms (Yoshimura et al. 1998) and CHD (Casas et al. 2006). It has 
already been noted that sepsis per se leads to endothelial dysfunction, which, in part, may be related 
to reduced eNOS expression and activity. In such conditions, further inhibition/dysfunction of 
eNOS can exacerbate endothelial dysfunction and further impair microvascular homeostasis 
(Thiemermann 1997). 
Some limitations must be conceded here. The studied subgroups of bacteraemia patients being 
small, with a limited number of clinical endpoints, no more than a few possible confounders could 
be added in the multiple regression model as covariates evaluating the independent role of the T 
allele in relation to hypotension in E. coli bacteraemia. Furthermore, there is of course a possibility 
that the observed associations could be attributable to another co-inherited variant in linkage 
disequilibrium with the eNOS Glu298Asp SNP. The present study, like genetic association studies 
in general, needs replication (Ioannidis et al. 2001).  
In summary, eNOS Glu298Asp polymorphism (T allele) was associated with hypotension in 
patients with E. coli bacteraemia but not in bacteraemia caused by a gram-positive organism. The 
effect on hypotension was most evident in the early stage of the disease. The results may indicate a 
pivotal role for the eNOS gene in the regulation of haemodynamic responses during the course of 
bacteraemic infection. 
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6.3. Host characteristics and underlying diseases and bacteraemia 
outcome  
6.3.1. Obesity 
Obesity emerged as an independent factor associated with case fatality in bacteraemia patients, BMI 
being significantly higher in deceased patients compared to survivors.  
Only a few studies have systematically evaluated the impact of obesity on the outcome of sepsis 
or infections in general (Falagas et al. 2009). BMI data are seldom reported in most cohort and 
population-based studies adressing the outcome of infections, as such studies are usually 
retrospective by design. In accord with the present findings, there is a study among pneumonia 
patients (Bochicchio et al. 2004) and one among cellulitis patients (Carratala et al. 2003) showing 
an association between obesity and increased case fatality in infection. In one prospective study of 
182 patients with pneumonia the mortality rate was higher in obese compared to non-obese subjects 
(Bochicchio et al. 2004) and in a retrospective study of over 300 patients with community-acquired 
cellulitis, morbid obesity was likewise associated with an increased mortality rate (Carratala et al. 
2003). In contrast with the present findings, a prospective study of over 800 ICU patients presenting 
with different kinds of infections found no significant association between high BMI and increased 
mortality rate (Smith et al. 2007). Similarly in a small prospective study of patients with intra-
abdominal sepsis, obesity was not associated with case fatality (Kalfarentzos et al. 1987). 
In contrast with the present findings, the results from two recent meta-analysises show no show 
increased mortality among obese ICU patients and obesity was even found to be protective 
compared to some other BMI subgroups (Akinnusi et al. 2008,  Hogue et al. 2009). However, 
duration of hospital stay and mechanical ventilation were adversely affected by obesity (Akinnusi et 
al. 2008,  Hogue et al. 2009). Both of these meta-analyses included studies with multiple reasons 
for ICU admission, and infections or sepsis data were insufficiently reported in most of them. 
Furthermore, most were retrospective by design. 
It remains obscure which factors contribute to the increased case fatality in obese bacteraemia 
patients in the present study. There are several possible mechanisms. Previous laboratory 
observations have shown that inflammatory responses are dys-regulated in patients with obesity 
(Marti et al. 2001). Obesity may also cause increased microvascular injury and activation of 
prothrombogenic factors upon exposure to infectious stimuli (Scott et al. 2004,  Vachharajani et al. 
2005,  Amar et al. 2007). Moreover, the accumulation of adipose tissue has been related to a higher 
degree of oxidative stress and platelet activation (Davi et al. 2002). Obesity is known to affect the 
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respiratory system adversely by reason of mechanical factors as well as the metabolic effects of the 
excess adipose tissue (McClean et al. 2008). In fact, the effect of obesity on case fatality was most 
evident in Str. pneumoniae bacteraemia, an agent causing infections involving the upper respiratory 
tract and lungs in particular. It could thus be assumed that obese patients may have diminished 
respiratory reserve function to cope with pulmonary infections compared with normal-weight 
subjects (Falagas et al. 2009). Obesity may adversely affect the outcome of skin and soft tissue 
infections, since normal adipose tissue has a relatively low blood supply (Rosell and Belfrage 1979) 
and the blood supply of skin and soft tissues may become impaired in the case of obesity by reason 
of microvascular changes related to the metabolic effects of obesity (Falagas et al. 2009). 
Furthermore, an impaired blood supply may be a cause for suboptimal recruitment of host immune 
mechanisms and consequently, delayed wound healing (Utley et al. 1989,  Falagas et al. 2009).  
Comorbid conditions related to obesity may be responsible, at least partly, for poorer outcome in 
patients with bacteraemia. A link to glucose metabolism is one possible mechanism, as type 2 
diabetes is a common comorbidity in obese individuals and hyperglycaemia is common in acutely 
ill patients. Diabetes mellitus is a cause of impaired cellular immune functions, including 
chemotaxis, phagocytosis and the bactericidical ability of neutrophils and monocytes/macrophages 
(Geerlings and Hoepelman 1999). Diabetic patients have been shown to have an adverse prognosis 
in the case of some infectious diseases (Falguera et al. 2005). The occurrence of hyperglycaemia,
 
in 
particular severe hyperglycaemia, has been shown to be associated with increased morbidity and 
mortality in a variety of groups of patients (Krinsley 2003,  Gale et al. 2007). Over forty per cent of 
obese patients in the present study had previously been diagnosed with diabetes mellitus. 
Furthermore, the burden of type 2 diabetes in the general population has been shown to be far more 
greater than the number of patients with diagnosed diabetes, this applying equally to the present 
population (Thomas et al. 2005). In a multivariate model, obesity remained an independent 
predictor of death, even after adjusting for diagnosed type 2 diabetes mellitus. The outcome of 
obese patients may be adversely influenced because knowledge of the pathophysiology and optimal 
treatment of obese critically ill patients, especially those with sepsis, is limited. Also limited are 
relevant data regarding the dosing of most antimicrobials in obesity (Pai and Bearden 2007). 
The usefulness of BMI in critically ill patients has been debated in the medical literature, some 
authors requiring adjustment of patient weights for fluid balances (Goulenok et al. 2004,  Schultz 
and Spronk 2005), since the most severely ill patients frequently need more fluids (especially when 
saline solutions are used for fluid therapy) which raises the total measured body weight and thus the 
BMI. However, in the present study the BMIs were based on weight and height as reported by the 
  78 
patient on admission. Thus, fluid therapy possibly given is an unlikely confounder in the present 
case. 
Low BMI (<18.5) was not associated with the outcome of bacteraemia in the present cohort. 
However, as there were only 3 underweight patients, no conclusions can be drawn regarding  
underweight and outcome. It cannot be ruled out that obesity might also have predisposed the 
present cohort to bacteraemia. However, the proportion of obese patients here (23.7%) was very 
similar to the prevalence of obesity in the Finnish population (23.5% in men, and 28.0% in women) 
(Saaristo et al. 2008). 
In summary, obesity comprised an independent factor associated with case fatality in 
bacteraemia in the present study. There are several possible pathophysiological mechanisms 
underlying the presented findings, which warrant further studies. 
6.3.2. Smoking 
The findings here showed smoking to be independently associated with case fatality in patients with 
bacteraemia. The effect on case fatality was most distinct when current smokers were compared to 
non-smokers, but it also remained significant after smoking cessation.  
In previous studies, it has not been adequately evaluated whether the predisposition to an 
infection in smokers may also translate into a poorer prognosis in patients who become infected. 
Data on smoking habits are seldom reported in most population-based studies adressing the 
outcome of infections, and only a few studies have systematically included smoking habits in their 
multivariate models in seeking factors significantly associated with case fatality in infections.  
In accord with the present findings, one retrospective cohort study of 136 patients with liver 
transplantation (Leithead et al. 2008), and one population-based study of patients with invasive 
pneumococcal disease (Laurichesse et al. 2001), found smoking to be independently associated with 
increased infection-related mortality. In contrast with the present findings, a prospective study of 
nosocomial bacteraemia patients showed smoking not to be associated with case fatality 
(Arvanitidou et al. 2005) and in a study conducted among septic ICU patients, smoking had no 
independent effect on mortality (Pittet et al. 1993). In a meta-analysis of 122 studies on factors 
associated with community-acquired pneumonia outcome, smoking data were available in 8 of the 
works included (Fine et al. 1996), and smoking was not associated with poor outcome (Fine et al. 
1996). One recent retrospective study has even shown reduced mortality among active smokers 
compared to non-smokers in community-acquired pneumonia (Garau et al. 2008).  
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The mechanisms whereby smoking affects the outcome in bacteraemic patients remain unclear. 
It has previously been shown that smoking has substantial effects on the immune system, affecting 
both innate and adaptive immunity (Sopori 2002). One limitation in the present study, as in others 
reporting the effects of smoking in infectious diseases (Arvanitidou et al. 2005,  Garau et al. 2008,  
Leithead et al. 2008), was that the quantity of cigarettes smoked per day and smoking duration  
(years) were not documented. This limits dose-dependent considerations on the effects of smoking. 
However, an advantage here was that smokers were classified as current smokers, ex-smokers and 
non-smokers, which enabled evaluation of the significance of smoking cessation on bacteraemia 
outcome. 
In summary, the findings here showed smoking to be independently associated with case fatality 
in patients with bacteraemia. The effect of smoking on case fatality remained significant in the 
multivariate model. The present data highlight the significant adverse effects of smoking on 
bacteraemia outcome. 
6.3.3. Other underlying conditions, age and sex 
Alcoholism did not remain an independent factor associated with case fatality in the multivariate 
model where smoking was included. The most likely explanation for this is that most alcohol 
abusers were also smokers, and the effect on case fatality may thus result from smoking, not alcohol 
itself.  
Alcohol abuse has adverse effects on the immune system (Pavia et al. 2004,  Moss 2005). 
Alcoholism has been shown to constitute a risk factor for sepsis, severe sepsis and hospital 
mortality (O'Brien et al. 2007), and for increased severity of community-acquired pneumonia (Ruiz 
et al. 1999,  de Roux et al. 2006). There are studies reporting an association between alcoholism and 
increased case fatality in pneumococcal bacteraemia (Klemets et al. 2008b), S. aureus bacteraemia 
(Kaech et al. 2006) and in ß-haemolytic streptococcus bacteraemia (Rantala et al. 2009b). In a study 
conducted by Moss and associates (2003), chronic alcohol abuse was a risk factor for acute 
respiratory distress syndrome and increased the severity of nonpulmonary organ dysfunction in 
patients with septic shock. However, of the above-mentioned studies, multivariate models where 
smoking was included as a covariate was performed only in the last-mentioned (Moss et al. 2003) 
and there are also studies where no independent association between alcoholism and case fatality in 
bacteraemia has been shown (Watakunakorn et al. 1993, Lääveri et al. 1996, Laupland et al 2004). 
There is also considerable heterogeneity between different studies in defining alcohol abuse and no 
unifrom approach has been implemented (Aalto et al. 2009). The methods of data collection vary 
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between studies, i.e. whether patient surveys or questionnaires, register-based data, prospective, or 
retrospective data registration were used to characterize alcohol dependence. In the present study, 
alcohol abuse was defined as patient inquiry-based consumption of !300g absolute alcohol per 
week or a known social or medical problem due to alcohol use. This definition excludes the 
evaluation of patients with moderate consumption; according to the definition used in here, all 
patients who were defined as alcohol abusers were thus clearly heavy drinkers (Sillanaukee et al. 
1992). 
Population-based studies constitute a large body of literature on the effect of various underlying 
diseases on the bacteraemia outcome (Brun-Buisson et al. 1995,  Angus et al. 2001,  Alberti et al. 
2003). In contrast with these, malignancies, ultimately or rapidly fatal underlying diseases or liver 
cirrhosis did not prove to be significant risk factors associated with outcome in the present study. 
This may be due to the small numbers of patients with the above-mentioned conditions. 
In contrast to several other studies (Angus et al. 2001,  Kaech et al. 2006,  Klemets et al. 2008b), 
advanced age was not a risk factor for case fatality here. Since this was not a population-based 
study, the oldest patients with severe underlying conditions and severe sepsis were probably missed, 
having been treated in primary health centre wards without admission to the university hospital. 
Hence the present study was not designed to consider the effect of age on the outcome of patients. 
Several studies suggest that men are more susceptible to infections (Klein 2000), and once an 
infection occurs, are more likely to die (Schroder et al. 1998,  Angus et al. 2001). In the present 
study, the genders did not differ from each other in numbers of deceased patients. 
In summary, alcoholism, other underlying conditions, age or sex did not have an independent 
effect on bacteraemia outcome. 
6.4. IDO activity as a predictor of outcome in bacteraemia 
The present study showed that the overexpression of IDO activity independently predicted severe 
disease and case fatality in patients with bacteraemia.  
This series was amongst the first to indicate decreased survival in patients with increased IDO 
activity in bacterial infections or sepsis. In accord with the present findings, recently acquired new 
data indicate that the degradation of tryptophan may be associated with the development of sepsis 
and poor outcome after major trauma (Pellegrin et al. 2005,  Logters et al. 2009,  Ploder et al. 
2009). One small study, again, was suggestive of an association between highly increased 
tryptophan degradation and the severity of Streptococcus pyogenes infection (Murr et al. 2001).  
  
 
81  
Kynurenine to tryptophan ratios reflecting IDO activity in patients with bacteraemia were over 
three times higher than in healthy Finnish blood donors (Pertovaara et al. 2006), reflecting increased 
IDO activity in bacteraemic patients. In accord with the present findings, immune cells, including 
dendritic cells (DCs), macrophages and eosinophils have been shown upon infectious stimuli to 
induce IDO enzyme expression following Th1-type cytokine interferon- ! (INF-!)-mediated 
stimulation (Mellor and Munn 2004). IDO, the rate-limiting enzyme for tryptophan catabolism, has 
long been known to be operative in antimicrobial defence (Taylor and Feng 1991,  Mellor and 
Munn 1999). Although some microbial organisms have been shown to be sensitive to the 
tryptophan-depleting activity of IDO in vitro (Pfefferkorn 1984,  Gupta et al. 1994), its biological 
efficacy in controlling infections in vivo has remained unclear (Mellor and Munn 2004). IDO is a 
natural immunoregulatory mechanism and suppresses T-cell proliferation (Hwu et al. 2000). 
However, its function in the immune system appears to diverge depending on the type of immune 
cell and the nature of the stimulus involved (Mellor and Munn 2004) and it is not clear whether IDO 
is beneficial or detrimental to the host.  
IDO activities varied significantly here between different causative organisms and focuses. 
Although the cellular mechanisms underlying the increased activity of IDO in bacteraemic patients 
remain unclear, this again reflects the fundamental differences in pathogenesis between the different 
pathogens, and the particular microorganism undoubtedly plays a particularly important role.  
Bacterial toxins such as superantigens and endotoxin are commonly implicated in the pathogenesis 
of gram-positive and gram-negative sepsis, respectively, yet they signal via disparate cellular 
mechanisms and induce markedly different inflammatory patterns (Hotchkiss and Karl 2003,  
Bhavsar et al. 2007,  Carlet et al. 2008). Furthermore, different organisms cause infections in 
different loci and the organ in which infection takes place is of paramount importance. For example, 
it is known that immune mechanisms in the lung and in the peritoneum are markedly dissimilar, 
leading to differential effects of therapeutic compounds aimed at manipulating the same 
inflammatory system (Bagby et al. 1991,  Carlet et al. 2008). Interestingly, IDO activities here 
increased markedly in nonsurvivors during the first days after blood culture, whereas in survivors 
IDO activities decreased, but the significance of and contributors to this finding are unclear.  
The findings presented here do not amount to a causal relationship between high IDO activity 
and case fatality in bacteraemia. One possible mechanism underlying high IDO activity in 
conjunction with poor outcome could lie in the effects of IDO on T-cell-mediated immunity. 
Currently, deregulated apoptotic immune-cell death has been suspected to play a major part in 
immune dysfunction and mortality in sepsis (Hotchkiss et al. 1999,  Hotchkiss and Karl 2003,  
Hotchkiss and Nicholson 2006). Caspase-inhibitors are currently being investigated, as potential 
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anti-sepsis strategies and their mechanism rely on inhibition of the dysregulated apoptopsis of 
immune cells (Hotchkiss and Nicholson 2006). Interestingly, the IDO enzyme, in addition to its role 
as a suppressor of T-cell function, induces apoptosis, and is induced by apoptosis (Lee et al. 2002). 
This latter study showed that T cells became susceptible to death via apoptosis in the absence of 
free tryptophan, in part through Fas-receptor-mediated signalling, and this was reversed by caspase 
inhibition. The first evidence supporting the conception of causal effects of IDO in sepsis came 
from a recent study in mice showing that survival from endotoxin shock was enhanced in IDO-
knockout (IDO
-/-
) and in IDO inhibitor 1-methyl-tryptophan-treated mice compared with wild-type 
mice (Jung et al. 2009). IDO is encoded by the gene INDO located in chromosome 8. The 
regulation of INDO transcription is complex and cell-type-specific, and the complete mechanisms 
are not well established (Mellor and Munn 2004). Recent studies indicate that infection-induced 
IDO activity may also be genetically determined by the expression of the transforming growth 
factor beta 1 (TGFB1) gene and cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (Raitala et al. 
2007). It remains to be established, whether genetic variation may regulate IDO expression and 
disease presentation in different clinical entities such as sepsis.  
The absence of measurements of IDO on the day of blood culture limits direct comparisons 
between CRP and IDO. There were generally multiple measurements available for each patient 
(median 4 per patient) on separate measurement days. This reduces the possibility of bias compared 
to single measurement protocols and enables evaluation of IDO activity changes during the course 
of disease. Of separate time-points, on days 3 and 4 IDO activity was significantly higher in non- 
survivors vs. survivors. IDO activity is commonly measured by determination of the kyn/trp ratio 
(Schrocksnadel et al. 2006) (i.e. by determination of the first metabolite to substrate). Determination 
of the IDO messenger ribonucleic acid (mRNA) of the cells is another possible method to study 
IDO activity. However, IDO mRNA determination would have required a rapid and timely analysis 
of study samples, live cells, and would not have been possible to perform from stored study 
samples. 
In summary, the overexpression of IDO was strongly associated with poor outcome in patients 
with bacteraemia. When high IDO activity was studied in a multivariate model adjusting for 
potential confounders, it was found that high IDO activity was an independent predictor of death in 
bacteraemia. 
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6.5. Future considerations 
The present study showed a novel gene-environment interaction between the MBL2 structural 
variant allele and smoking. Future work should be targeted to confirm these findings in population-
based studies, and the molecular mechanisms of smoking in the context of immunity should be 
investigated in detail.  
The present findings showed that genes regulating vascular tone may be involved in the 
pathogenesis of septic hypotension. Large, population-based case-control studies on genes involved 
in the regulation of vascular tone in relation to infection outcome should be undertaken. A 
haplotype analysis-based approach and genotyping of multiple SNPs simultaneously may be of 
value. 
The mechanisms underlying the excess case fatality in obese bacteraemia patients reported here 
remain unclear. Obesity-related comorbidities (e.g., insulin resistance), dys-regulated 
immunomechanisms, impaired respiratory function, altered antimicrobial pharmacokinetics and 
pharmacodynamics and obesity-related microvascular changes may be amongst the key elements in 
the adverse events related to sepsis. Obesity-related factors might complicate acute illness and 
impede the implementation and/or efficacy of evidence-based interventions. The adoption of 
evidence-based treatment options for obese individuals may be haphazard, as there is a paucity of 
information regarding the pathophysiology and treatment of obese critically ill sepsis patients. Thus, 
the impact of obesity-related mechanisms on infection outcome should be studied in large, 
population-based prospective studies in different infections. 
 Cigarette smoking is a worldwide epidemic, and constitutes one of the main preventable causes 
of death and disability. The present study showed an independent association between smoking and 
adverse outcome in bacteraemia. The target populations for preventive efforts, for example 
recommended vaccination populations, should be vigorously studied in order to characterize those 
likely to derive greatest potential benefit. A recent national population-based study showed that a 
high proportion (46%) of those who died of invasive pneumococcal disease during the years 1995-
2002 did not have a pneumococcal vaccine indication (Klemets et al. 2008b). These findings 
highlight the need for large, prospective studies investigating the effects of smoking on the outcome 
of bacteraemia. Studies on the effects of alcohol abuse on infection outcome should be adjusted for 
smoking habits, and the dose-dependent effects of smoking should be characterized by inclusion of 
detailed inquiry into smoking habits routinely in study protocols in this area. 
The prognostic potential of IDO measurement in sepsis is of paramount interest for the future, as 
more than 100 distinct molecules have been proposed as useful biological markers of sepsis but 
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only few are used in routine diagnostics. The utility of a biomarker is a function of the degree to 
which it adds value to the available clinical information in the domains of screening, diagnosis, risk 
stratification and monitoring of response to therapeutic strategies (Marshall and Reinhart 2009). 
The fact that IDO overexpression has been documented in various diseases may limit its clinical 
applications and specificity in the diagnosis of sepsis. Furthermore, to date measurement of 
tryptophan and kynurenine concentrations in peripheral blood has been challenging, requiring an 
HPLC method. The measurement of IDO enzymatic activity needs further studies in sepsis, in other 
infectious diseases, in critical illness, in all-cause hospital patients and in the healthy population. 
Assessment of the accuracy of IDO activity in differentiating bacterial infections from noninfective 
causes of inflammation and differentiating bacterial infections from viral infections calls likewise 
for further effort.  
Manipulating immune responses to improve patient outcomes is an important challenge in a 
range of inflammatory diseases, including cancer and infectious and autoimmune disorders (Mellor 
and Munn 2004). In cancer therapy, studies support the suitability of the IDO inhibitor D-1-methyl-
tryptophan (1-MT) for human trials aiming to assess the utility of IDO inhibition in blocking host-
mediated immunosuppression and enhancing antitumour immunity (Hou et al. 2007). Currently, 1-
MT is in phase 1 testing for solid tumours, and a new potent competitive IDO inhibitor has recently  
been developed (Yue et al. 2009). The potential of IDO inhibition in sepsis therapy warrants further 
studies. Possible caveats and limitations include its documented beneficial functions as a natural 
immunoregulatory mechanism. For example, Popov and associates (2006) have shown that in 
human listeriosis dendritic cells expressing IDO, together with macrophages, are major cellular 
components of suppurative granulomas in vivo, and that repression of IDO might result in 
exacerbation of granulomatous diseases. Furthermore, IDO is essential to normal, full-term 
gestation (Munn et al. 1998), and scavenging IDO in these circumstances would be detrimental to 
the host and the foetus.  
For decades, the pathogenesis of sepsis has been viewed as involving excessive inflammation, 
suggesting that down-regulation of immunity could be beneficial (Thomas 1972,  Llewelyn and 
Cohen 2002,  Sriskandan and Altmann 2008). More recently an alternative view is suggested by the 
finding that impaired monocyte activation and consequent immune deviation is associated with a 
poor clinical outcome (Hotchkiss and Karl 2003,  Remick 2007,  Sriskandan and Altmann 2008). 
Clinical trials on sepsis are indicative of a complex process and lack agreement as to whether we 
should seek to suppress immunity, boost it, or do both at different time-points (Remick 2007,  
Sriskandan and Altmann 2008). The studies on cytokine polymorphisms (Table 3) have not firmly 
established whether these polymorphisms really constitute a risk of susceptibility to or outcome of 
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infections. To date, the syndromes of sepsis, severe sepsis and septic shock are defined by 
nonspecific alterations in physiology rather than by specific cellular processes representing 
potential therapeutic targets. Thus, the question whether IDO constitutes a link between lymphocyte 
apoptosis, immunosuppression and excess mortality in sepsis, is a matter for further research. The 
determination of IDO enzymatic activity in peripheral blood mononuclear cells (PBMC) from septic 
patients would present a valuable continuum to the studies presented  here and the signalling 
pathways leading to IDO induction, IDO-related down-stream mechanisms, and the determination 
of IDO overexpression-related cytokine profiles in human sepsis urge to further efforts. Defining 
the possible contribution of IDO in sepsis pathophysiology could enable evaluation of the possible 
utility of modifying the tryptophan degradation pathway for therapeutic purposes. 
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7. SUMMARY AND CONCLUSIONS 
The influence of host genetic factors on the susceptibility to and clinical picture of bacteraemia, 
IDO activity as a predictor of case fatality in bacteraemia, and the influence of host underlying 
factors on the outcome of bacteraemia can be summarized as follows: 
 
I   Smoking proved a significant risk factor for gram-positive bacteraemia in carriers of the MBL2 
structural O allele. The same was not detected in carriers of the AA genotype. However, carriage of 
the MBL2 variant genotype had no independent effect on disease severity or mortality.  
 
II  The findings showed that the eNOS Glu298Asp polymorphism (T allele) was associated with 
hypotension in patients with E. coli bacteraemia but not in bacteraemia caused by a gram-positive 
organism such as S. aureus, Str. pneumoniae, or ß-haemolytic streptococcae. The effect on 
hypotension was most evident in the early stage of the disease. The T allele did not affect case 
fatality in any of the four pathogens studied.  
 
III  Obesity and smoking proved to be independently associated with case fatality in bacteraemia. 
The effect of smoking was most distinct when current smokers were compared to non-smokers, but 
it also remained significant after smoking cessation. 
 
IV The findings showed that a high kynurenine to tryptophan ratio reflecting IDO activity 
independently predicted case fatality in patients with bacteraemia. High IDO activity was strongly 
associated with several variables indicative of severe disease. 
 
In conclusion, MBL2 structural region O allele carriers who smoked were at markedly increased 
risk of gram-positive bacteraemia as compared to control subjects, this representing a novel 
interaction between genes and environment. The effects of smoking on immunity may thus, at least 
in part, be genetically determined. Future population-based studies should be targeted to investigate 
the mechanisms underlying these findings. 
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The T allele at nucleotide position 894, a common variant of the eNOS gene, is associated with 
hypotension in the early stage of disease in patients with E. coli bacteraemia but not in bacteraemia 
caused by a gram-positive organism. The observations in this context emphasize that in devising  
therapeutic interventions, not only organism-related differences in pathogenesis should be 
considered but also differences in patients` genetic background of modifying the outcome of 
bacteraemia and sepsis. The phenotypic expression of T allele carriage in different sepsis models 
and in population-based approaches should be a subject of future researches. 
The results here indicate that obesity and smoking constitute important factors associated with 
case fatality among bacteraemic patients. With the rising prevalence of obesity in Western 
countries, future research should focus on the search for mechanisms responsible for the increased 
mortality in obese bacteraemic patients. The adverse effect of smoking on bacteraemia outcome is 
an underestimated health risk, and its effects on immunity and infection outcome should be 
considered in future population-based studies. 
Since high IDO activity proved an independent risk factor for case fatality in bacteraemia, 
measurement of it may provide new insights into sepsis pathophysiology. Further studies are 
needed to establish whether IDO has an independent role in the pathogenesis of sepsis, and whether 
interference in tryptophan degradation pathway by specific therapy would prove beneficial to the 
host. Recent studies indicate that immunosuppression is a major factor implicated in excess 
mortality in sepsis. Further studies are needed to investigate whether IDO may represent a link 
between T-cell suppression, immunosuppression and death in bacteraemic and septic patients. 
A novel pharmaceutical strategy, rhAPC, raised great hopes at the beginning of the decade, but 
the beneficial effects of even this agent on survival were not uniform in all subgroups of patients, 
reflecting the fact that sepsis comprises a heterogeneous group of syndromes. Identification of the 
risk factors underlying fatal outcome in bacteraemia will allow targeting of preventive and 
therapeutic efforts on individuals likely to derive greatest potential benefit, and the present findings 
provide novel tools for the PIRO approach introduced in personalized medicine in the beginning of 
the ongoing decade. 
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Gene–environment Interaction between MBL2
Genotype and Smoking, and the Risk of
Gram-positive Bacteraemia
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Introduction
Mannose-binding lectin (MBL) is a serum acute-phase
reactant secreted by the liver. It activates the complement
system by binding to carbohydrate structures presented
by micro-organisms and is thus considered an important
component in the innate immune defence system [1, 2].
MBL is encoded by the MBL2 gene on chromosome 10.
MBL insufficiency is caused by polymorphisms in codons
52 (CGT-TGT, designated D, traditionally any of the
variants have also been given the generic designation of
O allele), 54 (GGC-GAC; B or O) and 57 (GGA-GAA,
C or O) in exon 1 of that gene leading to amino acid
substitutions Arg-Cys, Gly-Asp and Gly-Glu in the
peptide, which interfere with the encoded protein,
thereby lowering the circulating levels of MBL, compro-
mising ligand binding and reducing complement activa-
tion. Furthermore, the MBL concentration is highly
dependent upon promoter region polymorphisms, of
which that at position )221 (nucleotide change G-C;
alleles Y-X respectively) is clinically the most important.
Mannose-binding lectin insufficiency caused by MBL2
gene polymorphisms has been associated with increased
susceptibility to infections in both children and adults
[3–6]. It has been shown to be particularly important in
the presence of another immune deficiency, as in haema-
tological patients [5], while in non-selected patient popu-
lations its role in relation to infections has not been fully
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Abstract
Mannose-binding lectin (MBL) insufficiency caused by point mutations in the
MBL2 gene has been associated with increased susceptibility to bacteraemic
infections. We here investigated the effect of MBL2 polymorphisms on the
susceptibility and clinical course of bacteraemia. The study cohort comprised
145 patients with bacteraemia and 400 controls. In the case of patients with
bacteraemia, laboratory findings and clinical data were registered on admission
and during six consecutive days. MBL2 structural polymorphisms at codons
52 (CGT fi TGT; designated D or O), 54 (GGC fi GAC; B or O) and 57
(GGA fi GAA; C or O) in exon 1 of the MBL2 gene and promoter region
polymorphisms at position )221 (G fi C, designated Y or X alleles) were
determined. No difference in MBL2 genotype frequencies between the bacte-
raemic patients and controls was detected, and MBL2 genotype had no inde-
pendent effect on mortality, nor disease severity. However, smoking proved a
significant risk factor for Gram-positive (Staphylococcus aureus, Streptococcus pneu-
moniae or b-haemolytic streptococci) bacteraemia in patients carrying the vari-
ant O allele (53% current smokers in Gram-positive bacteraemia patients
compared with only 21% in controls, odds ratios 4.2, 95% confidence inter-
vals 2.0–9.0; P < 0.001), while it did not have an effect in those homozygous
for the A allele. The same effect was not detected in Escherichia coli bactera-
emia. In conclusion, MBL2 genotypes representing MBL insufficiency were not
associated with the overall risk of bacteraemia or disease severity, but smoking
in carriers of the structural variant O allele may have a deleterious effect
increasing the risk of Gram-positive bacteraemia.
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established [7–9]. MBL insufficiency is associated with an
increased risk of sepsis, severe sepsis and septic shock in
critically ill patients [10–13]. The majority of studies
have focused on the effect of MBL2 polymorphisms on
mortality and outcome in patients with severe septic
infection. Studies concerning the clinical course of bacter-
aemia with varying disease severity are few in number [8,
14, 15].
We sought here to elucidate the role of MBL2 gene
polymorphisms together with other clinical factors and
comorbidities affecting immunity in the risk of bactera-
emia and the outcome of patients with bacteraemia.
Materials and methods
The study material comprised 145 patients with bactera-
emia (77 male and 68 female) aged 59 years (mean, range
16–93) hospitalized in Tampere University Hospital,
Tampere, Finland, from June 1999 to February 2004.
MBL2 genotype frequencies in these patients were com-
pared with those in a control group of 400 adult persons
(151 male and 249 female) aged 60 years (mean, range
31–89), initially recruited from the normal population
for an asthma study, in whom only asthma and chronic
obstructive pulmonary disease had been excluded [16].
In our hospital blood cultures are routinely taken from
patients with symptoms or signs of systemic infection
[fever or hypothermia, tachycardia or tachypnoea com-
bined with leucocytosis or leucopenia and ⁄ or elevated
C-reactive protein (CRP)]. During the period in question
the BACTEC 9240 blood culture system (BD Diagnostic
systems, Sparks, MD, USA) with standard media was
used. Patients were identified according to the microbio-
logical blood culture finding and those with bacteraemia
caused by Staphylococcus aureus, Streptococcus pneumoniae,
b-haemolytic streptococci (b-hml. str.) or Escherichia coli,
the most common causative organisms among commu-
nity-acquired bacteraemia, were only included in the
study. According to the study plan, other microbes were
excluded beforehand. Bacteraemia was defined as commu-
nity-acquired on admission (n = 119, 82%), or hospital-
acquired (nosocomial) if a positive blood culture was
drawn >48 h after admission (n = 26, 18%). After being
informed by the clinical microbiologist (R.V.) the clini-
cians (J.S. and J.L.) asked patients to participate and
interviewed and examined those consenting. Information
was gathered from hospital records at hospital visits and
hospital records were also reviewed after hospitalization
(R.H.). Altogether 149 out of 152 patients agreed to par-
ticipate. MBL2 genetic polymorphism testing was carried
out in 97.3% (145 ⁄149) of the bacteraemia patients and
400 controls.
The recruitment of the patients and the clinical data
collection are described in detail elsewhere [17]. Underly-
ing conditions, alcohol and tobacco consumption were
registered. Alcohol abuse was defined as consumption of
300 g absolute alcohol per week or a known social or
medical problem due to alcohol use (data available on
145 patients). Smoking habits were registered, and
patients were defined as current smokers, ex-smokers, i.e.
those who had stopped smoking and non-smokers, i.e.
those who had never smoked (data available on 132
patients). Smoking data were available in 400 controls.
Calculation of body mass index (BMI) was based on
weight and height as reported by the patient on admis-
sion (data available on 111 patients).
The causative Gram-positive organisms were S. aureus
(40 patients, 27.6%), Str. pneumoniae (42 patients, 29%),
b-hml. str. (23 patients, 15.9%) and Gram-negative E.
coli (40 patients, 27.6%). All patients were treated with
an empiric antibiotic regimen, and where necessary, anti-
microbial treatment was changed according to culture
results.
Patients were closely monitored during hospitalization
and severely ill subjects were transferred to the ICU.
Clinical data were registered on admission and during
six consecutive days. The possible need for mechanical
ventilation was registered. Alterations in mental status
were evaluated on the Glasgow Coma Scale (GCS). A
patient was classified hypotensive if the mean arterial
pressure (MAP) was <70 mmHg during the bacteraemia
episode.
Sequential organ failure assessment (SOFA) score [18]
was calculated during the first 6 days after positive blood
culture. The highest SOFA score for every patient was
used in analysis. Severe organ failure was documented if
the highest SOFA score was ‡4. Laboratory findings were
registered on admission and during six consecutive days.
The laboratory tests included plasma CRP (mg ⁄ l), neu-
trophil count (109 ⁄ l), blood platelets (·109 ⁄ l), plasma
bilirubin (lmol ⁄ l) and plasma creatinine level (lmol ⁄ l).
The case fatality rate was studied within 30 days after
the positive culture (day 30 case fatality). The overall
case fatality among these patients was 13%.
MBL2 genotyping. Exon 1 of the MBL2 structural
gene was amplified by polymerase chain reaction [19].
Genotyping of codon 52 (CGT fi TGT; designated D,
traditionally any of the variants have also been given the
generic designation of O allele), 54 (GGC fi GAC; B or
O) and 57 (GGA fi GAA; C or O) polymorphisms was
performed by sequencing. Structural alleles lacking these
single nucleotide polymorphisms were classified as wild-
type (AA). For genotyping of promoter region polymor-
phism at position )221 bp (G fi C, designated Y or X
alleles respectively) commercially available fluorogenic
allele-specific TaqMan probes and primers were used
(rs7096206; Applied Biosystems, Foster City, CA, USA).
Genotyping was performed by means of the 5¢ nuclease
assay for allelic discrimination using the ABI Prism 7000
sequence detection system (Applied Biosystems).
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Statistical analysis. The SPSS package (version 7.5) was
used for statistical analyses and a two-sided P-value
<0.05 was taken as the level for statistical significance.
Categorical data were analysed by chi-squared test or
Fisher’s exact test when appropriate. Nonparametric data
were analysed by Mann–Whitney U-test. In a binary
logistic regression we analysed the interaction between
MBL genotype and current smoking, in relation to the
risk of bacteraemia in a model adjusted by age and sex,
as the patient and control groups were not matched by
age and sex. We also performed binary logistic regres-
sion, where severity of bacteraemia (SOFA score ‡4) or
need for ICU treatment were dependent factors, and
MBL genotype, current smoking, interaction between
MBL genotype and current smoking, age and sex were
independent factors. Odds ratios (ORs) were expressed
with their 95% confidence intervals (CI).
Results
The distribution of MBL2 genotypes in patients with
bacteraemia and in controls is shown in Table 1. Geno-
type frequencies in controls were in Hardy–Weinberg
equilibrium. The sources of bacteraemia are shown in
Table 2. No significant difference in MBL2 genotype fre-
quencies was detected between the patients with bactera-
emia and controls, nor between the different bacteria
groups, nor when Gram-positive or Gram-negative bac-
teraemia patients and controls were compared. Further-
more, no difference between genders was detected.
Predisposing factors and underlying diseases of
patients with bacteraemia in relation to MBL2 structural
genotype are shown in Table 3. Associations between
MBL2 promoter genotype and these predisposing param-
eters were not detected (data not shown). Bacteraemic
patients who carried the structural O allele were more
often current smokers than those homozygous for wild-
type allele [20 ⁄50 (40%) versus 17 ⁄82 (21%), OR 2.5,
95% CI 1.2–5.5; P = 0.017] (Table 2). The effect was
even more pronounced among patients with bacteraemia
caused by a Gram-positive organism [19 ⁄36 (53%) versus
14 ⁄59 (24%), OR 3.6, 95% CI 1.5–8.7; P = 0.004]
(Table 2), but it was not seen in those with bacteraemia
caused by a Gram-negative rod (E. coli, P = 1.0). Patients
with Gram-positive bacteraemia who were O-allele carri-
ers were significantly more often current smokers (53%),
compared also to controls carrying the O allele (21%)
(Table 4). The risk of Gram-positive bacteraemia in
O-allele carriers who smoked was 4.2-fold (Table 4). The
risk was most prominent in those suffering from pneu-
mococcal bacteraemia [11 ⁄18 (61%) versus 32 ⁄152
(21%), OR 5.9, 95% CI 2.1–16.4; P < 0.001]. However,
no significant difference in smoking was observed
between the patients with wild-type genotype (AA) suf-
fering from Gram-positive bacteraemia or pneumococcal
bacteraemia, compared with controls who were carrying
wild-type (AA) genotype (P = 0.328 and 0.119 respec-
tively), nor within the control group between O-allele
carriers and non-carriers (P = 0.474). Despite the fact
that smoking was more common among men in both
bacteraemic and control groups, an effect was detected
between smoking and Gram-positive bacteremia in
O-allele carriers in both genders (Table 4). When the
Table 1 MBL2 promoter and structural genotypes in patients with
bacteraemia and controls.
Genotype Bacteraemia (n = 145) Controls (n = 400)
Structural
A ⁄A 91 (63) 248 (62)
A ⁄O 48 (33) 136 (34)
A ⁄B 29 (20) 96 (24)
A ⁄C 4 (3) 8 (2)
A ⁄D 15 (10) 32 (8)
O ⁄Oa 6 (4) 16 (4)
P-value (v2-test) 0.788b and 0.980c
Promoter
Y ⁄Y 93 (64) 264 (66)
Y ⁄X 44 (30) 116 (29)
X ⁄X 8 (6) 20 (5)
P-value (v2-test) 0.915
aVariant with regard to both structural alleles: three bacteraemia
patients with B ⁄B, two with B ⁄D and one with D ⁄D genotype, and
five controls with B ⁄B, eight with B ⁄D, one with D ⁄D, one with B ⁄C
and one with C ⁄D genotype.
bThe groups between which the P-value was calculated in bacteraemia
patients versus controls (A ⁄A, A ⁄B, A ⁄C, A ⁄D, O ⁄O).
cThe groups between which the P-value was calculated in bacteraemia
patients versus controls (A ⁄A, A ⁄O, O ⁄O).
Values within parenthesis are expressed in percentage.
Table 2 Source of bacteraemia.
Focus
All,
n = 145a
(%)
E. coli,
n = 40a
S. aureus,
n = 40a
Str.
pneumoniae,
n = 42a
b-hml.
str,
n = 23a
Pneumonia 39 (27) 0 2 35 2
Skin 37 (26) 0 19 2 16
Urinary 30 (21) 28 1 0 1
Osteomyelitis ⁄
spondylitis
14 (10) 0 11 0 3
Gall bladder 7 (5) 4 0 3 0
Endocarditis 6 (4) 0 6 0 0
Gynaecological 3 (2) 1 0 0 2
Mediastinitis 4 (3) 0 4 0 0
Meningitis 3 (2) 0 1 1 1
Intravenous ⁄
intra-arterial
catheter related
3 (2) 0 3 0 0
Arthritis 6 (4) 0 5 0 1
Source unknown 15 (10) 5 3 4 3
aOne patient may have several focuses.
Values within parenthesis are expressed in percentage.
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interaction between MBL genotype and current smoking
in relation to the risk of Gram-positive bacteraemia was
studied in a binary logistic regression adjusted by age
and sex, the finding retained its significance (OR 3.2,
95% CI 1.1–9.0; P = 0.032) (Table 4).
Mannose-binding lectin 2 genotype had no effect on
mortality. The effect of MBL2 genotype on the clinical
course of patients with bacteraemia is shown in Table 5.
Carriage of MBL2 structural O allele seemed to be associ-
ated with an increased need for ICU treatment (OR 3.0,
95% CI 1.2–7.9; P = 0.022), high SOFA score (P =
0.006), lowered MAP (P = 0.011), lowered platelet count
(P = 0.016) and elevated creatinine level (P = 0.009) in
males only. Univariate model indicated no other signifi-
cant interactions between O allele and the underlying
conditions listed in Table 2 (data not shown) in associa-
tion with the severity of disease. However, we analysed
the effect of MBL genotype, current smoking, interaction
between MBL genotype and current smoking, age and
sex in relation to the severity of disease (SOFA ‡4) or
need for ICU treatment in a binary logistic regression
model. O allele or interaction between O allele and
smoking did not remain as a significant risk factor for
disease severity in this model, while smoking did (OR
4.4, 95% CI 1.3–15.1). O allele, or interaction between
O allele and smoking, did not remain as a significant risk
Table 3 Predisposing factors and underlying
diseases of bacteraemia in relation to MBL2
structural genotype.
Structural genotype, n (%)
P-value OR (95% CI)
AA
(n = 91)
AO or OO
(n = 54)
Malignancy 11 (12) 11 (20) 0.179 1.9 (0.7–4.6)
Solid malignancy 7 (8) 8 (15) 0.173 2.1 (0.7–6.1)
Haematological malignancy 5 (6) 3 (6) 1.0 1.0 (0.2–4.4)
Obesity (BMI ‡ 30)a 20 (30) 7 (16) 0.075 0.4 (0.2–1.1)
Rheumatoid arthritis 7 (8) 0 0.046 –f
Alcohol abuse 13 (14) 11 (20) 0.341 1.5 (0.6–3.7)
Current smokerb 17 (21) 20 (40) 0.017 2.5 (1.2–5.5)
Non-smokerb,c 50 (61) 17 (34) 0.003 0.3 (0.2–0.7)
Chronic diseased 69 (76) 44 (82) 0.427 1.4 (0.6–3.2)
McCabe II or IIIe 16 (18) 5 (9) 0.169 0.5 (0.2–1.4)
Liver cirrhosis 2 (2) 2 (4) 0.629 1.7 (0.2–12.5)
Age >60 years 49 (54) 28 (52) 0.816 0.9 (0.5–1.8)
Diabetes (type 1 or 2) 21 (23) 13 (24) 0.891 1.1 (0.5–2.3)
COPD 5 (6) 3 (6) 1.0 1.0 (0.2–4.4)
Male ⁄ female 49 (54) ⁄ 42 (46) 28 (52) ⁄ 26 (48) 0.816 0.9 (0.5–1.8)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CI, confidence intervals;
OR, odds ratios.
aData available on 111 patients.
bData available on 132 patients.
cThose who have never smoked.
dAt least one chronic disease.
eMcCabe class II or III: ultimately or rapidly fatal disease.
fCannot be calculated.
Table 4 Current smokers (%) with Gram-positive bacteraemia (Staphylococcus aureus, Streptococcus pneumoniae or b-haemolytic streptococci) and controls
in relation to MBL2 gene structural genotype.
Structural genotype
All Male Female
Controls
(n = 400)
Bacteraemia
(n = 95)
OR
(95% CI)
Controls
(n = 151)
Bacteraemia
(n = 59)
OR
(95% CI)
Controls
(n = 249)
Bacteraemia
(n = 36)
OR
(95% CI)
AO or OO n = 152 n = 36 n = 61 n = 19 n = 91 n = 17
Current smokers
(%)
32 (21) 19 (53) 4.2 (2.0–9.0) 14 (23) 11 (58) 4.6 (1.6–13.7) 18 (20) 8 (47) 3.6 (1.2–10.6)
AA n = 248 n = 59 n = 90 n = 40 n = 158 n = 19
Current smokers
(%)
45 (18) 14 (24) 1.4 (0.7–2.8) 22 (24) 10 (25) 1.0 (0.4–2.4) 23 (15) 4 (21) 1.6 (0.5–5.1)
CI, confidence intervals; OR, odds ratios.
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factor for ICU treatment, either, while smoking and male
sex remained so (OR 3.9, 95% CI 1.0–14.8 and OR 3.5,
95% CI 1.4–8.4 respectively). MBL2 promoter region
polymorphism did not have an effect on the clinical
course of the disease.
Discussion
In this study, carriage of MBL2 variant genotype had no
independent effect on disease severity or mortality. Fur-
thermore, MBL insufficiency was not connected with the
overall risk of bacteraemia. However, MBL2 structural
O-allele carriers who smoked had over a fourfold risk of
Gram-positive bacteraemia compared with O allele carry-
ing controls. This was not detected in carriers of the AA
genotype. O allele carriage in conjunction with smoking
was not associated with the risk of E. coli bacteraemia.
In several studies, only the homozygous variant geno-
type has been clearly associated with the risk of bactera-
emia [4, 10, 20, 21], although totally negative results
have also been published [8, 15]. The association between
MBL insufficiency and the risk of bacteraemia is clearer
in patients with a more severe course of the disease, e.g.
in ICU patients or in patients with comorbidities, e.g.
haematological malignancies affecting immunity [5, 22]
and in these patients the insufficiency is associated with
the development of sepsis, septic shock and severe inflam-
matory response syndrome [10–13] and even with fatal
outcome [12]. In our study, MBL insufficiency was not
associated with the overall risk of bacteraemia, which is a
somewhat controversial finding as regards some earlier
reports [14, 21]. In most of the earlier studies patients
had been recruited from ICU units [10–13], which may
induce a selection bias. In our study, in turn, all patients
with varying disease severity – patients with milder
symptoms and signs, as well as patients who needed ICU
treatment – were enrolled. Furthermore, in our study
only a few patients had severe underlying comorbidities,
e.g. malignancies, affecting significantly on host immu-
nity. Longitudinal follow-up studies will be needed to
avoid a possible selection bias when evaluating the effect
of MBL insufficiency on the overall risk and outcome of
bacteraemia.
There was a significant interaction between MBL2
genotype and current smoking in relation to the risk of
Gram-positive bacteraemia, when studied in a binary
logistic regression adjusted by age and sex. The finding
was consistent in both genders, which is noteworthy
because smoking was more common among males than
females. The risk was most prominent to bacteraemia
caused by Str. pneumoniae, an agent causing infections
involving the upper respiratory tract and lungs. There are
no previous studies in this field reporting similar findings
regarding the possible gene–environment interaction
between MBL2 genotype and smoking as presented here.
MBL, a member of the collectin family, is the most
abundant in blood but also present in the upper airways
and buccal cavity secretions where it may protect against
respiratory infections [23]. Smoking has substantial
effects on the immune system, affecting both innate and
adaptive immunity [24], and it has been reported
as a risk factor for pneumococcal bacteraemia [25].
MBL insufficiency causing opsonization deficiency [26],
together with smoking, may have deleterious effects on
Table 5 Clinical data on patients with bacteraemia in relation to MBL2 structural genotype.
Structural
All (n = 145)
AA
(n = 91)
AO or OO
(n = 54) OR (95% CI) P-value
Dieda (%) 12 (13) 7 (13) 1.0 (0.4–2.7) 0.969
Needed ICU stay (%) 24 (26) 22 (41) 1.9 (0.9–3.9) 0.072*
Highest CRP (mg ⁄ l), median (quartiles) 270 (186–352) 285 (188–414) 0.647
Neutrophil count (109 ⁄ l), median (quartiles)b 7.9 (4.4–11.5) 7.4 (4.0–11.5) 0.697
Highest SOFA score, median (quartiles) 2 (0–5) 3 (1–5) 0.082*
Needed mechanical ventilation (%) 12 (13) 10 (19) 1.5 (0.6–3.7) 0.387
Lowest platelet count (109 ⁄ l), median (quartiles) 168 (104–239) 137 (77–203) 0.159*
Highest bilirubin level (lmol ⁄ l), median (quartiles) 18 (12–33) 18 (14–34) 0.587
Lowest GCS, median (quartiles) 15 (14–15) 15 (14–15) 0.537
Lowest MAP (mmHg), median (quartiles)c 77 (64–90) 74 (61–83) 0.292*
Highest creatinine level (lmol ⁄ l), median (quartiles) 98 (75–161) 139 (79–226) 0.026*
CRP, C-reactive protein; SOFA, sequential organ failure assessment; GCS, Glasgow Coma Scale; MAP, mean arterial pressure.
aDeath due to bacteraemia episode occurred within 30 days from the day of positive blood culture.
bData available on 123 patients.
cThe lowest MAP = [(systolic + 2 · diastolic blood pressure) ⁄ 3] (median).
*Statistically significant difference in males (v2-test, P < 0.05).
Clinical data and laboratory findings were registered on admission and during six consecutive days.
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immunity, thus increasing the risk of Gram-positive bac-
teraemia and the risk of Str. pneumoniae bacteraemia partic-
ularly. Finally, the binding capacity of MBL to different
organisms has been shown to be varying [27]. This might
cause differences between susceptibilities to infections
caused by Gram-positive and Gram-negative bacteria in
MBL insufficiency. All bacteria studied bind MBL with
various binding capacity [28]. Staphylococcus aureus, and
some b-hml. str. exhibit strong binding of MBL, while
MBL binding pattern to E. coli is intermediate [27, 29].
Streptococcus pneumoniae, in turn, binds MBL rather weakly,
but in clinical studies [21] MBL insufficiency is clearly
associated with the risk of pneumococcal bacteraemia,
probably due to its infection route via the lungs.
There are certain limitations to our study protocol.
The control population was not originally chosen for this
study as it was initially recruited from the normal popu-
lation for an asthma study, in whom only asthma and
chronic obstructive pulmonary disease had been excluded
[16]. This might mean differences in smoking habits
compared with the normal population without such
exclusion criteria. However, the prevalence of current
smoking was relatively similar in both males and females
in this control group, when compared with the respective
results of the population-based Health 2000 Survey, a
health interview ⁄ examination survey of 8028 persons
aged 30 or over, carried out in Finland (24% versus 29%
in males and 17% versus 18% in females) (http://
www.ktl.fi/terveys2000/index.uk.html).
There was no demonstrable influence of MBL2 geno-
type on case fatality or disease severity in this study.
Although male patients with bacteraemia carrying the O
allele seemed to have a greater severity of disease in uni-
variate analysis, the independent role of O allele carriage
was not maintained in multivariate analysis adjusted by
age, sex and smoking habits. This might have been due
to the fact that smoking was more common in males
than in females, and the effect on disease severity might
thus have resulted from smoking, not male gender in
conjunction with MBL2 genotype itself [17]. Previous
studies have produced conflicting results regarding MBL2
polymorphisms and case fatality in sepsis ⁄ infection [8,
12, 13]. Indeed, there is a paper indicating that heterozy-
gosity of MBL2 genotypes predicts an advantage (hetero-
sis) in relation to fatal outcome in intensive care patients
[30]. It should also be noted that modern intensive care
has reduced the mortality rate in sepsis, even if patients
are critically ill.
In conclusion, MBL2 genotypes representing MBL
insufficiency had no effect on the overall risk of bactera-
emia nor on mortality in this study. Thus, the determi-
nation of MBL genotypes did not prove to be a useful
surrogate marker in assessing the risk or prognosis of
bacteraemia in unspecified patient populations. However,
MBL2 structural region O-allele carriers who smoked had
over a fourfold risk of Gram-positive bacteraemia com-
pared with control subjects. Our study should be fol-
lowed up by larger prospective studies in order to
confirm these findings and explore the possible gene–
environment interactions suggested by our findings.
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ENDOTHELIAL NITRIC OXIDE SYNTHASE G894T (GLU298ASP)
POLYMORPHISM IS ASSOCIATED WITH HYPOTENSION IN PATIENTS
WITH E. COLI BACTEREMIA BUT NOT IN BACTEREMIA CAUSED BY A
GRAM-POSITIVE ORGANISM
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ABSTRACT—Nitric oxide (NO) as a vasoactive substance is a crucial element in the pathogenesis of sepsis. Endothelial
NO synthase (eNOS) is, in turn, a key regulator of vascular NO production. The eNOS gene polymorphism at position 894
(G9T, Glu298Asp) resulting in T allele has been studied in the context of vascular diseases, but its role in sepsis has not
yet been explored. We here studied the effect of eNOS Glu298Asp polymorphism on the clinical course of the disease in
patients with bacteremia. The study comprised 147 patients with bacteremia caused by Staphylococcus aureus,
Streptococcus pneumoniae, "-hemolytic streptococci, or Escherichia coli. Laboratory findings and clinical data were
registered on admission and during 6 consecutive days. The polymorphism of eNOS gene, G894T, was genotyped.
Carriage of the T allele was associated with low MAP (P = 0.004) and high Sequential Organ Failure Assessment score
(P = 0.001) in patients with E. coli bacteremia. The effect on blood pressure was most prominent in the early stage of the
disease (MAP on admission = 52 mmHg in T-allele carriers vs. 91 mmHg in noncarriers; P G 0.001). However, the same
was not detected in bacteremia caused by a gram-positive organism (S. aureus, S. pneumoniae, or "-hemolytic
streptococci). The Glu298Asp polymorphism had no effect on case fatality in any pathogen. Carriage of the T allele of the
eNOS gene is a risk factor for hypotension in patients with E. coli bacteremia but not in bacteremia caused by a gram-
positive organism.
KEYWORDS—Bacteremia, NO, endothelial, polymorphism, MAP
INTRODUCTION
Nitric oxide (NO) is one of many vasoactive substances
released under conditions of endotoxemia and sepsis. Under
physiological conditions, it is produced by two constitutive
calcium-dependent enzymes including NO synthase (NOS) in
neurons (nNOS) and endothelial cells (eNOS) and has
functions ranging from neurotransmission and vasodilatation
to inhibition of platelet adhesion and aggregation (1, 2).
After bacterial infection, especially with gram-negative
organisms carrying LPS, NO formation from L-arginine is
enhanced because of the cytokine-mediated induction of an
iNOS enzyme in cells (e.g., cardiac myocytes, vascular
smooth muscle), which do not normally have the ability to
synthesize NO. The result of this excessive NO production is
enhanced bacterial lysis by activated macrophages, hypoten-
sion, and myocardial depression. There have therefore been
attempts to improve the prognosis of sepsis by NOS
inhibitors, but results have been inconsistent (3Y7).
Although a key event believed to be responsible for
hypotension and shock in sepsis is iNOS-derived overproduc-
tion of NO, an essential role for eNOS has also been indicated
(8, 9). NO from eNOS plays an important homeostatic role in
maintaining appropriate blood flow to vital organs such as the
kidney, liver, and lungs and exhibits cytoprotective effects, in
part by preventing platelet/neutrophil adhesion to the blood
vessel wall (10, 11). Furthermore, studies of animal models of
sepsis have shown that the pathogenesis of sepsis is
characterized by an initial eNOS activation, with the resultant
NO acting as a costimulus for the expression of iNOS, and
they therefore highlight a novel proinflammatory role for
eNOS (9, 12).
Endothelium-derived NO is formed from L-arginine by
eNOS encoded by the NOS3 gene on chromosome 7q35Y36
(13). The eNOS gene polymorphism in exon 7 at position 894
(Glu298Asp; glutamic acid substituted by aspartic acid), also
defined as G894T, resulting in T allele has been linked to the
pathogenesis of hypertension (14) and coronary artery spasms
(15), although negative results have also been published
(16Y18). In nonseptic state, the carriage of the T allele of
eNOS gene has been linked to reduced basal NO production
(19). In addition, mice lacking the eNOS gene have been
shown to become hypertensive (20).
Although NO plays a key role in the pathogenesis of sepsis
and an essential role for eNOS has been indicated, there are
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no data regarding the role of eNOS G894T polymorphism in
bacteremia/sepsis. We sought here to elucidate the role of this
polymorphism, G894T, of the eNOS gene in the clinical
course of the disease in patients with bacteremia.
MATERIALS AND METHODS
The study comprised 147 patients with bacteremia (78 men and 69
women) with a mean age of 59 years (range, 16Y93 years) hospitalized
in Tampere University Hospital, Tampere, Finland, from June 1999 to
February 2004.
All blood cultures were taken from patients with symptoms or signs of
systemic infection (fever or hypothermia, tachycardia or tachypnea combined
with leukocytosis or leukopenia, and/or elevated C-reactive protein). The
BACTEC 9240 (BD Diagnostic Systems, Sparks, Md) blood culture system
was used with standard media. Patients were identified according to micro-
biological blood culture findings and those with bacteremia caused by
Staphylococcus aureus, Streptococcus pneumoniae, "-hemolytic streptococci,
or Escherichia coli, the most common causative organisms in community-
acquired bacteremia, were included in the study. After being informed by the
clinical microbiologists (R.V. and J.A.), the clinicians (J.S. and J.L.) asked the
patients to participate and interviewed and examined those who consented.
Information was gathered from hospital records at hospital visits, and hospital
records were also reviewed after hospitalization (R.H.). Altogether, 149 of
152 patients agreed to participate. eNOS genetic polymorphism testing was
carried out in 147 (99%) of 149 patients with bacteremia.
The causative organisms involved were S. aureus (40 patients, 27%),
S. pneumoniae (42 patients, 29%), "-hemolytic streptococci (23 patients,
16%), and E. coli (42 patients, 29%). All patients were treated with an empiric
antibiotic regimen, and when necessary, antimicrobial treatment was changed
according to culture results. In all patients, the causative organism was
susceptible to the selected empiric antibiotic treatment. Bacteremia was
community acquired in 119 patients (81%) and nosocomial in 28 (19%).
The recruitment of the patients and the clinical data collection are de-
scribed in detail elsewhere (21). Underlying diseases were registered. Alcohol
abuse was defined as consumption of 300 g absolute alcohol per week or a
known social or medical problem due to alcohol use. Smoking habits were
registered, and patients were defined as current smokers, ex-smokers (those
who have stopped smoking), or nonsmokers (those who have never smoked).
Calculation of body mass index (BMI) was based on weight and height as
reported by the patient on admission. Body mass index was recorded, and
patients were defined as obese if their BMI was greater than 30 kg/m2.
Patients were closely monitored during hospitalization, and severely ill
subjects were transferred to the intensive care unit (ICU). Clinical data were
registered on admission and during 6 consecutive days. The possible need for
mechanical ventilation was registered. Alterations in mental status were
evaluated on the Glasgow Coma Scale. MAP [(systolic + 2 ! diastolic blood
pressure) / 3] was calculated. The lowest MAP was calculated for every
patient on day 0 (the day of positive blood culture), during days 1 to 4 (1 to 4
days after the positive blood culture), or during days 5 to 6 (5 to 6 days after
the positive blood culture). A patient was classified hypotensive if MAP was
less than 70 mmHg at least once on day 0, during days 1 to 4, or during days 5
to 6. The need for vasopressive support was also recorded on day 0, during
days 1 to 4, or during days 5 to 6.
Sequential Organ Failure Assessment (SOFA) score (22) was calculated
during 6 consecutive days after positive blood culture. The highest SOFA
score for every patient was used in analysis. Disease severity was assessed by
SOFA score, and severe disease was defined if SOFA score was 4 or higher.
Laboratory findings were registered on admission and during 6 consecutive
days. The laboratory tests included blood platelets (!109/L), plasma bilirubin
(2mol/L), and plasma creatinine level (2mol/L). The whole-blood sample for
genomic DNA extraction was taken during days 1 to 4 and stored in j70-C
until extraction. The case fatality rate was studied within 30 days after the
positive blood culture (day-30 case fatality).
eNOS GENOTYPING
Genotyping was performed afterward from frozen whole-
blood sample taken during days 1 to 4. Genomic DNA was
extracted from whole blood using a commercially available
kit (Qiagen Inc, Hilden, Germany) in accordance with the
manufacturer’s instructions. DNA samples were genotyped by
using the 5¶ nuclease assay in combination with specific
TABLE 1. eNOS genotype frequencies at nucleotide position 894 in
patients with bacteremia
All
n = 147 (%)
E. coli
n = 42 (%)
S. aureus
n = 40 (%)
S. pneumoniae
n = 42 (%)
"-Hemolytic
streptococci
n = 23 (%) P
Genotype
GG 89 (61) 30 (71) 22 (55) 21 (50) 16 (70) 0.354*
TG 48 (33) 10 (24) 16 (40) 17 (41) 5 (22)
TT 10 (7) 2 (5) 2 (5) 4 (10) 2 (9)
*The difference between groups of patients with bacteremia caused by
different organisms.
TABLE 2. Predisposing factors and underlying diseases of bacteremia stratified by eNOS genotype at position 894
Variable
All E. coli Gram-positive organism
GG
n = 89 (%)
TG or TT
n = 58 (%)
GG
n = 30 (%)
TG or TT
n = 12 (%)
GG
n = 59 (%)
TG or TT
n = 46 (%)
Malignancy* 16 (18) 8 (14) 7 (23) 2 (17) 9 (15) 6 (13)
Obesity (BMI 930 kg/m2)† 17 (25) 10 (23) 3 (12)¶ 5 (50)¶ 14 (32) 5 (15)
Cardiac disease‡ 27 (30) 17 (29) 9 (30) 5 (42) 18 (31) 12 (26)
Essential hypertension 24 (27) 10 (17) 10 (33) 2 (17) 14 (24) 8 (17)
Alcohol abuse 18 (20) 6 (10) 4 (13) 0 14 (24) 6 (13)
Current smoker§ 25 (31) 12 (22) 4 (14) 0 21 (41) 12 (27)
McCabe II or IIIk 15 (17) 8 (14) 7 (23) 1 (8) 8 (14) 7 (15)
Age 960 y 47 (53) 31 (53) 18 (60) 9 (75) 29 (49) 22 (48)
Diabetes (type 1 or type 2) 18 (20) 16 (28) 8 (27) 7 (58) 10 (17) 9 (20)
Male/female 41 (46)/48 (54)¶ 37 (64)/21 (36)¶ 8 (27)/22 (73) 4 (33)/8 (67) 33 (56)/26 (44) 33 (72)/13 (28)
*Solid malignancy or hematologic malignancy.
†Data available on 113 patients.
‡Coronary artery disease, valvular disease, heart failure, or cardiac myopathy.
§Data available on 134 patients.
kMcCabe class II or III: ultimately or rapidly fatal disease.
¶The difference between groups of patients with GG genotype and TG/TT genotype statistically significant, P G 0.05.
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fluorogenic TaqMan MGB probes, using the ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster City,
Calif ). The nucleotide sequences of primers and allele-
specific probes, labeled with reporter dyes, were deduced
from sequences deposited in the GenBank database and
synthesized in conjugation with Applied Biosystems using
the Assays-by-Design tool. Polymerase chain reaction tests
containing genomic DNA, 1! Universal PCR Master Mix
(Applied Biosystems, Foster City, Calif), 900 nM of each
primer and 200 nM of each probe, were performed in 96-well
plates in a total volume of 25 2L, in accordance with the
standard protocol. The end-point reading of fluorescence was
measured using the allelic discrimination analysis module, this
resulting in clear identification of three genotypes.
Statistical analysis
The SPSS package (version 7.5; SPSS Inc Headquarters,
Chicago, Ill) was used for statistical analyses, and a two-sided
TABLE 3. Sources of bacteremia
All (n = 147) E. coli (n = 42)
Gram-positive organism†
(n = 105)
Focus*
GG
n = 89 (%)
GT or TT
n = 58 (%)
GG
n = 30 (%)
GT or TT
n = 12 (%)
GG
n = 59 (%)
GT or TT
n = 46 (%)
Pneumonia 19 (21) 20 (35) 0 0 19 (32) 20 (44)
Skin 23 (26) 14 (24) 0 0 23 (39) 14 (30)
Urinary 21 (24) 9 (16) 20 (67) 8 (67) 1 (2) 1 (2)
Osteomyelitis/spondylitis 6 (7) 8 (14) 0 0 6 (10) 8 (17)
Gall bladder 3 (3) 4 (7) 2 (7) 2 (17) 1 (2) 2 (4)
Endocarditis 6 (7) 0 0 0 6 (10)‡ 0‡
Gynecological 1 (1) 2 (3) 0 1 (8) 1 (2) 1 (2)
Mediastinitis 2 (2) 2 (3) 0 0 2 (3) 2 (4)
Meningitis 2 (2) 1 (2) 0 0 2 (3) 1 (2)
Intravenous/intra-arterial catheter related 1 (1) 2 (3) 0 0 1 (2) 2 (4)
Arthritis 5 (6) 1 (2) 0 0 5 (9) 1 (2)
Source unknown 11 (12) 5 (9) 6 (20) 0 5 (9) 5 (11)
Nosocomial infection 17 (19) 11 (19) 5 (17) 1 (8) 12 (20) 10 (22)
*One patient may have more than 1 focus.
†Bacteremia caused by S. aureus, S. pneumoniae, or "-hemolytic streptococci.
‡P = 0.034.
TABLE 4. Clinical data on patients with E. coli or gram-positive bacteremia in relation to eNOS G894T (Glu298Asp) polymorphism
E. coli Gram-positive organism
GG
n = 30
GT or TT
n = 12
OR
(95% CI) P
GG
n = 59
GT or TT
n = 46
OR
(95% CI) P
Died* 0 1 (8%) † 0.286 11 (19%) 7 (15%) 0.8 (0.3Y2.2) 0.644
Needed ICU stay 2 (7%) 4 (33%) 7.0 (1.1Y45.4) 0.046 25 (42%) 16 (35%) 0.7 (0.3Y1.6) 0.429
Acute myocardial infarction‡ 2 (7%) 4 (33%) 7.0 (1.1Y45.4) 0.046 4 (7%) 1 (2%) 0.3 (0Y2.8) 0.383
Highest SOFA score, median
(quartiles)
1.5 (0Y2.3) 5 (3Y13) 0.001 4 (1Y9) 1.5 (1.0Y4.3) 0.021
Needed mechanical ventilation 0 2 (17%) † 0.077 15 (25%) 5 (11%) 0.4 (0.1Y1.1) 0.06
Lowest platelet count, median
(quartiles), !109/L
178 (120Y200) 105 (36Y163) 0.045 128 (62Y225) 184 (126Y254) 0.023
Lowered GCS 15 (15Y15) 15 (14Y15) 0.170 14 (13Y15) 15 (14Y15) 0.052
Highest bilirubin value, median
(quartiles), 2mol/L
15 (10Y29) 20 (16Y79) 0.085 19.5 (12Y50) 17.5 (13Y29) 0.451
Lowest MAP, median
(quartiles), mmHg
80 (75Y90) 60 (47Y80) 0.004 70 (58Y84) 77 (63Y94) 0.071
Highest creatinine value, median
(quartiles), 2mol/L
98 (72Y193) 148 (83Y190) 0.328 124 (83Y202) 91 (71Y165) 0.098
*Death due to bacteremia episode that occurred within 30 days from the day of positive blood culture.
†Cannot be calculated.
‡Acute myocardial infarction within 30 days from the positive blood culture.
GCS indicates Glasgow Coma Scale.
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P G 0.05 was taken as the level for statistical significance.
Categorical data were analyzed by W2 test or Fisher exact test
when appropriate. Nonparametric data were analyzed by
Mann-Whitney U test. Odds ratios (ORs) were expressed
with their 95% confidence intervals (CIs). The effect of
G894T amino acid substitution on hypotension or disease
severity was studied in a multivariate model adjusting for
confounding factors. Binary logistic regression was used to
calculate ORs and their 95% CIs.
RESULTS
The distribution of the eNOS genotypes at nucleotide
position 894 in patients with bacteremia is shown in Table 1.
The genotype frequencies followed the Hardy-Weinberg
equilibrium. Table 2 shows the most important predisposing
factors and underlying diseases; and Table 3, the sources of
bacteremia in relation to eNOS G894T polymorphism in all
patients and in patients with E. coli or gram-positive
bacteremia, including S. aureus, S. pneumoniae, or "-
hemolytic streptococci. The effect of the eNOS G894T
polymorphism on the clinical characteristics of patients with
E. coli and gram-positive bacteremia is shown in Table 4.
Among those with E. coli bacteremia, carriage of the T allele
was associated with lower MAP (P = 0.004) and higher SOFA
score (P = 0.001), and there were more hypotensive patients
among the T-allele carriers compared with noncarriers (7/12
vs. 6/30; P = 0.015). The effect on blood pressure was most
prominent in the early stage of the disease: on admission,
MAP (median) was 52 mmHg in T-allele carriers compared
with 91 mmHg in noncarriers (P G 0.001), as shown in
Table 5. The same was not detected in bacteremia caused by a
gram-positive organism. In fact, the patients with gram-
positive bacteremia and who have GG genotype had greater
severity of disease (assessed by SOFA score) than those
carrying T allele (Table 4). The effect was most prominent in
those with S. aureus bacteremia; SOFA score was lower in
carriers of the T allele compared with noncarriers (P = 0.008).
T allele did not have an effect on case fatality in any of the
four pathogens studied. The overall case fatality among these
patients was 13%.
T-allele carriage remained a significant risk factor (OR,
10.8; 95% CI, 2.0Y57.7; P = 0.005) for hypotension on day 0
in E. coli bacteremia in a model adjusted by age (continuous
variable) and sex. The number of obese patients (BMI
930 kg/m2) was higher in patients with E. coli bacteremia
carrying T allele compared with noncarriers (Table 2).
However, obesity was not associated with hypotension in E.
coli bacteremia (data not shown). T-allele carriage also
remained a significant risk factor for hypotension on day 0
in a logistic regression model adjusted by obesity (OR, 10.9;
95% CI, 1.4Y84.0; P = 0.02).
The effect of eNOS T-allele carriage on disease severity
(assessed by SOFA score) in gram-positive bacteremia was also
studied in a multivariate logistic regression analysis. In gram-
positive bacteremia, carriage of T allele preserved its protective
role as regards severe disease (OR, 0.4) in a model adjusted for
the effect of age, sex, and endocarditis. Endocarditis was
included in the model because there were significantly more
patients with endocarditis in patients with GG genotype in
gram-positive bacteremia as shown in Table 3.
DISCUSSION
The present findings show the eNOS Glu298Asp poly-
morphism (T allele) to be associated with hypotension in
TABLE 5. The occurrence of hypotension in patients with E. coli and gram-positive bacteremia in relation to eNOS G894T (Glu298Asp)
polymorphism during observation period of day 0, days 1 to 4, and days 5 to 6
E. coli Gram-positive organism
GG n = 30 GT or TT n = 12 OR (95% CI) P GG n = 59 GT or TT n = 46 OR (95% CI) P
On day 0*
Hypotensive† 4 (14%) 7 (58%) 8.8 (1.8Y41.6) 0.003 15 (25%) 5 (11%) 0.4 (0.1Y1.1) 0.06
MAP,‡ median (quartiles) 91 (81Y97) 52 (46Y81) G0.001 80 (67Y97) 87 (76Y106) 0.08
Needed vasopressives§ 1 (3%) 4 (33%) 14 (1.4Y144.0) 0.02 6 (10%) 0 k 0.034
During days 1Y4¶
Hypotensive† 0 4 (33%) k 0.004 15 (25%) 7 (15%) 0.5 (0.2Y1.4) 0.202
MAP,‡ median (quartiles) 94 (88Y107) 80 (74Y91) 0.02 85 (73Y100) 92 (80Y107) 0.236
Needed vasopressives§ 0 4 (33%) k 0.004 12 (20%) 5 (11%) 0.5 (0.2Y1.5) 0.191
During days 5Y6L
Hypotensive† 0 0 7 (18%) 3 (10%) 0.5 (0.1Y2.2) 0.358
MAP‡, median (quartiles) 99 (90Y107) 83 (75Y94) 0.025 89 (71Y100) 97 (81Y110) 0.045
Needed vasopressives§ 0 0 5 (11%) 3 (9%) 0.8 (0.2Y3.7) 0.796
*On the day of positive blood culture.
†MAP G70 mmHg at least once during the observation period (on day 0, during days 1Y4, or during days 5Y6).
‡The lowest value for each patient during the observation period was recorded.
§Needed vasopressive support at least once during the observation period.
kCannot be calculated.
¶One to 4 days after the positive blood culture.
LFive to 6 days after the positive blood culture.
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patients with E. coli bacteremia but not in bacteremia caused
by gram-positive organisms such as S. aureus, S. pneumoniae,
or "-hemolytic streptococci. The effect on hypotension was
most evident in the early stage of the disease. T allele did not
affect case fatality in any of the four pathogens studied.
Cytokine-induced iNOS plays a key role in septic
hypotension, whereas eNOS is considered to be physiolog-
ical, releasing small amounts of NO to maintain tissue flow.
The carriage of the T allele of eNOS gene has been
previously linked to reduced basal NO production in non-
septic state (19). The balance of eNOS and iNOS during
sepsis has not been fully established. Yamashita and asso-
ciates (23) have shown that transgenic mice overexpressing
eNOS in endothelial cells are resistant to LPS-induced
hypotension, although iNOS-mediated NO production does
not differ between transgenic and control mice. In contrast,
recent studies have indicated an essential proinflammatory
role for eNOS (12). Connelly and associates (12) have found
that macrophages from eNOS knockout mice demonstrate
reduced nuclear factor .B activity, iNOS expression, and NO
production after LPS exposure, compared with wild-type
mice. However, no previous study has linked G894T
(Glu298Asp) polymorphisms to septic hypotension or studied
the functional effects of this polymorphism in sepsis. In
contrast, this polymorphism has been linked to hypertension,
although the data are still somewhat ambiguous and its
functional consequences are not yet well established
(17, 24). The reason why T allele was associated with hy-
potension in E. coli bacteremia in this study remains un-
known. The carriage of T allele in patients with E. coli
bacteremia seemed to be weakly associated with an increased
risk of acute myocardial infarction. One explanation may be
coronary artery spasms, which have been associated with T-
allele carriage (15). Although the functional consequences of
T-allele carriage in sepsis are not well known, and systemic
hypotension might be a plausible explanation responsible for
decreased myocardial perfusion, this observation could also
be a consequence of reduced basal eNOS-derived NO
secretion as a result of T-allele carriage.
In our study, the effects of the T allele on disease severity
in E. coli and in gram-positive bacteremia were in contrast to
each other. One possible explanation is the tie to Toll-like
receptors (TLRs); gram-negative bacteria activate TLR4,
whereas gram-positive bacteria activate TLR2. Toll-like
receptor agonistic molecules such as LPS can regulate NO
generation through upregulation of expression of NOS iso-
forms through nuclear factor .B activation (11, 25). Further-
more, the signaling pathways leading to iNOS induction have
been shown to be different in S. aureus and E. coli infections,
and E. coli or LPS has been shown to induce the release of
NO at earlier time points compared with S. aureus (26).
There are limitations in our study. First, the study group is
fairly small. To follow acceptable statistical practices, we
cannot include more than a few possible confounders in the
multiple regression model as covariates evaluating the
independent role of T allele in relation to hypotension in E.
coli bacteremia. Second, in bacteremia caused by gram-
positive bacteremia, there were significantly more patients
with endocarditis in GG genotype compared with T-allele
carriers (Table 3). This might cause bias when evaluating the
independent role of genotype associated with the severity of
disease in gram-positive bacteremia. However, T allele
remained a significant factor associated with milder disease
severity also in logistic regression model, where endocarditis
was included. The strength of our study is that patients with
different disease severity were included, those needing ICU
treatment and being hypotensive as well as those with milder
disease spectrum.
It remains a subject of debate whether NO or NOS is
beneficial or detrimental in sepsis (27, 28). Attempts to
improve the prognosis of sepsis by introducing NOS inhibitors
have yielded inconsistent results (5Y7). One explanation here
lies in the cytostatic and cytotoxic effects associated with NO
production that facilitate host defense (1, 29), and another is
the nonselectivity of hitherto introduced NOS inhibitors
attributed to the toxic effects of inappropriate eNOS inhibition
(3). Although T-allele carriage was associated with hypoten-
sion in E. coli bacteremia, T-allele carriage did not affect
survival. It should be noted that there are also other factors
that have been shown to affect the course of sepsis, especially
the quality of care (30, 31).
In conclusion, our results indicate that the T allele at
nucleotide position 894, a common variant of the eNOS gene,
is a risk factor for hypotension in the early stage of disease in
patients with E. coli bacteremia but not in bacteremia caused
by a gram-positive organism. Larger studies are needed to
confirm these preliminary findings in bacteremia. Our
observations emphasize that, in efforts to devise therapeutic
interventions, not only organism-related differences in the
pathogenesis should be considered, but also differences in the
genetic background of patients modifying the outcome of
sepsis.
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Abstract
Background: Bacteraemia is still a major cause of case fatality in all age groups. Our aim was to
identify the major underlying conditions constituting risk factors for case fatality in bacteraemia
patients.
Methods: The study involved 149 patients (79 male and 70 female) with bacteraemia caused by
Staphylococcus aureus (S. aureus) (41 patients), Streptococcus pneumoniae (Str. pneumoniae) (42
patients), !-hemolytic streptococcae (!-hml str.) (23 patients) and Eschericia coli (E. coli) (43
patients). Underlying diseases, alcohol and tobacco consumption and body mass index (BMI) were
registered. Laboratory findings and clinical data were registered on admission and 6 consecutive
days and on day 10–14. Case fatality was studied within 30 days after positive blood culture.
Associations between underlying conditions and case fatality were studied in univariate analysis and
in a multivariate model.
Results: Nineteen patients (12.8%) died of bacteraemia. We found obesity (p = 0.002, RR 9.8; 95%
CI 2.3 to 41.3), smoking (p < 0.001, RR 16.9; 95% CI 2.1 to 133.5), alcohol abuse (p = 0.008, RR
3.9; 95% CI 1.3 to 11.28), COPD (p = 0.01, RR 8.4; 95% CI 1.9 to 37.1) and rheumatoid arthritis
(p = 0.045, RR 5.9; 95% CI 1.2 to 28.8) to be significantly associated with case fatality in bacteraemia
in univariate model. The median BMI was significantly higher among those who died compared to
survivors (33 vs. 26, p = 0.003). Obesity and smoking also remained independent risk factors for
case fatality when their effect was studied together in a multivariate model adjusted with the effect
of alcohol abuse, age (continuos variable), sex and causative organism.
Conclusion: Our results indicate that obesity and smoking are prominent risk factors for case
fatality in bacteraemic patients. Identification of risk factors underlying fatal outcome in bacteraemia
may allow targeting of preventive efforts to individuals likely to derive greatest potential benefit.
Published: 9 March 2007
BMC Infectious Diseases 2007, 7:13 doi:10.1186/1471-2334-7-13
Received: 15 August 2006
Accepted: 9 March 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/13
© 2007 Huttunen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BMC Infectious Diseases 2007, 7:13 http://www.biomedcentral.com/1471-2334/7/13
Page 2 of 8
(page number not for citation purposes)
Background
Bacteraemia is a common infection with significant mor-
bidity and in most severe instances also mortality. The
importance of underlying conditions such as immunosu-
pression, ultimately and rapidly fatal diseases and chronic
organ insufficiency for bacteraemia outcome has been
emphasized in a number of studies [1-3].
Obesity is an increasing health concern in Western coun-
tries. In the general population, a relationship between
obesity and increased mortality has been shown [4-6].
Data on the incidence and outcome of specific infections,
especially community-acquired infections, in obese peo-
ple are so far limited [7]. There are no papers on the effect
of obesity on case fatality in bacteraemia patients.
Smokers and alcohol abusers display an increased suscep-
tibility to bacterial infections, especially those involving
the lung. In addition, smoking [8] and alcoholism [9] are
major risk factors for invasive pneumococcal disease.
There are data showing that alcoholism is a risk factor for
case fatality in S. aureus [10] and Str. pneumoniae bacterae-
mia [11,12]. However, some studies have found no statis-
tically significant association between alcoholism and
case fatality [2,3,13]. A recent study of epidemiological
and clinical features as potential prognostic factors for
outcomes of hospital-acquired bacteraemia found no dif-
ferences between non-survivors and survivors in sex, age
or smoking habit [14]. In bacteraemias other than pneu-
mococcal, the effect of smoking and alcoholism on case
fatality has not been widely studied.
Moreover, studies of bacteraemia with varying disease
severity are few in number. Most materials in this field
consist of patients merely treated with severe infection in
ICU; patients originally evincing milder signs and symp-
toms of infection are not included. The aim of our study
was to elucidate the underlying conditions, especially the
role of obesity, smoking and alcohol abuse, as risk factor
for case fatality in bacteramia.
Methods
The study material comprised 149 patients (79 male and
70 female) with bacteraemia hospitalized in Tampere
University Hospital, Tampere, Finland, from June 1999 to
February 2004. Their ages ranged from 16 to 93 years
(mean 59 years).
In our hospital blood cultures are routinely taken from
patients with symptoms or signs of systemic infection
(fever or hypothermia, tachycardia or tachypnea com-
bined with leucocytosis or leucopenia and/or elevated C-
reactive protein (CRP)). The study focused on patients
with bactaeremia caused by S. aureus, Str. pneumoniae, !-
hml str. or E. coli, the most common causative organisms
among community-acquired bacteraemia. Patients were
identified according to microbiological culture finding.
The clinicians (J.S. or J.La.) were informed by clinical
microbiologist (R.V.) of a positive blood culture from
Mondays to Thursdays and the patients were enrolled to
the study whenever possible to adjust to the daily sched-
ule. We were able to recruit zero to two patients per week
during the study period. Since the clinicians were unable
to know any details about the patients nor their disease
severity before the recruitment, the selection was purely
based on the blood culture finding. After being informed
by clinical microbiologist the clinician asked patients to
participate and interviewed and examined those consent-
ing. Information was gathered from hospital records at
the time of hospital visit and hospital records were also
reviewed after hospitalization (R.H.). Altogether 149 out
of 152 patients agreed to participate. The causative organ-
isms involved were S. aureus (41 patients, 27.5 %), Str.
pneumoniae (42 patients, 28.2%), !-hml str. (23 patients,
15.4%), and E. coli (43 patients, 28.9%). Patients with
two episodes of bacteraemia were not included in the
study. During the period in question the BACTEC 9240
(BD Diagnostic Systems, Sparks, MD, USA) blood culture
system with standard media was used. Bacteraemia was
defined hospital-aqcuired (nosocomial) if positive blood
culture was drawn >48 h after admission.
Underlying conditions, social status and alcohol and
tobacco consumption were registered. Alcohol abuse was
defined as consumption of 300 g absolute alcohol per
week or a known social or medical problem due to alco-
hol use. Smoking habits were registered and patients were
defined as current smokers, ex-smokers i.e. those who
have stopped smoking and nonsmokers i.e. those who
have never smoked (data available from 136 out of 149
patients). Calculation of BMI was based on weight and
length as reported by the patient on admission. BMI was
recorded and patients were defined as obese if their BMI
was > 30 (data available from 114 out of 149 patients; 10/
19 of deceased patients and 104/128 of survivors).
Chronic diseases were registered and McCabe (and Jack-
son) classification was used to assess the severity of the
underlying medical condition [15]. Preceding corticoster-
oid treatment was registered if corticosteroids were used
in a dose of over 5 mg per day during 1 month before the
bacteremia episode. All patients were treated with an
empiric antibiotic regimen and antimicrobial treatment
was changed according to culture results if necessary.
Patients were closely monitored during hospitalization
and severely ill subjects were transferred to the ICU. Clin-
ical data were registered on admission and during 6 con-
secutive days and on day 10–14 after admission. Possible
need for mechanical ventilation was registered. Altera-
tions in mental status were evaluated on the Glasgow
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Coma Scale (GCS). A patient was classified hypotensive if
mean arterial pressure (MAP) was < 70 mmHg during the
bacteraemia episode.
A SOFA score (Sequential Organ Failure Assessment) [16]
was calculated on 1–3 days after positive blood culture
finding (data available from 135/149 patients). Severe
organ failure was documented if the SOFA score was " 4.
A patient did not need ICU treatment if the SOFA score
was lower than 4. Laboratory findings were registered on
admission, during 6 consecutive days and on day 10–14.
The laboratory tests included plasma C-reactive protein
(mg/l), blood white cell count (× 109/l), blood platelets
(× 109/l), plasma bilirubin (#mol/l), plasma creatinine
level (#mol/l), plasma alanine aminotransferase (U/l)
and plasma alkaline phosphatase (U/l). The case fatality
rate was studied within 30 days after the positive blood
culture (day 30 case fatality).
The study was approved by the Ethics Committee of Tam-
pere University Hospital. Written informed consent was
obtained from patients or first degree relatives.
The SPSS package (version 7.5) was used for statistical
analyses and a two-sided p-value < 0.05 was taken as the
level for statistical significance. Categorical data were ana-
lysed by X2 test or Fisher's exact test when appropriate.
Nonparametric data were analysed by Mann-Whitney U-
test. Multivariate logistic regression analysis (method
enter) was used to assess the effects of independent factors
on mortality, controlling for differences in other factors
possibly affecting the outcome. Risk ratios (RRs) were
expressed with their 95% confidence intervals (CI). We
studied the effect of obesity, smoking and alcohol abuse
in a multivariate model adjusted with the effect of age
(continuous variable), sex and organism (S. Aureus, Str.
Pneumoniae, !-hl str., or E. coli).
Results
Nineteen patients (12.8%) died of bacteraemia. The case
fatality rate differed in bacteraemias caused by different
organisms: S. aureus 8/41 (19.5%), Str. pneumoniae 8/42
(19.0%), !-hml str.2/23 (8.7%), and E. coli 1/43 (2.3%).
Bacteraemia was community-acquired in 119 patients
(79.9%) and nosocomial in 30 (20.1%).
Predisposing factors and underlying diseases of bacterae-
mia are given in Table 1. Four differed bacteraemias dif-
fered statistically significantly from each other in the
number of smoking patients (current smokers or ex-
smokers, p = 0.007). Smoking was common in pneumo-
coccal bacteraemic patients (65.0% of patients current
smokers or ex-smokers) whereas 27.5% of E. coli bacterae-
mic patients were current smokers or ex-smokers. S. aureus
bacteraemia was the most common pathogen in patients
with rheumatoid arthritis. Bacteramias differed statisti-
cally significantly from each other in the number of male
patients (p = 0.003). Only 30.2% of E. coli bacteramia
patients were male whereas 68.3% of S. aureus bacterae-
mic patients were male. S. aureus was a common pathogen
in nosocomial infection; 39% of S. aureus bacteraemias
were nosocomial infections.
The sources of the infection were identifiable in 132
patients and are listed in Table 2. Clinical data on all
patients and on patients with bacteraemia caused by dif-
ferent organisms are shown in Table 3. The case fatality
rate in relation to predisposing factors and underlying dis-
eases is given in Table 4. Obesity, smoking, alcohol abuse,
COPD and rheumatoid arthritis proved significant risk
factors for case fatality in univariate analysis (table 4).
Myocardial infarction occurred in 11 (7.4%) patients and
cerebral infarction in 7 (4.7%) during the month follow-
ing positive blood culture. Twenty-six per cent of patients
older than 60 years were treated in ICU compared to 38
per cent of those aged 60 or younger (p = 0.104).
Obesity
Day 30 case fatality was higher in obese bacteraemic
patients than in nonobese patients (25.9% vs. 3.4%, p =
0.002, RR 9.8; 95% CI 2.3–41.3). The median BMI was
significantly higher among those who died compared to
survivors (33 vs. 26, p = 0.003). Obese and nonobese
study groups did not differ statistically significantly from
each other in numbers needing ICU treatment (25.9% vs.
28.7%, p = 0.78, RR 0.9; 95% CI 0.3–2.3). Obese patients
needed mechanical ventilation more often than non-
obese, but the difference was not statistically significant
(18.5% vs 8.0%, p = 0.152, RR 2.6; 95% CI 0.8–9.0).
However, more obese than nonobese patients died in ICU
treatment (5/7 vs. 3/25; p = 0.005, RR 18.3; 95% CI 2.4–
140.4). The obese had high SOFA scores (value >4 on day
1–3 after positive blood culture finding) more often than
nonobese, but the difference was not statistically signifi-
cant (44.0% vs 23.8%, p = 0.05, RR 2.5; 95% CI 1.0–6.5).
The obese and nonobese groups did not differ statistically
significantly in the occurrence of hypotension (37.0% vs
31.0%, p = 0.561, RR 1.3; 95% CI 0.5–3.2), or in the
number of patients with neurological deficit (lowered
GCS) (44.4% vs 33.3%, p = 0.293, RR 1.6; 95% CI 0.7–
3.9)
Forty-four per cent of obese bacteraemic patients had pre-
viously been diagnosed with type 2 diabetes as against
12.6% of nonobese patients (p < 0.001). Patients with
type 2 diabetes died more often than those without type 2
diabetes, but the difference was not statistically significant
(Table 4).
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Table 2: Source of bacteraemiaa
Focus All S. aureus Str. pneumoniae !-hml str. E. coli
n = 170b n = 56b n = 45b n = 29b n = 40b
(%) (%) (%) (%) (%)
Pneumonia 39 (22.9) 2 (3.6) 35 (77.8) 2 (6.9) 0 (0)
Skin 37 (21.8) 19 (33.9) 2 (4.4) 16 (55.2) 0 (0)
Urinary 30 (17.6) 1 (1.8) 0 (0) 1 (3.4) 28 (70.0)
Source unknown 17 (10.0) 3 (5.4) 4 (8.9) 3 (10.3) 7 (17.5)
Osteomyelitis/spondylitis 15 (8.8) 12 (21.4) 0 (0) 3 (10.3) 0 (0)
Gall bladder 7 (4.1) 0 (0) 3 (6.7) 0 (0) 4 (10.0)
Endocarditis 6 (3.5) 6 (10.7) 0 (0) 0 (0) 0 (0)
Arthritis 6 (3.5) 5 (8.9) 0 (0) 1 (3.4) 0 (0)
Mediastinitis 4 (2.4) 4 (7.1) 0 (0) 0 (0) 0 (0)
Meningitis 3 (1.8) 1 (1.8) 1 (2.2) 1 (3.4) 0 (0)
Gynaecological 3 (1.8) 0 (0) 0 (0) 2 (6.9) 1 (2.5)
Intravenous/intra-arterial catheter-related 3 (1.8) 3 (5.4) 0 (0) 0 (0) 0 (0)
aOne patient may have several focuses
bIndicating the number of focuses
Table 1: Predisposing factors and underlying diseases of bacteraemia
Predisposing factor All patients S. aureus Str. pneumoniae !-haemolytic streptococci E. coli p-value
N = 149 N = 41 N = 42 N = 23 N = 43
n (%) n (%) n (%) n (%) n (%)
Obesitya 27 (23.7) 9 (25.7) 4 (16.7) 6 (31.6) 8 (22.2) 0.698
Current smoker or ex-smokerb 66 (48.5) 18 (48.6) 26 (65.0) 11 (57.9) 11 (27.5) 0.007
Alcohol abuse 24 (16.1) 5 (12.2) 9 (21.4) 6 (26.1) 4 (9.3) 0.211
Type 1 diabetes 5 (3.4) 1 (2.4) - - 4 (9.3) 0.1
Type 2 diabetes 29 (19.5) 9 (22.0) 5 (11.9) 4 (17.4) 11 (25.6) 0.426
COPD 8 (5.4) - 5 (11.9) 2 (8.7) 1 (2.3) 0.053
Haematological malignancy 11 (7.4) 2 (4.9) 3 (7.1) 1 (4.3) 5 (11.6) 0.723
Solid malignancy 15 (10.1) 6 (14.6) 3 (7.1) 1 (4.3) 5 (11.6) 0.589
Rheumatoid arthritis 7 (4.7) 5 (12.2) - 1 (4.3) 1 (2.3) 0.034
Liver cirrhosis 4 (2.7) 2 (4.9) - 1 (4.3) 1 (2.3) 0.511
Cardiac diseasec 44 (29.5) 14 (34.1) 10 (23.8) 6 (26.1) 14 (32.6) 0.705
McCabe II or IIId 24 (16.1) 8 (19.5) 5 (11.9) 2 (8.7) 9 (20.9) 0.462
Corticosteroid treatmente 18 (12.1) 6 (14.6) 4 (9.5) 2 (8.7) 6 (14.0) 0.857
Chronic diseasef 117 (78.5) 33 (80.5) 27 (64.3) 17 (73.9) 40 (93.0) 0.013
Age >60 years 78 (52.3) 21 (51.2) 20 (47.6) 10 (43.5) 27 (62.8) 0.391
Male sex 79 (53.0) 28 (68.3) 24 (57.1) 14 (60.9) 13 (30.2) 0.003
Nosocomial infection 30 (20.1) 16 (39.0) 4 (9.5) 3 (13.0) 7 (16.3) 0.004
a(BMI >30), data available from 114 patients
bData available from 136 patients
cCoronary artery disease, valvular disease or documented heart failure
dMcCabe class II or III: ultimately fatal or rapidly fatal disease
eCorticosteroids used in a dose of over 5 mg per day during one month prior to the episode of bacteraemia
fAt least one chronic disease
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Table 4: Case fatality in relation to predisposing factors and underlying diseases (univariate analysis)
Predisposing factor All patients Deceased Survivors p-value RR (95% CI)
N = 149 N = 19 N = 130
n (%) n (%) n (%)
Obesitya 27 (23.7) 7 (70.0) 20 (19.2) 0.002 9.8 (2.3–41.3)
Current smoker or ex-smokerb 66 (48.5) 13 (92.9) 53 (43.4) <0.001 16.9 (2.1–133.5)
Alcohol abuse 24 (16.1) 7 (36.8) 17 (13.1) 0.008 3.9 (1.3–11.2)
Type 1 diabetes 5 (3.4) 0 (0) 5 (3.8) 1 1.0 (0.9–1.0)
Type 2 diabetes 29 (19.5) 6 (31.6) 23 (17.7) 0.153 2.1 (0.7–6.2)
COPD 8 (5.4) 4 (21.1) 4 (3.1) 0.01 8.4 (1.9–37.1)
Haematological malignancy 11 (7.4) 0 (0) 11 (8.5) 0.36 0.9 (0.9–1.0)
Solid malignancy 15 (10.1) 3 (15.8) 12 (9.2) 0.41 1.8 (0.5–7.2)
Rheumatoid arthritis 7 (4.7) 3 (15.8) 4 (3.1) 0.045 5.9 (1.2–28.8)
Liver cirrhosis 4 (2.7) 1 (5.3) 3 (2.3) 0.42 2.4 (0.2–23.8)
Cardiac diseasec 44 (29.5) 6 (31.6) 38 (29.2) 0.834 1.1 (0.4–3.2)
McCabe II or IIId 24 (16.1) 3 (15.8) 21 (16.2) 1 1.0 (0.3–3.6)
Corticosteroid treatmente 18 (12.1) 2 (10.5) 16 (12.3) 0.824 0.8 (0.2–4.0)
Chronic diseasef 117 (78.5) 18 (94.7) 99 (76.2) 0.065 5.6 (0.7–43.9)
Age over 60 years 78 (52.3) 11 (57.9) 67 (51.5) 0.604 1.3 (0.5–3.4)
Male sex 79 (53.0) 14 (73.7) 65 (50.0) 0.053 2.8 (1.0–8.2)
Nosocomial infection 30 (20.1) 1 (5.3) 29 (22.3) 0.084 0.2 (0.03–1.5)
a(BMI >30), data available from 114 patients
bData available from 136 patients
cCoronary artery disease, valvular disease or documented heart failure
dMcCabe class II or III: ultimately fatal or rapidly fatal disease
eCorticosteroids used in a dose of over 5 mg per day during one month prior to the episode of bacteraemia
fAt least one chronic disease
Table 3: Clinical data on 149 patients with 4 different bacteraemias
Disease severity All S. aureus Str. Pneumoniae !-hemolytic streptococci E. coli p-value*
n = 149 n = 41 n = 42 n = 23 n = 43
(%) (%) (%) (%) (%)
Dieda 19 (12.8) 8 (19.5) 8 (19.0) 2 (8.7) 1 (2.3) 0.031
Needed ICU stay 47 (31.5) 15 (36.6) 16 (38.1) 10 (43.5) 6 (14.0) 0.029
Needed mechanical ventilation 22 (14.8) 7 (17.1) 10 (23.8) 3 (13.0) 2 (4.7) 0.092
Needed CVVHD 7 (4.7) 5 (12.2) 0 (0) 2 (8.7) 0 (0) 0.006
Needed haemodialysis 2 (1.3) 2 (4.9) 0 (0) 0 (0) 0 (0) 0.097
Sofa Score >4b 39 (28.9) 9 (25.0) 10 (26.3) 11 (50.0) 9 (23.1) 0.122
Low platelet countc 21 (14.1) 8 (19.5) 3 (7.1) 4 (17.4) 6 (14.0) 0.411
Elevated bilirubin leveld 51 (34.2) 14 (34.1) 12 (28.6) 10 (43.5) 15 (34.9) 0.687
Lowered GCSe 60 (40.3) 19 (46.3) 18 (42.9) 10 (43.9) 13 (30.2) 0.45
Hypotensivef 56 (37.6) 13 (31.7) 19 (45.2) 11 (47.8) 13 (30.2) 0.299
aDeath due to bacteraemia episode occurred within 30 days from the day of positive blood culture.
bSOFA score was registered 1–4 days after positive blood culture finding (median 3 days). Data available from 135 patients.
cPlatelet count at least once lower than 50 10E9/L 0–8 days after positive blood culture
dBilirubin level elevated (>25 #mol/L) at least once 0–8 days after positive blood culture
eGlasgow coma scale lowered (<15) at least once 0–6 days after positive blood culture
fHypotensive (MAP <70 mmhg) at least once 0–6 days after positive blood culture
*The difference between groups of patients with bacteraemia caused by different organisms
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Smoking
The day 30 case fatality rate in bacteraemic patients was
higher in current or ex-smokers than in nonsmokers
(19.7% vs. 1.4%, p < 0.001, RR 16.9; 95% CI 2.1–133.5);
ninety-three per cent of patients who died were current or
ex-smokers (Table 4). Current or ex-smokers needed ICU
treatment (39.4% vs 18.6%, p = 0.007, RR 2.9; 95% CI
1.3–6.2) and mechanical ventilation (21.2% vs 5.7%, p =
0.008, RR 4.4; 95% CI 1.4–14.3) more often than non-
smokers during the bacteremia episode. Current or ex-
smokers died more often in ICU treatment compared to
nonsmokers (10/26 vs 1/13, p = 0.044, RR 7.5; 95% CI
0.8–66.9) and had high SOFA scores (value > 4 on day 1–
3 after positive blood culture finding) more often than
nonsmokers (33.3% vs 16.4%, p = 0.029, RR 2.6; 95% CI
1.1–6.0). The current or ex-smoker patient groups did not
differ statistically significantly from the nonsmoker group
in the occurrence of hypotension (42.4% vs 28.6%, p =
0.091, RR 1.8; 95% CI 0.9–3.8) or in numbers with neu-
rological deficit (lowered GCS) (43.9% vs 32.9%, p =
0.184, RR 1.6; 95% CI 0.8–3.2).
Thirty-eight patients (35.2%) were current smokers while
70 (64.8%) had never smoked. When current smokers
were compared to nonsmokers (ex-smokers excluded
from this analysis) the adverse effect of smoking for prog-
nosis of bacteraemia was emphasized. The day 30 case
fatality rate in bacteraemic patients were higher in current
smokers than in nonsmokers (21.1% vs. 1.4%, p < 0.001,
RR 18.4; 95% CI 2.2–153.7). Current smokers needed
ICU treatment (50.0% vs 18.6%, p = 0.001, RR 4.4; 95%
CI 1.8–10.5) and mechanical ventilation (31.6% vs 5.7%,
p < 0.001, RR 7.6; 95% CI 2.3–25.8) more often than non-
smokers during the bacteremia episode. This adverse
effect remained even after smoking cessation; 5/28
(17.9%) patients died in the ex-smoker group compared
to 1/70 (1.4%) of those who had never smoked (p =
0.007, RR 15.0; 95% CI 1.7–135.1). Fifty-nine per cent of
males were current or ex-smokers as against 36.9% of
females (p = 0.01).
Alcohol abuse
The day 30 case fatality rate in bacteraemic patients was
higher in alcohol abusers compared to those not given to
alcohol abuse (29.2% vs 9.6%, p = 0.008, RR 3.9; 95% CI
1.3–11.2). Alcohol abusers needed ICU treatment (66.7%
vs 24.8%, p < 0.001, RR 6.1; 95% CI 2.4–15.5) and
mechanical ventilation (41.7% vs 9.6%, p < 0.001, RR
6.7;95% CI 2.5–18.4) more often than those not abusing.
Alcohol abusers died more often in ICU treatment, the
difference being, however, not statistically significant (7/
16 vs 8/31, p = 0.211, RR 2.2, 95% CI 0.6–8.0). Alcohol
abusers had high SOFA scores (value >4 on day 1–3 after
positive blood culture finding) more often than those
without alcohol abuse (65.2% vs 21.4%, p < 0.001, RR
6.9; 95% CI 2.6–18.1). The occurrence of hypotension
was more common among abusers than in their counter-
parts (70.8% vs 31.2%, p < 0.001, RR 5.4; 95% CI 2.1–
14.0) and were more likely to develop neurological deficit
(lowered GSC) (75.0% vs 33.6%, p < 0.001, RR 5.9; 95%
CI 2.2–16.0). Eighteen out of 21 (85.7%) alcohol abusers
were current smokers or ex-smokers and 4 out of 24
(16.7%) had liver cirrhosis.
The effect of obesity, smoking and alcohol abuse on day
30 case fatality were studied together with age, sex and
organism in a multivariate model. Obesity remained a sig-
nificant risk factor associated with case fatality also in this
adjusted model (p = 0.03, RR 6.4; 95% CI 1.2–34.4),
together with smoking (P = 0.02, RR 23.0; 95% CI 1.7–
321.6).
Discussion
Obesity, smoking, alcohol abuse, COPD and rheumatoid
arthritis proved to be significantly associated with case
fatality in bacteraemia in univariate model. The effect of
obesity and smoking on case fatality also remained signif-
icant when studied in a multivariate model together with
alcohol abuse, age (continuos variable), sex and causative
organism.
Instead of focusing on the clinical findings associated
with poor prognosis in bacteraemia, which have been well
studied (such as hypotension, leukopenia or leukocytosis
or the number of evolving organ dysfunctions) [17,18],
we sought to focus on the underlying conditions and
chronic illnesses possibly constituting risk factors for case
fatality in bacteraemic patients. Most studies in this field
deal with patients with severe bacteraemia requiring ICU
treatment [3,18]. One of the major advantages of our
study was the enrolment of patients evincing different dis-
ease severity; patients with milder symptoms and signs as
well as patients with septic shock who needed ICU treat-
ment. One of the limitations was that we could not enrol
all patients with bacteraemia in our university hospital
district during the study period. This limitation excludes
determination of population-based incidence rates. How-
ever, the investigators did not select the patients they
included in the study, the inclusion being based on the
microbiological culture finding, and all patients having
the same possibility to be recruited by the investigators
from Mondays to Thursdays during the study period.
Since the clinicians were unable to know any details about
the patients nor their disease severity before the recruit-
ment, the selection was purely based on the blood culture
finding. This kind of recruitment of patients probably did
not cause any selection bias.
Obesity emerged as an independent risk factor for case
fatality and obese patients died more often despite ICU
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treatment compared to nonobese patients. The published
studies examining the association between obesity and in-
hospital case fatality give conflicting results concerning
the role of body mass index (BMI) as a risk factor for in-
hospital case fatality. We found no studies reporting
increased mortality due to bacteraemia among obese
patients. There are three papers reporting an increased
obesity-related case fatality rate in ICU [19-21], these
involving patients with multiple reasons for ICU admis-
sion, not only infectious causes. In contrast to our study
there are also studies where high BMI is not found to be a
predictor of case fatality in ICU patients [22-25], and
where a low BMI is independently associated with higher
case fatality [22,23].
The physiologic mechanisms prevailing between obesity
and mortality are unknown. It remains obscure which fac-
tors contribute to the increased case fatality in obese in-
hospital patients reported in some series. One study
showed that obesity exacerbates sepsis-induced inflam-
mation and microvascular dysfunction in the mouse brain
[26]. The investigators in question noted microvascular
inflammatory and thrombogenic responses, including
activation of endothelial cells with subsequent expression
of adhesion molecules such as P-selectin in obese mice
[26]. Bornstein and associates found that plasma leptin
levels are increased in survivors of acute sepsis [27]. The
group found that mean leptin levels were three-fold
higher in patients who survived the episode than in non-
survivors, and concluded that in addition to its function
as an anti-obesity factor, leptin may play a role in a severe
stress state such as acute sepsis [27]. Recent findings indi-
cate that obesity is an independent risk factor for lipid per-
oxidation [28] and impaired endothelial cell function
[29]. In addition, there appears to be a chronic low-grade
inflammation state with elevated acute-phase mediators,
cytokines and soluble adhesion molecules which persists
in obese individuals [30,31].
Smoking was an independent risk factor for case fatality
due to bacteraemia in our study. The effect was most dis-
tinct when current smokers were compared to nonsmok-
ers, but it also remained significant after smoking
cessation. Smokers more often needed mechanical venti-
lation and ICU stay, their SOFA score was more often
higher than in nonsmokers and they died more often
despite ICU treatment. Although the importance of smok-
ing cessation has been emphasized in the therapeutic plan
of patients with serious infections [32], there are only a
few other studies of the effect of smoking on case fatality
in bacteraemia. Arvanitidou and colleagues studied epide-
miological and clinical features as potential prognostic
factors for outcomes of hospital-acquired bacteraemia in
a tertiary care teaching hospital in Greece [14]. They found
no differences between non-survivors and survivors in sex,
age or smoking habit [14]. Pittet and associates concluded
that smoking or alcohol abuse did not reach statistical sig-
nificance as independent risk factors for case fatality in
septicaemia. However, the number of co-morbidities, also
including smoking and alcohol abuse, predicted mortality
[2].
Alcoholism emerged as a risk factor for case fatality in uni-
variate analysis, this effect being however diminished
when studied in an adjusted model together with obesity,
smoking, sex, age and organism. This might be explained
by the fact that most alcohol abusers were also smokers,
and the effect on case fatality may thus result from smok-
ing, not alcohol itself. In accordance with our findings,
there are studies showing that alcoholism is a risk factor
for case fatality in pneumococcal bacteraemia in univari-
ate analysis [11,12]. There are however also studies where
such an association is not confirmed. Lääveri and associ-
ates found no statistically significant association between
alcohol abuse and increased case fatality in bacteraemic
pneumococcal disease [13], while a group under Laup-
land et al conducted a population-based surveillance
cohort study of severe bloodstream infections and found
that alcoholism increased the case fatality rate in bacterae-
mic patients althought the difference was not statistically
significant [3].
We had seven patients with rheumatoid arthritis, three of
whom died of bacteraemia. The number of patients with
rheumatoid arthritis is small, but the results in univariate
model suggest that rheumatoid patients have increased
case fatality in bacteraemia. Sihvonen and associates con-
ducted a cross-sectional cohort study of rheumatoid
arthritis patients and concluded that they carried an
increased risk of death from various causes, and they were
at increased risk of dying of infections when compared to
the general population or controls [33].
Conclusion
In conclusion, our results indicate that obesity, together
with smoking, constitutes an important risk factor for case
fatality in bacteraemic patients. With the rising prevalence
of obesity in Western countries, future research should
focus on finding mechanisms responsible for increased
mortality in obese bacteraemic patients. The adverse effect
of smoking on bacteraemia outcome is an underestimated
health risk. Identification of risk factors underlying fatal
outcome in bacteraemia may allow targeting of preventive
efforts to individuals likely to derive greatest potential
benefit.
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ABSTRACT—Indoleamine 2,3-dioxygenase (IDO), which is the rate-limiting enzyme for tryptophan (trp) catabolism, may
play a critical role in various inflammatory disorders. Recent studies on trauma patients have suggested that the
degradation of trp is associated with the development of sepsis. The role of IDO activity in bacteremic patients is unclear.
We studied IDO activity in 132 patients with bacteremia caused by Staphylococcus aureus, Streptococcus pneumoniae,
"-hemolytic streptococcae, or Eschericia coli. The serum concentrations of trp and its metabolite kynurenine (kyn) were
measured by reverse-phase high-performance liquid chromatography 1 to 4 days after the positive blood culture and on
recovery. The kyn-to-trp ratio (kyn/trp), reflecting the activity of the IDO enzyme, was calculated. The maximum value in
the ratio for every patient during 1 to 4 days after positive blood culture was used in analysis. The maximum kyn/trp ratio
was significantly higher in nonsurvivors versus those who survived (193.7 vs. 82.4 2mol/mmol; P = 0.001). The AUCROC of
maximal kyn/trp in the prediction of case fatality was 0.75 (95% confidence interval, 0.64Y0.87), and the kyn/trp ratio at a
cutoff level of 120 2mol/mmol showed 83% sensitivity and 69% specificity for fatal disease. A kyn/trp ratio greater than
120 2mol/mmol was associated with increased risk of death versus low (e120 2mol/mmol) ratios (odds ratio, 10.8;
confidence interval, 3.0Y39.8). High IDO activity also remained an independent risk factor for case fatality in a multivariate
model adjusted for potential confounders. The data in this report demonstrate that IDO activity is markedly increased in
bacteremia patients, constituting an independent predictor of severe disease and case fatality.
KEYWORDS—Bacteremia, indoleamine 2,3-dioxygenase, kynurenine, tryptophan, case fatality, enzyme, IDO, T cell
INTRODUCTION
Severe sepsis is characterized by systemic release of a num-
ber of proinflammatory and anti-inflammatory mediators, and
the mortality rate is associated with the magnitude of this in-
flammatory process (1). However, the significance of the blood
concentration of any given individual inflammatory mediator
as a predictor of clinical outcome is still largely unknown.
Indoleamine 2,3-dioxygenase (IDO) is expressed in a
variety of cells, including antigen-presenting cells such as
monocyte-derived macrophages and dendritic cells, and is
preferentially induced by Th1-type cytokine INF-+ (2). Other
cytokines and LPS are also capable of inducing IDO (2).
Indoleamine 2,3-dioxygenase catalyzes the degradation of the
essential amino acid tryptophan (trp) to kynurenine (kyn) and
its derivatives, thereby limiting the availability of trp. Because
trp is required for protein synthesis, withdrawal of this
essential amino acid from the microenvironment arrests this
process, and subsequent growth of pathogens and proliferating
cells (2, 3). A decreased trp concentration and increased
concentrations of kyn have been described in various clinical
conditions, for example, infection, autoimmune syndromes,
malignancies, neurodegenerative disorders, and pregnancy
(3). Indoleamine 2,3-dioxygenase induces inhibition of T-cell
proliferation (4) and may thus contribute to the pathophysi-
ology of immunodeficiency. On the other hand, IDO may
serve as a natural immunoregulatory mechanism. For exam-
ple, it prevents rejection of the fetus during pregnancy (5).
Physiological IDO activity has been implicated in T-cell
tolerance to tumors (6) and as a protective negative regulator
in autoimmune disorders (7). Although the mechanism of
T-cell suppression has been shown to be mediated by trp
shortage, toxic catabolites may also play a role (2, 8). In-
doleamine 2,3-dioxygenase activity in human serum can be
measured by determining the ratio of kyn to trp (i.e., the first
metabolite to substrate).
According to a recently increasing body of new data, it is
clear that IDO serves more than one function in the immune
system (2, 9). However, its precise role in different disease
processes is largely unknown. In particular, it is not clear
whether it is beneficial or detrimental to the host (2). Previous
studies on trauma patients have suggested that degradation of
trp is associated with the development of sepsis and poor
outcome after major trauma (10, 11). One recent study in mice
has shown that survival from endotoxin shock is increased in
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IDO knockout (IDOj/j) and IDO inhibitor 1-methyl-trpY
treated mice compared with wild-type mice (9).
We determined here the IDO activity in sera from bac-
teremia patients to study the possible association of IDO with
various clinical parameters and case fatality.
MATERIALS AND METHODS
The study material comprised 132 adult patients with bacteremia (70 men
and 62 women) aged 60 years (mean; range, 18Y93 y) admitted to Tampere
University Hospital, Tampere, Finland, from June 1999 to February 2004.
Patient recruitment, clinical data collection, and sample collection were
prospective. Samples for kyn and trp measurements were analyzed after
hospitalization.
In our hospital, blood cultures are routinely taken from patients with
symptoms or signs of systemic infection (fever or hypothermia, tachycardia
or tachypnea combined with leukocytosis or leukopenia and/or elevated C-
reactive protein [CRP]). The BACTEC 9240 (BD Diagnostic Systems, Sparks,
Md) blood culture system was used with standard media. Patients were
identified according to the microbiological blood culture finding, and only
those with bacteremia caused by Staphylococcus aureus, Streptococcus
pneumoniae, "-hemolytic streptococcus, or Escherichia coli, the most
common causative organisms among community-acquired bacteremia, were
included in the study. According to the study plan, other microbes were
excluded beforehand. Blood cultureYnegative patients with or without sepsis
syndrome and those not consenting were not included. Only patients at least
16 years old were enrolled. The clinicians (J.S. or J.L.) were informed by the
clinical microbiologist (R.V.) of a positive blood culture from Mondays to
Thursdays, and the patients were enrolled in the study whenever possible to
adjust to the daily schedule. We were able to recruit zero to two patients per
week during the study period. Because the clinicians had no knowledge of
details regarding the patients or their disease severity before recruitment, the
selection was based solely on the blood culture finding. After being informed
by the clinical microbiologist, the clinicians (J.L. and J.S.) asked patients to
participate and interviewed and examined those consenting. Information was
gathered from hospital records at the time of a hospital visit, and hospital
records were also reviewed subsequent to hospitalization (R.H.). Altogether,
149 of 152 patients agreed to participate. Indoleamine 2,3-dioxygenase
activity during 1 to 4 days after positive blood culture was determined in
132 patients, and these were recruited into the final study population. The
study was approved by the ethics committee of Tampere University Hospital.
Written informed consent was obtained from patients or first-degree relatives.
Underlying diseases and sources of bacteremia were registered. Alcohol
abuse was defined as consumption of 300 g absolute alcohol per week or a
known social or medical problem due to alcohol use. Patients were defined as
current smokers and nonsmokers, that is, those who had never smoked or had
stopped smoking. Calculation of body mass index (BMI) was based on weight
and height as reported by the patient on admission. Patients were defined as
obese if their BMI was greater than 30 kg/m2.
Clinical data and laboratory findings were registered on admission and
during 6 consecutive days. Alterations in mental status were evaluated on the
Glasgow Coma Scale. MAP ([systolic + 2 ! diastolic blood pressure] / 3) and
Sequential Organ Failure Assessment (SOFA) score (12) were calculated. The
maximum SOFA score (days 0Y6) for every patient was used in analysis.
Disease severity was assessed by SOFA score, and severe disease was defined
as a SOFA score greater than or equal to 4. Laboratory tests included plasma
CRP (milligram per liter), blood platelets (!109/L), plasma bilirubin (micro-
mole per liter), plasma creatinine level (micromole per liter), and blood
leukocyte count (!109/L). The case fatality rate was studied within 14 and
30 days after a positive blood culture (d-14 and d-30 case fatality).
trp and kyn determinations
The samples for kyn and trp determination were taken during patients’
hospitalization. Samples were available for 132 patients altogether on days 1
to 4 after the positive blood culture. The serum samples were stored at j20-C
until analyzed. Tryptophan (millimole per liter) and kyn (micromole per liter)
concentrations in peripheral blood were measured by reverse-phase high-
performance liquid chromatography, as previously described (13). Tryptophan
was separated with a Shimadzu liquid chromatograph LC-10AD VP
(Shimadzu Co, Kyoto, Japan) using a 50-mm BDS Hypersil C18 5 2m
column (Thermo Electron Co, Bellefonte, Pa). It was monitored by
fluorescence with a Shimadzu RF-10A XL detector at 266-nm excitation
and 366-nm emission wavelengths. Kynurenine was separated with a Hewlett
Packard 1100 liquid chromatograph (Palo Alto, Calif) using a Merck
LiChroCart 55Y4150 mm cartridge containing a Purospher STAR RP-18
3 2m column (Merck Co, Darmstadt, Germany). It was determined by
TABLE 1. Maximum kyn/trp ratio 1 to 4 days after positive blood
culture in 132 patients with bacteremia and after
stratification by causative organism
Maximum kyn/trp ratio,
2mol/mmol, median (quartiles) P
All patients* 89.9 (54.7Y167.6) 0.006†
Staphylococcus aureus 117.3 (64.4Y197.5)
Streptococcus pneumoniae 90.9 (52.5Y194.0)
"-hemolytic streptococcus 123.0 (69.6Y312.3)
Escherichia coli 67.5 (42.3Y113.4)
*Median trp concentration, 50.7 2mol/L and median kyn concentration,
4.48 2mol/L on the day of maximal kyn/trp ratio. On recovery (926 days
after the positive blood culture), the median kyn/trp ratio was 36.8 2mol/
mmol (median of trp concentration, 81.8 2mol/L and kyn concentration,
3.18 2mol/L).
†P value was calculated between four patient groups classified by
causative organisms (Kruskal-Wallis test).
TABLE 2. Maximum kyn/trp ratios 1 to 4 days after positive blood
culture in 132 patients with bacteremia in relation to
sources of infection
Maximum kyn/trp ratio 2mol/mmol,
median (quartiles)
Source, yes Source, no P*
Source of infection†
Pneumonia (n = 33) 124.6 (67.6Y246.7) 85.7 (50.7Y143.8) 0.025
Urinary (n = 29) 61.3 (41.3Y106.3) 100.0 (62.3Y193.8) 0.003
Skin (n = 33) 123.5 (66.0Y229.7) 89.5 (51.2Y146.2) 0.057
Osteomyelitis/
spondylitis (n = 13)
82.5 (56.3Y104.8) 90.9 (54.6Y176.8) 0.549
Gall bladder (n = 6) 135.0 (84.4Y321.2) 89.7 (53.2Y165.7) 0.146
Endocarditis (n = 4) 160.3 (138.7Y193.3) 89.5 (54.0Y163.4) 0.097
Mediastinitis (n = 4) 106.5 (90.5Y248.7) 89.5 (54.0Y167.6) 0.346
Gynecological (n = 3) 145.0 (66.0Y) 89.8 (54.2Y166.7) 0.298
*Mann-Whitney U test.
†One patient may have several focuses.
FIG. 1. Receiver operating characteristic curve for maximal kyn/trp
(2mol/mmol) ratio detected on days 1 to 4 after positive blood culture in
bacteremic patients in relation to case fatality.
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ultraviolet absorption at 360-nm wavelength with a Hewlett Packard G13144
detector. The kyn-to-trp ratio (kyn/trp; micromole per millimole) was
calculated by relating concentrations of kyn (micromole per liter) to trp
(millimole per liter), thus allowing estimation of IDO activity.
Samples for trp and kyn determinations were available on days 1 and 2
(1Y2 days after the blood culture was taken), 34 patients; on day 3, 80
patients; on day 4, 104 patients. In addition, 93 patients gave a sample on
recovery (926 days after the positive blood culture). Because patient
recruitment was based on blood culture, which only became positive the day
after blood culture, no samples for trp and kyn determinations were available
on day 0 (blood culture day). There were 1 to 5 samples (median, 4) available
per patient collected on separate days. Multiple samplings in the same patient
were always performed on separate days. Patients with no measurements on
days 1 to 4 after positive blood culture were excluded from the analysis. The
maximum value in kyn and kyn/trp ratio and the minimum value in trp for
every patient measured during 1 to 4 days after the positive blood culture
were used in analysis.
Statistical analysis
An SPSS package (version 7.5) was used for statistical analyses, and a two-
sided P value less than 0.05 was taken as cutoff for statistical significance.
Categorical data were analysed by chi-square test or Fisher exact test when
appropriate, nonparametric data by Mann-Whitney U test or Kruskal-Wallis
test. A logistic regression model was used to study the independent effect of
high IDO activity on mortality models adjusted for potential confounders.
Odds ratios (ORs) were expressed with their 95% confidence intervals (CIs).
The survival curves were calculated using the Kaplan-Meier method, and
survival differences between groups were compared using the log-rank test.
The accuracy of maximal kyn/trp ratio and maximal CRP and blood culture
day CRP in predicting case fatality was evaluated using receiver operating
characteristic (ROC) curves (14). By this method, a test that is perfect has
100% sensitivity and no false positives (1-specificity = 0) and will have an
area under the curve (AUC) of 1.0, whereas a test of no diagnostic value
would have an AUC of 0.5. The 95% CIs were calculated.
RESULTS
The causative organisms involved here were S. aureus
(32 patients; 24%), Str. pneumoniae (37 patients; 28%), "-
hemolytic streptococcus (22 patients; 17%), and E. coli (41
patients; 31%). All subjects were treated with an empiric
antibiotic regimen, and when necessary, antimicrobial treat-
ment was changed according to culture results. In all patients,
the causative organism proved susceptible to the first empiric
antibiotic treatment selected on admission. The maximum
kyn/trp ratios detected 1 to 4 days after positive blood culture
in 132 patients with bacteremia, stratified by causative
bacteria, are shown in Table 1 and by the source of infection
in Table 2. The maximum kyn/trp ratios were high in acute
illness, and ratios decreased on recovery (Table 1). A sig-
nificant difference in maximal kyn/trp ratios was detected
between the causative organisms; ratios were highest in those
patients with "-hemolytic streptococcus bacteremia and low-
est in those with E. coli bacteremia (Table 1). Furthermore,
ratios were significantly higher in patients with pneumonia
and lower in those with urinary tract infection compared with
those without (Table 2).
TABLE 3. Underlying conditions and clinical data in 132 bacteremic patients stratified by maximum kyn/trp ratio 1 to 4 days
after positive blood culture (e120 2mol/mmol vs. those with 9120 2mol/mmol)
Character
Maximum kyn/trp ratio
e120 2mol/mmol (n = 81)
Maximum kyn/trp ratio
9120 2mol/mmol (n = 51) OR (95% CI) P
Underlying condition
Obesity (BMI 930 kg/m2)* 14/62 (23%) 12/39 (31%) 1.5 (0.6Y3.8) 0.359
Alcohol abuse 8 (10%) 13 (26%) 3.1 (1.2Y8.2) 0.017
Current smoking† 16/74 (22%) 17/46 (37%) 2.1 (0.9Y4.8) 0.067
Cancer (solid or hematological) 17 (21%) 6 (12%) 0.5 (0.2Y1.4) 0.174
Diabetes mellitus (type 1 or 2) 22 (27%) 11 (22%) 0.7 (0.3Y1.7) 0.470
Rheumatoid arthritis 3 (4%) 4 (8%) 2.2 (0.5Y10.3) 0.429
Cardiac disease‡ 23 (28%) 18 (35%) 1.4 (0.6Y2.9) 0.404
Male 39 (48%) 31 (61%) 1.7 (0.8Y3.4) 0.157
Age 960 y 41 (51%) 30 (59%) 1.4 (0.7Y2.8) 0.357
Clinical data
Died (d-30 case fatality) 3 (4%) 15 (29%) 10.8 (3.0Y39.8) G0.001
Died (d-14 case fatality) 2 (3%) 10 (20%) 9.6 (2.0Y46.0) 0.001
Needed ICU stay 16 (20%) 26 (51%) 4.2 (1.9Y9.2) G0.001
Needed mechanical ventilation 3 (4%) 17 (33%) 13.0 (3.6Y47.3) G0.001
Highest SOFA score Q4 23 (28%) 32 (63%) 4.2 (2.0Y8.9) G0.001
Lowest MAP median (quartiles) 78 (70Y93) 63 (54Y77) G0.001
Lowest platelet count (109/L), median (quartiles) 189 (117Y243) 108 (65Y166) G0.001
Highest SOFA score, median (quartiles) 1 (0Y4) 5 (2Y10) G0.001
Highest bilirubin level (2mol/L), median (quartiles) 14 (11Y23) 30 (17Y60) G0.001
Highest creatinine level (2mol/L), median (quartiles) 90 (71Y123) 173 (114Y249) G0.001
Lowest GCS, median (quartiles) 15 (15Y15) 14 (13Y15) G0.001
Highest CRP, median (quartiles) 224 (170Y347) 333 (249Y405) 0.004
Median neutrophil count (!109/L) (quartiles) (n = 112) 6.6 (3.8Y9.4) 9.3 (6.6Y13.3) 0.001
Categorical data were analysed by chi-square test or Fisher exact test and continuous data by Mann-Whitney U test.
*Obesity data available on 101 patients.
†Smoking data available on 120 patients.
‡Valvular, coronary artery disease, heart failure, or cardiac myopathy.
GCS indicates Glasgow Coma Scale.
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Eighteen bacteremic patients died (d-30 case fatality) (8/32
patients in S. aureus, 7/37 patients in Str. pneumonie, 2/22
patients in "-hemolytic streptococcus, and 1/41 patients in
E. coli bacteremia). The maximum kyn/trp ratio, detected on
days 1 to 4 after positive blood culture, was significantly
higher in those who died (d-30 case fatality) versus those who
survived (median, 193.7 2mol/mmol [quartiles 124.1Y253.3
2mol/mmol] vs. 82.4 2mol/mmol [quartiles 51.0Y138.9
2mol/mmol], respectively; P = 0.001). The same was de-
tected in relation to d-14 case fatality (185.3 2mol/mmol
[quartiles 123.0Y247.8 2mol/mmol] vs. 86.9 2mol/mmol
[quartiles 51.2Y146.9 2mol/mmol], respectively; P = 0.005).
The optimal cutoff value for maximal kyn/trp ratio in
predicting fatal disease was estimated using ROC curve,
illustrated in Figure 1. The kyn/trp ratio at a cutoff level of
120 2mol/mmol showed a sensitivity of 83% and a specificity
of 69% in detecting fatal disease, and this cutoff point was
used to classify patients into those with less than or equal to
120 2mol/mmol or greater than 120 2mol/mmol kyn/trp.
Underlying conditions and clinical data in cases with kyn/trp
greater than 120 2mol/mmol versus less than or equal to
120 2mol/mmol are shown in Table 3. Of underlying
conditions, alcohol abusers had somewhat more often high
kyn/trp ratios (9120 2mol/mmol) than the patients with no
alcohol abuse. High maximum kyn/trp ratio was associated
with all clinical parameters indicative of severe disease and
poor outcome (Table 3).
The effect of predisposing factors and underlying condi-
tions on case fatality in patients with bacteremia is shown in
Table 4. The maximum CRP level did not predict case fatality
at any cutoff level in the ROC curve (P = 0.292). However,
the AUCROC for CRP on the day of positive blood culture was
0.66 (0.58Y0.782; P = 0.03). The CRP at a cutoff level of
224 mg/L showed a sensitivity of 72% and specificity of 61%
in detecting fatal disease, and this cutoff point was used to
classify patients into those with CRP less than or equal to
224 mg/L or greater than 224 mg/L in the multivariate model.
The following grouping variables were associated with case
fatality in univariate model: obesity, smoking, alcohol abuse,
TABLE 4. The effect of predisposing factors and clinical parameters on case fatality in 132 patients with bacteremia in univariate model
Deceased, n = 18 Survivors, n = 118 OR (95% CI) P
Grouping variables in univariate model
Obesity* 7/10 (70%) 19/91 (21%) 8.8 (2.1Y37.5) 0.003
Alcohol abuse 6 (33%) 15 (13%) 3.3 (1.1Y10.1) 0.041
Current smoking† 7/13 (54%) 26/107 (24%) 3.6 (1.1Y11.8) 0.024
McCabe class II or III‡ 3 (17%) 19 (17%) 1.0 (0.3Y3.8) 1.0
Male 13 (72%) 57 (50%) 2.6 (0.9Y7.8) 0.079
kyn/trp 9120 2mol/mmol 15 (83%) 36 (32%) 10.8 (3.0Y39.8) G0.001
CRP 9224 g/L (blood culture day)§ 13/18 (72%) 41/106 (39%) 4.1 (1.4Y12.4) 0.008
SOFA score (Q4) 16 (89%) 39 (34%) 15.4 (3.4Y70.3) G0.001
Continuous variables, median (quartiles)
kyn/trp on days 1 to 2 (n = 34) 143.8 (123.5Y312.2) 100.0 (55.3Y229.3) 0.166
kyn/trp on day 3 (n = 80) 164.8 (92.7Y227.9) 88.7 (54.8Y130.8) 0.014
kyn/trp on day 4 (n = 104) 193.8 (72.7Y242.5) 66.9 (43.6Y110.3) 0.003
Maximum kyn/trp ratio (days 1Y4) (2mol/mmol)k 193.7 (124.1Y253.3) 82.4 (51.0Y138.9) 0.001
Maximum kyn concentration (days 1Y4) (2mo/L) 8.76 (5.15Y12.26) 4.27 (2.92Y6.72) G0.001
Minimum trp concentration (days 1Y4) (2mo/L) 46.5 (38.0Y59.7) 51.1 (38.1Y64.4) 0.450
Maximum CRP (mg/L) 304 (209Y411) 268 (182Y380) 0.292
CRP (mg/L) on the day of positive blood culture§ 246 (198Y400) 186 (85Y303) 0.03
Continuous variables are expressed in medians (Mann-Whitney test).
*Obesity data available on 101 patients.
†Smoking data available on 120 patients.
‡McCabe classes III or III: ultimately fatal or rapidly fatal disease.
§CRP data available on 124 patients.
kThe day of maximum kyn/trp ratio: median trp concentration 43.2 2mo/L in nonsurvivors and 51.1 2mo/L in survivors (P = 0.208) and kyn
concentration 7.45 2mo/L in nonsurvivors and 4.29 2mo/L in survivors (P = 0.001).
TABLE 5. The effect of maximum kyn/trp ratio (9120 2mol/mmol)
detected 1 to 4 days after positive blood culture
on case fatality in bacteremia adjusted for
potential confounders
Variables in multivariate model
OR for high kyn/trp ratio
(9120 2mol/mmol)
kyn/trp 9120 + age + male sex 10.0 (2.7Y37.3)
kyn/trp 9120 + CRP 9224 g/L
(blood culture day)*
9.8 (2.6Y37.3)
kyn/trp 9120 + McCabe class II or III 11.3 (3.0Y42.0)
kyn/trp 9120 + causative organism 9.5 (2.5Y36.1)
kyn/trp 9120 + SOFA score (Q4)† 6.6 (1.7Y25.6)
kyn/trp 9120 + obesity†,‡ 7.8 (1.4Y42.2)
kyn/trp 9120 + alcohol abuse 9.7 (2.6Y36.1)
kyn/trp 9120 + current smoking§ 10.0 (2.1Y48.3)
kyn/trp 9120 + high creatinine (9120 2mo/L) 7.4 (1.8Y29.5)
*CRP data available on 124 patients.
†Also remained a significant risk factor associated with case fatality in
multivariate model (P G 0.05).
‡Obesity data available on 101 patients.
§Smoking data available on 120 patients.
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high maximum kyn/trp ratio (9120 2mol/mmol), and high
CRP (9224 mg/L) on the day of positive blood culture
(Table 3). Interestingly, the median values of kyn/trp ratios
increased from days 1 to 2 to day 4 in those who died,
whereas in those who survived, the ratios decreased (Table 4).
The effect of high (9120 2mol/mmol) maximum kyn/trp
ratio on case fatality adjusted for confounders in multivariate
models is shown in Table 5. High kyn/trp ratio retained its
significance in the multivariate model in all combinations.
Obesity and high SOFA score (Q4) also remained independent
factors associated with case fatality. Figure 2 shows the cumu-
lative 30-d survival in patients with low and high kyn/trp ratios
and after stratification by underlying conditions, proving sig-
nificant risk factors for case fatality in univariate analysis.
DISCUSSION
In the present study, the maximum kyn/trp ratio in patients
with bacteremia was more than three times higher than in
healthy Finnish blood donors (15), reflecting increased IDO
activity in bacteremic patients. Moreover, the present findings
show that high IDO activity independently predicts severe
disease and case fatality in patients with bacteremia.
Indoleamine 2,3-dioxygenase is an inducible enzyme in
immune cells, including dendritic cells, macrophages, and
eosinophils. However, its function in the immune system
seems to diverge depending on the type of immune cell and
the nature of the stimulus (2, 9). It is not clear whether it
is beneficial or detrimental to the host. Indoleamine 2,3-
dioxygenase, the rate-limiting enzyme for trp catabolism, has
long been known to be operative in antimicrobial defence
(16, 17). Some organisms, for example, Clamydia pneumo-
niae, Toxoplasma gondii, and mycobacteria, have been shown
to be sensitive to the trp-depleting activity of IDO in vitro
(18Y20), but the biological efficacy of IDO in controlling
infections in vivo has remained unclear (2). Indoleamine 2,3-
dioxygenaseYdependent suppression of T-cell responses, in
turn, has been shown to function as a natural immunoregulatory
mechanism (17). This conception is based mainly on evidence
that this mechanism inhibits maternal T-cell immunity against
fetal tissues during mammalian gestation (5).
Our findings leave it unclear whether IDO is simply a marker
of severe disease or whether it also plays an independent caus-
ative role in the pathophysiology of sepsis. The first evidence
supporting the latter conception came from a recent study in
mice showing that survival from endotoxin shock was increased
in IDOj/j and in IDO inhibitor 1-methyl-trpYtreated mice
compared with wild-type mice (9). Blocking or knocking out
IDO reduced IL-12 levels while increasing those of IL-10 in
LPS-induced endotoxin shock, resulting in increased survival.
FIG. 2. Cumulative 30-d survival in bacteremia patients with maximum kyn/trp ratio (days 1 to 4 after positive blood culture) e120 2mol/mmol
versus those with greater than 120 2mol/mmol (first inset) and after stratification by underlying conditions proving significant risk factors for case
fatality in univariate analysis (alcohol abuse, current smoking, and obesity (BMI 930 kg/m2). Of underlying conditions, only obesity remained as an
independent predictor for case fatality in addition to high kyn/trp ratio in the multivariate model. Day 0 = the day of positive blood culture (admission). The
survival curves were calculated using the Kaplan-Meier method, and survival differences between groups were compared using log-rank test.
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TNF-! and IL-6, which are important proinflammatory
cytokines in sepsis pathophysiology and have been shown to
lead to septic shock (21), were also markedly lower after LPS
challenge in IDOj/j mice (9), indicating that IDO may in-
crease case fatality in sepsis by potentiating the inflammatory
reaction. In humans, two previous studies on trauma patients
have suggested that the degradation of trp might be associated
with the development of sepsis and poor outcome after major
trauma (10, 11), and one small study was suggestive of an
association between highly increased trp degradation and the
severity of Streptococcus pyogenes infection (22).
Although high kyn levels and IDO activity were clearly
associated with case fatality in this study, trp levels did not
predict case fatality. One explanation here could be nutritional
status sufficient to maintain endogenous trp levels despite
increased degradation. However, nutritional factors are an
unlikely explanation for the increased kyn/trp ratios in the
present context because kyn and kyn/trp levels are not
affected by dietary intake (3). Enhanced trp degradation may
result from the activation of either IDO or the hepatic trp
2,3 dioxygenase enzyme. However, IDO seems a more
likely activator of the enhanced trp degradation, as trp 2,3
dioxygenase is known to regulate homeostatic serum trp
concentrations, and IDO is up-regulated in response to
inflammatory conditions. The ratio of kyn/trp is commonly
used to reflect IDO activity (3), and it is regarded as a more
reliable marker of IDO-induced trp catabolism than serum trp
concentration, which may be influenced by dietary intake of
the essential amino acid. Alcoholics had high maximum kyn/
trp ratios in the present cohort. However, maximum kyn/trp
predicted case fatality independently of alcohol abuse in the
multivariate model. Although the kyn/trp ratio correlated here
with creatinine in bacteremia patients, and hyperkynurinemia
has been found in previous studies also in patients with renal
failure (23), IDO predicted case fatality also independently of
high creatinine.
The study has some limitations. Indoleamine 2,3-dioxyge-
nase activity was not measured on admission, and there were
only few patients whose IDO activity was measured 1 to 2
days after the positive blood culture was drawn. However, on
days 3 and 4, IDO activity was significantly higher in
nonsurvivors versus survivors. The maximum IDO activity
in each patient during 1 to 4 days after the positive blood
culture was used in analysis. This was considered acceptable
because all patients were admitted to the hospital at subjective
time points in relation to their disease course, and the duration
of symptoms of sepsis could have varied considerably
between different individuals on hospital admission. High
kyn/trp ratios on days 5 and thereafter are less likely to be
bacteremia related than are ratios closer to the time point of
positive blood culture.
The current shortage of validated biomarkers of disease
severity in sepsis is an important limitation when attempting
to stratify patients into homogeneous groups, to study patho-
genesis, or develop therapeutic interventions. Further studies
are needed to address the specific contribution of IDO to host
defence against infection and to establish whether blocking
IDO may have effects beneficial to the host.
ACKNOWLEDGMENTS
The authors thank Heidi Ha¨llstro¨m, Kati Yli-Nikkila¨, Raija Repo, and Mirja
Ikonen for skillful technical assistance. They also thank Robert McGilleon for the
language revision of the manuscript.
REFERENCES
1. Monneret G, Venet F, Pachot A, Lepape A: Monitoring immune dysfunctions in
the septic patient: a new skin for the old ceremony. Mol Med 14:64Y78, 2008.
2. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and
tryptophan catabolism. Nat Rev Immunol 4:762Y774, 2004.
3. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D: Monitoring tryptophan
metabolism in chronic immune activation. Clin Chim Acta 364:82Y90, 2006.
4. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-
dioxygenase production by human dendritic cells results in the inhibition of T
cell proliferation. J Immunol 164:3596Y3599, 2000.
5. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown
C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophan
catabolism. Science 281:1191Y1193, 1998.
6. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH: Cells expressing
indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168:
3771Y3776, 2002.
7. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM: Effect of indoleamine
2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.
J Neuroimmunol 129:186Y196, 2002.
8. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G:
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-
expressing dendritic cells: mediation of suppression by tryptophan metabolites.
J Exp Med 196:447Y457, 2002.
9. Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, Lee CM, Park WS, Han J,
Seo SK, Lee SY, et al.: Blockade of indoleamine 2,3-dioxygenase protects
mice against lipopolysaccharide-induced endotoxin shock. J Immunol 182:
3146Y3154, 2009.
10. Logters TT, Laryea MD, Altrichter J, Sokolowski J, Cinatl J, Reipen J,
Linhart W, Windolf J, Scholz M, Wild M: Increased plasma kynurenine values
and kynurenine: tryptophan ratios after major trauma are early indicators for
the development of sepsis. Shock 32:29Y34, 2009.
11. Pellegrin K, Neurauter G, Wirleitner B, Fleming AW, Peterson VM,
Fuchs D: Enhanced enzymatic degradation of tryptophan by indoleamine
2,3-dioxygenase contributes to the tryptophan-deficient state seen after major
trauma. Shock 23:209Y215, 2005.
12. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H,
Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/failure. On behalf of the
Working Group on Sepsis-Related Problems of the European Society of
Intensive Care Medicine. Intensive Care Med 22:707Y710, 1996.
13. Laich A, Neurauter G, Widner B, Fuchs D: More rapid method for
simultaneous measurement of tryptophan and kynurenine by HPLC. Clin
Chem 48:579Y581, 2002.
14. Boyd JC: Mathematical tools for demonstrating the clinical usefulness of
biochemical markers. Scand J Clin Lab Invest Suppl 227:46Y63, 1997.
15. PertovaaraM, Raitala A, Lehtimaki T, Karhunen PJ, Oja SS, Jylha M, Hervonen
A, Hurme M: Indoleamine 2,3-dioxygenase activity in nonagenarians is mark-
edly increased and predicts mortality. Mech Ageing Dev 127:497Y499, 2006.
16. Taylor MW, Feng GS: Relationship between interferon-gamma, indoleamine
2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516Y2522, 1991.
17. Mellor AL, Munn DH: Tryptophan catabolism and T-cell tolerance: immuno-
suppression by starvation? Immunol Today 20:469Y473, 1999.
18. Pfefferkorn ER: Interferon gamma blocks the growth of Toxoplasma gondii in
human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl
Acad Sci U S A 81:908Y912, 1984.
19. Gupta SL, Carlin JM, Pyati P, Dai W, Pfefferkorn ER, Murphy MJ Jr:
Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase
enzyme expression in human fibroblasts. Infect Immun 62:2277Y2284, 1994.
20. Hayashi T, Rao SP, Takabayashi K, Van Uden JH, Kornbluth RS, Baird SM,
Taylor MW, Carson DA, Catanzaro A, Raz E: Enhancement of innate immunity
againstMycobacterium avium infection by immunostimulatory DNA is mediated
by indoleamine 2,3-dioxygenase. Infect Immun 69:6156Y6164, 2001.
21. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza
MT, Castro-Faria-Neto HC, Bozza PT: Cytokine profiles as markers of disease
severity in sepsis: a multiplex analysis. Crit Care 11:R49, 2007.
22. Murr C, Gerlach D, Widner B, Dierich MP, Fuchs D: Neopterin production
and tryptophan degradation in humans infected by Streptococcus pyogenes.
Med Microbiol Immunol 189:161Y163, 2001.
23. Martinsons A, Rudzite V, Groma V, Bratslavska O, Widner B, Fuchs D:
Kynurenine and neopterin in chronic glomerulonephritis. Adv Exp Med Biol
467:579Y586, 1999.
154 SHOCK VOL. 33, NO. 2 HUTTUNEN ET AL.
